Alt	Chromosome	Direction	Drug	DrugID	End	Evidence.Level	Feature.Names	Gene	Mutation	Phenotype.Description	Phenotype.Family	Phenotype.ID	Ref	Sequence.ID	Start	Direction_Short	Mutation_Class
G	2	sensitive	CERITINIB	CID57379345	29484957	A	ALK  positive	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0000475	29484957	Sensitive	positively_autoregulated
A	X	sensitive	CRIZOTINIB	CID11626560	64924202	A	ALK  fusion	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0000806	64924202	Sensitive	fusion
NA	7	sensitive	GEFITINIB	CID123631	55324313	A	EGFR E746_A750del 	EGFR	[u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	NA	55086714	Sensitive	Unknown
G	7	sensitive	AFATINIB	CID10184653	55259515	A	EGFR L858R 	EGFR	[u'L858R']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	NA	55259515	Sensitive	Unknown
A	7	sensitive	GEFITINIB	CID123631	55259524	A	EGFR L861Q 	EGFR	[u'L861Q']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	NA	55259524	Sensitive	Unknown
NA	12	not applicable	NA	NA	12048336	A	ETV6-NTRK3	ETV6	[]	congenital fibrosarcoma	connective tissue cancer	DOID:8418	NA	SO:0000806	11802788	Unknown	fusion
NA	NA	1	NA	NA	NA	A	NA	CSF3R	NA	atypical chronic myeloid leukemia	bone marrow cancer	DOID:0060597	NA	NA	NA	Unknown	Unknown
NA	1	1	NA	NA	43815010	A	MPL codon(s) 515 missense	MPL	NA	essential thrombocythemia	bone marrow cancer	DOID:2224	NA	SO:0001583	43815008	Unknown	missense_variant
NA	1	1	NA	NA	120458436	A	NOTCH2 I2304fs	NOTCH2	NA	diffuse large B-cell lymphoma	lymphoma	DOID:0050745	NA	SO:0000865	120458436	Unknown	frameshift
NA	NA	1	NA	NA	NA	A	NA	FANCL	NA	myelodysplastic syndrome	hematologic cancer	DOID:0050908	NA	NA	NA	Unknown	Unknown
NA	2	1	NA	NA	198267493	A	SF3B1 codon(s) 700, 666, 662, 625, 622 missense	SF3B1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0001583	198267491	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	WHSC1	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
T	4	1	NA	NA	55599321	A	KIT D816V	KIT	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	A	SO:0001583	55599321	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	TET2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FBXW7	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
AT	7	1	NA	NA	140453136	A	BRAF V600D	BRAF	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	TG	SO:0001583	140453135	Unknown	missense_variant
T	9	1	NA	NA	133748283	A	ABL1 T315I	ABL1	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	C	SO:0001583	133748283	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	GATA3	NA	acute T cell leukemia	leukemia	DOID:5603	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PTEN	NA	acute T cell leukemia	leukemia	DOID:5603	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CBL	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PRPF40B	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CD79B	NA	diffuse large B-cell lymphoma	lymphoma	DOID:0050745	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	SETBP1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CEBPA	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	GATA1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PIGA	NA	NA	NA	NA	NA	NA	NA	Unknown	Unknown
A	7	1	NA	NA	140453136	A	BRAF V600E	BRAF	NA	adenocarcinoma	carcinoma	DOID:299	T	SO:0001583	140453136	Unknown	missense_variant
NA	11	1	NA	NA	533875	A	HRAS codon(s) 12, 13, 61 any	HRAS	NA	follicular thyroid carcinoma	thyroid cancer	DOID:3962	NA		533873	Unknown	Unknown
NA	2	1	NA	NA	209113113	A	IDH1 codon(s) 132 any	IDH1	NA	Astrocytoma, Anaplastic	malignant glioma	DOID:3069	NA		209113111	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	NA	NA	Unknown	Unknown
A	4	1	NA	NA	55593613	A	KIT V560D	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:0001583	55593613	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	VHL	NA	clear cell renal cell carcinoma	kidney cancer	DOID:4467	NA	NA	NA	Unknown	Unknown
T	17	1	NA	NA	37868208	A	ERBB2 S310F	ERBB2	NA	adenocarcinoma	carcinoma	DOID:299	C	SO:0001583	37868208	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	NCOA2	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDKN2A	NA	glioblastoma classical subtype	astrocytoma	DOID:0050803	NA	NA	NA	Unknown	Unknown
A	2	1	NA	NA	29432664	A	ALK R1275Q	ALK	NA	neuroblastoma	peripheral nervous system neoplasm	DOID:769	G	SO:0001583	29432664	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	9	1	NA	NA	5078362	A	JAK2 codon(s) 683 missense	JAK2	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	SO:0001583	5078360	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	TP53	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	SMO	NA	basal cell carcinoma	skin cancer	DOID:2513	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	KIT	NA	renal cell carcinoma	kidney cancer	DOID:4450	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDKN2B	NA	bladder urachal urothelial carcinoma	urinary bladder cancer	DOID:7244	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	BRCA1	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	AKT2	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDK6	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
A	7	1	NA	NA	140453136	A	BRAF V600E	BRAF	NA	craniopharyngioma	nervous system benign neoplasm	DOID:3840	T	SO:0001583	140453136	Unknown	missense_variant
G	1	resistant	CETUXIMAB	CHEMBL1201577	115251171	A	NRAS G13X 	NRAS	[u'G13X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
G	1	resistant	CETUXIMAB	CHEMBL1201577	115251171	A	NRAS  mutant	NRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:1000002	115251171	Resistant	substitution
T	1	resistant	PANITUMUMAB	CHEMBL1201827	115252204	A	NRAS A146T 	NRAS	[u'A146T']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	115252204	Resistant	Unknown
C	4	sensitive	Imatinib	CID5291	55139713	A	PDGFRA  rearrange	PDGFRA	[u'']	myelodysplastic/myeloproliferative neoplasm	hematologic cancer	DOID:4972	T	SO:0000138	55139713	Sensitive	gene_rearranged_at_DNA_level
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25368402	A	KRAS G12X 	KRAS	[u'G12X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12C 	KRAS	[u'G12C']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398285	Resistant	Unknown
G	12	sensitive	CETUXIMAB	CHEMBL1201577	25368405	A	KRAS  wild-type	KRAS	[u'']	cancer	cancer	DOID:162	A	SO:0000817	25368405	Sensitive	wild_type
G	12	sensitive	PANITUMUMAB	CHEMBL1201827	25368405	A	KRAS  wild-type	KRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	A	SO:0000817	25368405	Sensitive	wild_type
T	12	resistant	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13D 	KRAS	[u'G13D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398281	Resistant	Unknown
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13D 	KRAS	[u'G13D']	cancer	cancer	DOID:162	C	NA	25398281	Resistant	Unknown
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13D 	KRAS	[u'G13D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398281	Resistant	Unknown
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13D 	KRAS	[u'G13D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398281	Resistant	Unknown
A	12	resistant	CETUXIMAB	CHEMBL1201577	25378561	A	KRAS A146V 	KRAS	[u'A146V']	colorectal cancer	intestinal cancer	DOID:9256	G	NA	25378561	Resistant	Unknown
A	12	resistant	CETUXIMAB	CHEMBL1201577	25368402	A	KRAS G13X 	KRAS	[u'G13X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
G	12	resistant	CETUXIMAB	CHEMBL1201577	25378647	A	KRAS K117N 	KRAS	[u'K117N']	colorectal cancer	intestinal cancer	DOID:9256	T	NA	25378647	Resistant	Unknown
T	9	Responsive	RUXOLITINIB	CID25126798	5073770	A	JAK2:V617F	JAK2	NA	myelofibrosis	hematologic cancer	DOID:4971	G	SO:1000002	5073770	Sensitive	substitution
NA	4	Responsive	SUNITINIB	CID5329102	55606881	A	KIT mutation in exon 9,11,13,14 or 17	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	SO:1000002	55524085	Sensitive	substitution
A	4	Resistant	Imatinib	CID5291	55564577	A	KIT (D816)	KIT	NA	Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis	gastrointestinal system cancer	DOID:9253	T	SO:1000002	55564577	Resistant	substitution
G	1	Resistant	mAb	CHEMBL2109423	115251171	A	NRAS (12,13,59,61,117,146)	NRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	T	SO:1000002	115251171	Resistant	substitution
C	4	Responsive	REGORAFENIB	CID11167602	55133777	A	PDGFRA (552-596,631-668,814-854)	PDGFRA	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:1000002	55133777	Sensitive	substitution
T	9	Resistant	DASATINIB	CID3062316	133748283	A	ABL1:T315I	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748283	Resistant	substitution
T	9	Resistant	DASATINIB	CID3062316	133738290	A	ABL1:V299L	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133738290	Resistant	substitution
NA	9	Responsive	PONATINIB	CID24826799	133763062	A	ABL1-BCR fusion	ABL1	NA	Chronic myeloid leukemia;Acute lymphoblastic leukemia	hematologic cancer	DOID:8552	NA	SO:0001902	133589333	Sensitive	splice_region
A	X	Responsive	CRIZOTINIB	CID11626560	64924202	A	ALK fusion	ALK	NA	Non-small cell lung;Lung adenocarcinoma	lung cancer	DOID:3908	G	SO:0001902	64924202	Sensitive	splice_region
A	X	Responsive	BRIGATINIB	CID68165256	64924202	A	ALK fusion	ALK	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001902	64924202	Sensitive	splice_region
C	7	Responsive	VEMURAFENIB	CID42611257	140426304	A	BRAF:V600D	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	G	SO:1000002	140426304	Sensitive	substitution
T	7	Responsive	TRAMETINIB	CID11707110	140453136	A	BRAF:V600E	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	A	SO:1000002	140453136	Sensitive	substitution
T	7	Responsive	COBIMETINIB	CID16222096	140453136	A	BRAF:V600E	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	A	SO:1000002	140453136	Sensitive	substitution
NA	17	Responsive	OLAPARIB	CID23725625	41277500	A	BRCA1 oncogenic mutation	BRCA1	NA	ovarian cancer	reproductive organ cancer	DOID:2394	NA	SO:1000002	41196312	Sensitive	substitution
C	1	Increased Toxicity	2-fluoropyrimidine	CID141643	97981303	A	DPYD splice donor variant	DPYD	NA	cancer	cancer	DOID:162	G	SO:1000002	97981303	Sensitive	substitution
NA	7	Responsive	GEFITINIB	CID123631	55324313	A	EGFR exon 19 deletions	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	SO:1000002	55086714	Sensitive	substitution
G	7	Responsive	Erlotinib	CID176870	55259515	A	EGFR:L858R	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:1000002	55259515	Sensitive	substitution
T	7	Resistant	AFATINIB	CID10184653	55249071	A	EGFR:T790M	EGFR	NA	lung cancer	respiratory system cancer	DOID:1324	C	SO:1000002	55249071	Resistant	substitution
T	7	Resistant	Erlotinib	CID176870	55249071	A	EGFR:T790M	EGFR	NA	lung cancer	respiratory system cancer	DOID:1324	C	SO:1000002	55249071	Resistant	substitution
T	7	Responsive	OSIMERTINIB	CID71496458	55249071	A	EGFR:T790M	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:1000002	55249071	Sensitive	substitution
C	7	Resistant	mAb	CHEMBL2109423	55086994	A	EGFR overexpression	EGFR	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	G	SO:0001025	55086994	Resistant	polymorphic_sequence_variant
NA	17	Responsive	mAb	CHEMBL2109423	37886679	A	ERBB2 amplification	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	NA	SO:0001880	37844167	Sensitive	feature_amplification
NA	17	Responsive	mAb	CHEMBL2109423	37886679	A	ERBB2 amplification	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	NA	SO:0001880	37844167	Sensitive	feature_amplification
A	X	Increased Toxicity (Haemolytic Anemia)	DABRAFENIB	CID44462760	153764361	A	G6PD (V98M) + G6PD (N156D)	G6PD	NA	cancer	cancer	DOID:162	G	SO:1000002	153764361	Sensitive	substitution
NA	16	Responsive	EVEROLIMUS	CID6442177	2138716	A	TSC2 oncogenic mutation	TSC2	NA	Renal angiomyolipoma;Giant cell astrocytoma	urinary system benign neoplasm	DOID:8411	NA	SO:1000002	2097466	Sensitive	substitution
A	2	Increased Toxicity (Hyperbilirubinemia)	NILOTINIB	CID644241	234669144	A	UGT1A1:G71R	UGT1A1	NA	cancer	cancer	DOID:162	G	SO:1000002	234669144	Sensitive	substitution
None	22	Sensitivity	NILOTINIB	CID644241	23632600	A	BCR-ABL	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	None	SO:0001886	23522397	Sensitive	transcript_fusion
C	1	Adverse Response	CAPECITABINE	CID60953	97981343	A	DPYD*13 HOMOZYGOSITY	DPYD	HOMOZYGOSITY	cancer	cancer	DOID:162	A	SO:0001583	97981343	Resistant	missense_variant
C	X	Positive	NA	NA	52729563	A	SS18-SSX2	SSX2	NA	synovial sarcoma	connective tissue cancer	DOID:5485	T	SO:0001886	52729563	Sensitive	transcript_fusion
TCTG	5	Positive	NA	NA	170837548	A	W288FS	NPM1	W288FS	acute myeloid leukemia	hematologic cancer	DOID:9119		SO:0001909	170837547	Sensitive	frameshift_elongation
None	4	Sensitivity	Imatinib	CID5291	54294350	A	FIP1L1-PDGFRA	PDGFRA	NA	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1	hematologic cancer	DOID:0080164	None	SO:0001886	54243812	Sensitive	transcript_fusion
C	7	1	GEFITINIB	CID123631	55086994	A	A763_Y764insFQEA	EGFR	A763_Y764insFQEA	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001821	55086994	Unknown	inframe_insertion
NA	7	1	GEFITINIB	CID123631	55324313	A	Exon 19 deletion/insertion	EGFR	Exon 19 deletion/insertion	non-small cell lung carcinoma	lung cancer	DOID:3908	NA		55086714	Unknown	Unknown
T	7	1	GEFITINIB	CID123631	55241707	A	G719C	EGFR	G719C	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55241707	Unknown	missense_variant
G	7	1	GEFITINIB	CID123631	55259515	A	L858R	EGFR	L858R	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0001583	55259515	Unknown	missense_variant
G	7	1	GEFITINIB	CID123631	55259439	A	L833V	EGFR	L833V	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0001583	55259439	Unknown	missense_variant
G	7	1	GEFITINIB	CID123631	55259524	A	L861R	EGFR	L861R	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0001583	55259524	Unknown	missense_variant
T	15	1	Enasidenib	CID89683805	90631934	A	R140Q	IDH2	R140Q	acute myeloid leukemia	hematologic cancer	DOID:9119	C	SO:0001583	90631934	Unknown	missense_variant
C	15	1	Enasidenib	CID89683805	90631839	A	R172G	IDH2	R172G	acute myeloid leukemia	hematologic cancer	DOID:9119	T	SO:0001583	90631839	Unknown	missense_variant
G	15	1	Enasidenib	CID89683805	90631837	A	R172S	IDH2	R172S	acute myeloid leukemia	hematologic cancer	DOID:9119	C	SO:0001583	90631837	Unknown	missense_variant
T	5	1	Imatinib	CID5291	149499573	A	Fusions	PDGFRB	Fusions	myeloproliferative neoplasm	hematologic cancer	DOID:2226	A		149499573	Unknown	Unknown
C	4	1	Imatinib	CID5291	55139713	A	Fusions	PDGFRA	Fusions	myelodysplastic syndrome	hematologic cancer	DOID:0050908	T		55139713	Unknown	Unknown
C	7	1	TRAMETINIB	CID11707110	140426304	A	V600D	BRAF	V600D	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	140426304	Unknown	missense_variant
T	7	1	TRAMETINIB	CID11707110	140453137	A	V600M	BRAF	V600M	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	140453137	Unknown	missense_variant
T	7	1	TRAMETINIB	CID11707110	140453136	A	V600E	BRAF	V600E	melanoma	cell type cancer	DOID:1909	A	SO:0001583	140453136	Unknown	missense_variant
G	7	1	TRAMETINIB	CID11707110	140534535	A	V600K	BRAF	V600K	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	140534535	Unknown	missense_variant
-	7	MET c.2888-14_2888-4delCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411899	A	MET c.2888-14_2888-4delCTCTCTGTTTT	MET	[u'c.2888-14_2888-4delCTCTCTGTTTT']	lung adenocarcinoma	lung cancer	DOID:3910	CTCTCTGTTTT	SO:0000188	116411889	Sensitive	intron
G	12	ERBB3 Q809R confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	56490980	A	ERBB3 Q809R	ERBB3	[u'Q809R']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	56490980	Sensitive	missense_variant
GGGTTA	7	EGFR D770_N771insGL confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insGL	EGFR	[u'D770_N771insGL']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	MET c.2888-20_2888-2delTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411901	A	MET c.2888-20_2888-2delTTCTTTCTCTCTGTTTTAA	MET	[u'c.2888-20_2888-2delTTCTTTCTCTCTGTTTTAA']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTTTCTCTCTGTTTTAA	SO:0000188	116411883	Sensitive	intron
TT	12	KRAS G13N confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13N	KRAS	[u'G13N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
C	10	RET C634R confers sensitivity to Cabozantinib in patients with Medullary thyroid carcinoma	CABOZANTINIB	CID25102847	43609948	A	RET C634R	RET	[u'C634R']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	T	SO:0001583	43609948	Sensitive	missense_variant
ACC	12	KRAS G13_V14insG confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398279	Resistant	Unknown
-	7	MET c.3005_3028+1delACTACCGAGCTACTTTTCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3005_3028+1delACTACCGAGCTACTTTTCCAGAAGG	MET	[u'c.3005_3028+1delACTACCGAGCTACTTTTCCAGAAGG']	lung adenocarcinoma	lung cancer	DOID:3910	ACTACCGAGCTACTTTTCCAGAAGG	SO:0000188	116412020	Sensitive	intron
TT	12	KRAS G13E confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13E	KRAS	[u'G13E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GC	SO:0001583	25398280	Resistant	missense_variant
A	12	KRAS G12C confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12C	KRAS	[u'G12C']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398285	Resistant	synonymous
	12	KRAS G12 confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12	KRAS	[u'12G']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984			25398283	Resistant	Unknown
T	4	SLC34A2-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	25664146	A	SLC34A2-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	25664146	Sensitive	fusion
G	7	EGFR L861R confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55259524	A	EGFR L861R	EGFR	[u'L861R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
-	7	MET c.2888-18_2888-7delCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411896	A	MET c.2888-18_2888-7delCTTTCTCTCTGT	MET	[u'c.2888-18_2888-7delCTTTCTCTCTGT']	lung adenocarcinoma	lung cancer	DOID:3910	CTTTCTCTCTGT	SO:0000188	116411885	Sensitive	intron
G	7	EGFR L858R confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55259515	A	EGFR L858R	EGFR	[u'L858R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	55259515	Sensitive	synonymous
GACAACCCT	7	EGFR P772_H773insDNP confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249019	A	EGFR P772_H773insDNP	EGFR	[u'D770_P772dupDNP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
CAT	12	KRAS G13M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13M	KRAS	[u'G13M']	lung adenocarcinoma	lung cancer	DOID:3910	GCC	SO:0001583	25398280	Resistant	missense_variant
ACACAACCTCCT	7	EGFR H773_V774insTQPP confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249022	A	EGFR H773_V774insTQPP	EGFR	[u'H773_V774insTQPP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
NNN	7	EGFR P772_H773insX confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249016	A	EGFR P772_H773insX	EGFR	[u'P772_H773insX']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249015	Resistant	Unknown
C	7	EGFR G719A confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55241708	A	EGFR G719A	EGFR	[u'G719A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241708	Sensitive	missense_variant
T	1	DPYD c.1905+1G>A confers an unfavorable response to Fluorouracil in patients with Neoplasm of colorectum	FLUOROURACIL	CID3385	97915614	A	DPYD c.1905+1G>A	DPYD	[u'c.1905+1G>A']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0000162	97915614	Unknown	splice_site
-	7	MET c.2888-80_3028+401delAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412444	A	MET c.2888-80_3028+401delAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTG	MET	[u'c.2888-80_3028+401delAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTG']	lung adenocarcinoma	lung cancer	DOID:3910	AGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTG		116411823	Sensitive	Unknown
G	7	MET c.3028+2T>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412045	A	MET c.3028+2T>G	MET	[u'c.3028+2T>G']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001627	116412045	Sensitive	intron_variant
-	7	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTA	MET	[u'c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTA']	lung adenocarcinoma	lung cancer	DOID:3910	CAAGCTCTTTCTTTCTCTCTGTTTTA	SO:0000188	116411875	Sensitive	intron
G	10		CABOZANTINIB	CID25102847	43609950	A	RET C634W	RET	[u'C634W']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	C	SO:0001583	43609950	Unknown	missense_variant
-	12	KRAS G12fs*3 confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000159	25398284	Resistant	deletion
AA	12	KRAS G12F confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12F	KRAS	[u'G12F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
AA	12	KRAS G12F confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12F	KRAS	[u'G12F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
AA	12	KRAS G12F confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12F	KRAS	[u'G12F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
A	7	EGFR G719S confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55241707	A	EGFR G719S	EGFR	[u'G719S']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	55241707	Sensitive	synonymous
NA	17	ERBB2 Amplification confers sensitivity to Ado-trastuzumab emtansine	TRASTUZUMAB	CHEMBL1201585	37886679	A	ERBB2 Amplification	ERBB2	[]	breast cancer	thoracic cancer	DOID:1612	NA	SO:0001889	37844167	Sensitive	transcript_amplification
GTGGCC	7	EGFR N771>SGH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR N771>SGH	EGFR	[u'N771delinsSGH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
A	12	KRAS G12V confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398284	A	KRAS G12V	KRAS	[u'G12V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	EGFR G225Afs*55 confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55220283	A	EGFR G225Afs*55	EGFR	[u'G225Afs*55']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000159	55220283	Sensitive	deletion
NA	6	ESR1 and ESR1 Amplification confers sensitivity to Fulvestrant in patients with Neoplasm of breast	FULVESTRANT	CID104741	152450754	A	ESR1 Amplification	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA	NA	151977826	Sensitive	Unknown
T	12	KRAS G12D confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398284	A	KRAS G12D	KRAS	[u'G12D']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
G	12	KRAS G12A confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398284	A	KRAS G12A	KRAS	[u'G12A']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
CCA	12	KRAS G12W confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12W	KRAS	[u'G12W']	breast cancer	thoracic cancer	DOID:1612	ACC	SO:0001583	25398283	Resistant	missense_variant
CGC	12	KRAS G12_G13insA confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	breast cancer	thoracic cancer	DOID:1612	-		25398282	Resistant	Unknown
A	12	KRAS G13C confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13C	KRAS	[u'G13C']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
TT	12	KRAS G13N confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13N	KRAS	[u'G13N']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
T	12	KRAS Q61K confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001583	25380277	Resistant	missense_variant
C	12	KRAS Q61E confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001583	25380277	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
A	12	KRAS G12C confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12C	KRAS	[u'G12C']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398285	Resistant	synonymous
CCA	12	KRAS G12W confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12W	KRAS	[u'G12W']	breast cancer	thoracic cancer	DOID:1612	ACC	SO:0001583	25398283	Resistant	missense_variant
AT	12	KRAS G13I confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13I	KRAS	[u'G13I']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
AA	12	KRAS G13F confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13F	KRAS	[u'G13F']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS G13A confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398281	A	KRAS G13A	KRAS	[u'G13A']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G13 confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25368462	A	KRAS G13	KRAS	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		25368462	Resistant	Unknown
TGT	12	KRAS G13_V14>DI confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	ACA		25398279	Resistant	Unknown
TGGCAACACCTA	7	EGFR D770_N771insMATP confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR D770_N771insMATP	EGFR	[u'D770_N771insMATP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
-	7	EGFR E746_T751delinsA confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242481	A	EGFR E746_T751delinsA	EGFR	[u'E746_T751delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAA	SO:0000159	55242467	Sensitive	deletion
A	12	KRAS G13 confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25368462	A	KRAS G13	KRAS	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		25368462	Resistant	Unknown
G	12	KRAS Q61H confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	25380275	Resistant	synonymous
ACACAACCTCCT	7	EGFR H773_V774insTQPP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249022	A	EGFR H773_V774insTQPP	EGFR	[u'H773_V774insTQPP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
-	7	EGFR L747_S752del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55242486	A	EGFR L747_S752del	EGFR	[u'L747_S752del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAAGCAACATCT	SO:0000159	55242469	Sensitive	deletion
A	12	KRAS G12C confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12C	KRAS	[u'G12C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
C	12	KRAS G13G confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398280	A	KRAS G13G	KRAS	[u'G13G']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	25398280	Resistant	synonymous
T	7	EGFR G719C confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55241707	A	EGFR G719C	EGFR	[u'G719C']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241707	Sensitive	missense_variant
AACCCCT	7	EGFR P772_H773insTP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249018	A	EGFR P772_H773insTP	EGFR	[u'P772_H773insTP']	lung adenocarcinoma	lung cancer	DOID:3910	C		55249018	Resistant	Unknown
AATTC	7	EGFR E746_A750delinsIP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242478	A	EGFR E746_A750delinsIP	EGFR	[u'E746_A750delinsIP']	non-small cell lung carcinoma	lung cancer	DOID:3908	GGAATTAAGAGAAG	SO:0000159	55242465	Sensitive	deletion
TA	12	KRAS G13Y confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
T	12	KRAS G12S confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12S	KRAS	[u'G12S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
GCAGCGTGG	7	EGFR V769_D770insGSV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249011	A	EGFR V769_D770insGSV	EGFR	[u'V769_D770insGSV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
-	7	MET c.2888-26_2888-5delAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411898	A	MET c.2888-26_2888-5delAGCTCTTTCTTTCTCTCTGTTT	MET	[u'c.2888-26_2888-5delAGCTCTTTCTTTCTCTCTGTTT']	lung adenocarcinoma	lung cancer	DOID:3910	AGCTCTTTCTTTCTCTCTGTTT	SO:0000188	116411877	Sensitive	intron
TT	7	BRAF V600K confers sensitivity to Vemurafenib in patients with MM - Malignant melanoma of skin	VEMURAFENIB	CID42611257	140453137	A	BRAF V600K	BRAF	[u'V600K']	skin melanoma	integumentary system cancer	DOID:8923	AC	SO:0001583	140453136	Sensitive	missense_variant
-	7	MET c.3028+1delG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3028+1delG	MET	[u'c.3028+1delG']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000188	116412044	Sensitive	intron
-	7	MET c.2888-5_2909delTTAAGATCTGGGCAGTGAATTAGTTCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411924	A	MET c.2888-5_2909delTTAAGATCTGGGCAGTGAATTAGTTCG	MET	[u'c.2888-5_2909delTTAAGATCTGGGCAGTGAATTAGTTCG']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGATCTGGGCAGTGAATTAGTTCG	SO:0000188	116411898	Sensitive	intron
C	14	KLC1-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	104153420	A	KLC1-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	104153420	Sensitive	fusion
CT	12	KRAS G12E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398284	A	KRAS G12E	KRAS	[u'G12E']	lung adenocarcinoma	lung cancer	DOID:3910	AC	SO:0001583	25398283	Resistant	missense_variant
CGCTGGCCA	7	EGFR A767_S768insTLA confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249005	A	EGFR A767_S768insTLA	EGFR	[u'A767_S768insTLA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249004	Resistant	Unknown
-	7	MET c.3021_3028+9delTCCAGAAGGTATATTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412052	A	MET c.3021_3028+9delTCCAGAAGGTATATTTC	MET	[u'c.3021_3028+9delTCCAGAAGGTATATTTC']	lung adenocarcinoma	lung cancer	DOID:3910	TCCAGAAGGTATATTTC	SO:0000188	116412036	Sensitive	intron
GCACCGTGG	7	EGFR D770_N771insAPW confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insAPW	EGFR	[u'D770_N771insAPW']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	MET c.2888-28_2888-2delCAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411901	A	MET c.2888-28_2888-2delCAAGCTCTTTCTTTCTCTCTGTTTTAA	MET	[u'c.2888-28_2888-2delCAAGCTCTTTCTTTCTCTCTGTTTTAA']	lung adenocarcinoma	lung cancer	DOID:3910	CAAGCTCTTTCTTTCTCTCTGTTTTAA	SO:0000188	116411875	Sensitive	intron
-	10	RET E632_L633del confers sensitivity to Cabozantinib in patients with Medullary thyroid carcinoma	CABOZANTINIB	CID25102847	43609947	A	RET E632_L633del	RET	[u'E632_L633del']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	GAGCTG	SO:0000159	43609942	Sensitive	deletion
GT	12	KRAS G12T confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12T	KRAS	[u'G12T']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
AT	12	KRAS G12I confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12I	KRAS	[u'G12I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
TGCACC	12	KRAS G12_G13insAG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398281	Resistant	Unknown
TT	12	KRAS G12N confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12N	KRAS	[u'G12N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
A	12	KRAS G12C confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12C	KRAS	[u'G12C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
C	10	RET M918T confers sensitivity to Cabozantinib in patients with Medullary thyroid carcinoma	CABOZANTINIB	CID25102847	43617416	A	RET M918T	RET	[u'M918T']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	T	SO:0001583	43617416	Sensitive	missense_variant
CCA	12	KRAS G12W confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12W	KRAS	[u'G12W']	lung adenocarcinoma	lung cancer	DOID:3910	ACC	SO:0001583	25398283	Resistant	missense_variant
A	6	GOPC-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	117642448	A	GOPC-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117642448	Sensitive	fusion
-	12	KRAS G12fs*3 confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0000159	25398284	Resistant	deletion
CCA	7	EGFR D770_N771insT confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249014	A	EGFR D770_N771insT	EGFR	[u'D770_N771insT']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
-	7	MET c.3021_3028+4delTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412047	A	MET c.3021_3028+4delTCCAGAAGGTAT	MET	[u'c.3021_3028+4delTCCAGAAGGTAT']	lung adenocarcinoma	lung cancer	DOID:3910	TCCAGAAGGTAT	SO:0000188	116412036	Sensitive	intron
T	2	ALK F1174L confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29443695	A	ALK F1174L	ALK	[u'F1174L']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	29443695	Sensitive	missense_variant
ACCGGC	7	EGFR N771_P772insRH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR N771_P772insRH	EGFR	[u'N771_P772insRH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
T	12	KRAS G12D confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398284	A	KRAS G12D	KRAS	[u'G12D']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
CCCTAA	7	MET c.2930_2887+63delGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACinsCCCTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411945	A	MET c.2930_2887+63delGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACinsCCCTAA	MET	[u'c.2930_2887+63delGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACinsCCCTAA']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000706	116411771	Sensitive	trans_splice_acceptor_site
ATA	7	MET c.2888-5_2890delTTAAGATCinsATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411905	A	MET c.2888-5_2890delTTAAGATCinsATA	MET	[u'c.2888-5_2890delTTAAGATCinsATA']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411898	Sensitive	intron
CGC	12	KRAS G12_G13insA confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398282	Resistant	Unknown
GCCATA	7	EGFR A767_S768insIA confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249001	A	EGFR A767_S768insIA	EGFR	[u'A767_S768insIA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249000	Resistant	Unknown
NA	7	MET Amplification confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	116438440	A	MET Amplification	MET	[]	lung adenocarcinoma	lung cancer	DOID:3910	NA	SO:0001889	116312444	Resistant	transcript_amplification
AT	12	KRAS G12I confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12I	KRAS	[u'G12I']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS G12A confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398284	A	KRAS G12A	KRAS	[u'G12A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	MET c.2888-9_2951delTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411966	A	MET c.2888-9_2951delTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT	MET	[u'c.2888-9_2951delTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT']	lung adenocarcinoma	lung cancer	DOID:3910	TGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT	SO:0000188	116411894	Sensitive	intron
CGC	12	KRAS G12_G13insA confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398282	Resistant	Unknown
NA	7	EGFR Amplification confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	55324313	A	EGFR Amplification	EGFR	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	SO:0001889	55086714	Sensitive	transcript_amplification
-	7	MET c.2888-20_2888-3delTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-20_2888-3delTTCTTTCTCTCTGTTTTA	MET	[u'c.2888-20_2888-3delTTCTTTCTCTCTGTTTTA']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTTTCTCTCTGTTTTA	SO:0000188	116411883	Sensitive	intron
GCGTAGACA	7	EGFR D770_N771insSVD confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249014	A	EGFR D770_N771insSVD	EGFR	[u'S768_D770dupSVD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
ACAACCCCC	7	EGFR N771_H773dup confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249011	A	EGFR N771_H773dup	EGFR	[u'N771_H773']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
TGGCAACACCTA	7	EGFR D770_N771insMATP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR D770_N771insMATP	EGFR	[u'D770_N771insMATP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
TC	7	EGFR E746_S752delinsV confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242486	A	EGFR E746_S752delinsV	EGFR	[u'E746_S752delinsV', u'E746_S752delinsV']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACATCT	SO:0000159	55242467	Sensitive	deletion
ACC	12	KRAS G13_V14insG confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398279	Resistant	Unknown
-	7	MET c.2888-16_2888-4delTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411899	A	MET c.2888-16_2888-4delTTCTCTCTGTTTT	MET	[u'c.2888-16_2888-4delTTCTCTCTGTTTT']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTCTCTGTTTT	SO:0000188	116411887	Sensitive	intron
GGT	7	EGFR D770_N771insG confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insG	EGFR	[u'D770_N771insG', u'D770_N771insG']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	MET c.2888-17_2888-4delTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411899	A	MET c.2888-17_2888-4delTTTCTCTCTGTTTT	MET	[u'c.2888-17_2888-4delTTTCTCTCTGTTTT']	lung adenocarcinoma	lung cancer	DOID:3910	TTTCTCTCTGTTTT	SO:0000188	116411886	Sensitive	intron
CCTCAT	7	EGFR H773_V774insPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249022	A	EGFR H773_V774insPH	EGFR	[u'P772_H773dupPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
	12	KRAS G12 confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12	KRAS	[u'12G']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984			25398283	Resistant	Unknown
TA	12	KRAS G13Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
G	10	KIF5B-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	32310205	A	KIF5B-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	32310205	Sensitive	fusion
T	2	EML4-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	42396763	A	EML4-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000806	42396763	Sensitive	fusion
C	12	KRAS Q61E confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	G	SO:0001583	25380277	Resistant	missense_variant
ACC	12	KRAS G13_V14insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398279	Resistant	Unknown
AA	12	KRAS G13F confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13F	KRAS	[u'G13F']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
TT	12	KRAS G13N confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13N	KRAS	[u'G13N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
G	2	ALK R1192P confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	29443642	A	ALK R1192P	ALK	[u'R1192P']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	29443642	Sensitive	missense_variant
CGT	7	EGFR N771_P772insV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249015	A	EGFR N771_P772insV	EGFR	[u'N771_P772insV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249014	Resistant	Unknown
CAC	7	EGFR N771>TH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR N771>TH	EGFR	[u'N771delinsTH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
-	7	MET c.3017_3028+4delCTTTTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412047	A	MET c.3017_3028+4delCTTTTCCAGAAGGTAT	MET	[u'c.3017_3028+4delCTTTTCCAGAAGGTAT']	lung adenocarcinoma	lung cancer	DOID:3910	CTTTTCCAGAAGGTAT	SO:0000188	116412032	Sensitive	intron
T	17	ERBB2 D769Y confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880261	A	ERBB2 D769Y	ERBB2	[u'D769Y']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37880261	Sensitive	missense_variant
T	7	MET c.3028+3A>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3028+3A>T	MET	[u'c.3028+3A>T']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001627	116412046	Sensitive	intron_variant
CAT	12	KRAS G13M confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13M	KRAS	[u'G13M']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GCC	SO:0001583	25398280	Resistant	missense_variant
	12	KRAS Q61 confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380277	A	KRAS Q61	KRAS	[u'61Q']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984			25380275	Resistant	Unknown
A	12	KRAS G12V confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398284	A	KRAS G12V	KRAS	[u'G12V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
CCCACG	7	EGFR H773_V774insAH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249023	A	EGFR H773_V774insAH	EGFR	[u'H773_V774insAH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
C	12	KRAS Q61R confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
AT	12	KRAS G12I confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12I	KRAS	[u'G12I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	EGFR E746_T751delinsA confers sensitivity to Afatinib in patients with Non-small cell lung cancer	AFATINIB	CID10184653	55242481	A	EGFR E746_T751delinsA	EGFR	[u'E746_T751delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAA	SO:0000159	55242467	Sensitive	deletion
T	7	EGFR T790M confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249071	A	EGFR T790M	EGFR	[u'T790M']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	55249071	Resistant	missense_variant
-	7	MET c.2888-18_2888-4delCTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411899	A	MET c.2888-18_2888-4delCTTTCTCTCTGTTTT	MET	[u'c.2888-18_2888-4delCTTTCTCTCTGTTTT']	lung adenocarcinoma	lung cancer	DOID:3910	CTTTCTCTCTGTTTT	SO:0000188	116411885	Sensitive	intron
ACC	7	EGFR N771_P772insH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249017	A	EGFR N771_P772insH	EGFR	[u'N771_P772insH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249016	Resistant	Unknown
G	12	KRAS G12R confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12R	KRAS	[u'G12R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398285	Resistant	missense_variant
NA	7	EGFR confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	55324313	A	EGFR	EGFR	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	55086714	Sensitive	Unknown
-	7	EGFR L747_S752del confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242486	A	EGFR L747_S752del	EGFR	[u'L747_S752del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAAGCAACATCT	SO:0000159	55242469	Sensitive	deletion
CATCAT	7	EGFR Y764_V765insHH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55248995	A	EGFR Y764_V765insHH	EGFR	[u'Y764_V765insHH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55248994	Resistant	Unknown
TGCACC	12	KRAS G12_G13insAG confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398281	Resistant	Unknown
C	14	KLC1-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	104153420	A	KLC1-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	104153420	Sensitive	fusion
G	12	KRAS Q61H confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001815	25380275	Resistant	synonymous
NA	NA	BRCA2,BRCA1 and BRCA confers sensitivity to Rucaparib in patients with Carcinoma of ovary	RUCAPARIB	CID9931954	NA	A	BRCA	BRCA1	[]	ovarian cancer	reproductive organ cancer	DOID:2394	NA	NA	NA	Sensitive	Unknown
-	7	MET c.2888-28_2888-7delCAAGCTCTTTCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411896	A	MET c.2888-28_2888-7delCAAGCTCTTTCTTTCTCTCTGT	MET	[u'c.2888-28_2888-7delCAAGCTCTTTCTTTCTCTCTGT']	lung adenocarcinoma	lung cancer	DOID:3910	CAAGCTCTTTCTTTCTCTCTGT	SO:0000188	116411875	Sensitive	intron
C	6	sensitive	CRIZOTINIB	CID11626560	117710940	A	ROS1  rearrange	ROS1	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0000138	117710940	Sensitive	gene_rearranged_at_DNA_level
A	X	sensitive	CERITINIB	CID57379345	64924202	A	ALK  fusion	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0000806	64924202	Sensitive	fusion
A	X	sensitive	CERITINIB	CID57379345	64924202	A	ALK  fusion	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0000806	64924202	Sensitive	fusion
G	7	sensitive	COBIMETINIB	CID16222096	140534535	A	BRAF V600K 	BRAF	[u'V600K']	melanoma	cell type cancer	DOID:1909	A	SO:0001587	140534535	Sensitive	stop_gained
NA	NA	sensitive	COBIMETINIB	CID16222096	NA	A	BRAF V600E/K 	BRAF	[u'V600E/K']	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Sensitive	Unknown
A	12	resistant	CETUXIMAB	CHEMBL1201577	25368402	A	KRAS G12X 	KRAS	[u'G12X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
A	12	resistant	GEFITINIB	CID123631	25368402	A	KRAS G12X 	KRAS	[u'G12X']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	25368402	Resistant	stop_gained
G	12	resistant	CETUXIMAB	CHEMBL1201577	25378562	A	KRAS A146P 	KRAS	[u'A146P']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25378562	Resistant	Unknown
G	12	resistant	PANITUMUMAB	CHEMBL1201827	25378562	A	KRAS A146P 	KRAS	[u'A146P']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25378562	Resistant	Unknown
G	12	sensitive	PANITUMUMAB	CHEMBL1201827	25368405	A	KRAS  wild-type	KRAS	[u'']	cancer	cancer	DOID:162	A	SO:0000817	25368405	Sensitive	wild_type
T	12	predicted – resistant	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12D 	KRAS	[u'G12D']	cancer	cancer	DOID:162	C	NA	25398284	Resistant	Unknown
T	7	predicted – resistant	PANITUMUMAB	CHEMBL1201827	140453136	A	BRAF V600E 	BRAF	[u'V600E']	colorectal cancer	intestinal cancer	DOID:9256	A	NA	140453136	Resistant	Unknown
A	17	predicted – sensitive	RUCAPARIB	CID9931954	41245877	A	BRCA1  mutant	BRCA1	[u'']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:1000002	41245877	Sensitive	substitution
A	17	sensitive	NIRAPARIB	CID24958200	41245877	A	BRCA1  mutant	BRCA1	[u'']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:1000002	41245877	Sensitive	substitution
C	13	predicted – sensitive	RUCAPARIB	CID9931954	32893443	A	BRCA2  mutant	BRCA2	[u'']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:1000002	32893443	Sensitive	substitution
G	17	sensitive	Docetaxel	CID148124	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
A	12	resistant	GEFITINIB	CID123631	25368402	A	KRAS G13X 	KRAS	[u'G13X']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	25368402	Resistant	stop_gained
T	12	resistant	CETUXIMAB	CHEMBL1201577	25378562	A	KRAS A146T 	KRAS	[u'A146T']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25378562	Resistant	Unknown
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25368402	A	KRAS Q61X 	KRAS	[u'Q61X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
A	12	resistant	CETUXIMAB	CHEMBL1201577	25368402	A	KRAS  mutant	KRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:1000002	25368402	Resistant	substitution
A	X	Responsive	ALECTINIB	CID49806720	64924202	A	ALK fusion	ALK	NA	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001902	64924202	Sensitive	splice_region
T	7	Responsive	TRAMETINIB	CID11707110	140453136	A	BRAF:V600E	BRAF	NA	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:1000002	140453136	Sensitive	substitution
NA	17	Responsive	RUCAPARIB	CID9931954	41277500	A	BRCA1 oncogenic mutation	BRCA1	NA	ovarian cancer	reproductive organ cancer	DOID:2394	NA	SO:1000002	41196312	Sensitive	substitution
C	1	Increased Toxicity	2-fluoropyrimidine	CID141643	97981303	A	DPYD biallelic inactivation	DPYD	NA	cancer	cancer	DOID:162	G		97981303	Sensitive	Unknown
G	7	Responsive	AFATINIB	CID10184653	55259515	A	EGFR:L858R	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:1000002	55259515	Sensitive	substitution
A	7	Responsive	GEFITINIB	CID123631	55259524	A	EGFR:L861Q	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:1000002	55259524	Sensitive	substitution
C	7	Responsive	mAb	CHEMBL2109423	55086994	A	EGFR overexpression	EGFR	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	G	SO:0001025	55086994	Sensitive	polymorphic_sequence_variant
G	17	Responsive	mAb	CHEMBL2109423	37883691	A	ERBB2 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
G	17	Responsive	mAb	CHEMBL2109423	37883691	A	ERBB2 overexpression	ERBB2	NA	Stomach;Gastroesophageal junction adenocarcinoma	gastrointestinal system cancer	DOID:10534	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
C	X	Increased Toxicity (Haemolytic Anemia)	DABRAFENIB	CID44462760	153760459	A	G6PD biallelic inactivation	G6PD	NA	cancer	cancer	DOID:162	T		153760459	Sensitive	Unknown
NA	4	Responsive	Imatinib	CID5291	55606881	A	KIT mutation in exon 9,11,13,14 or 17	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	SO:1000002	55524085	Sensitive	substitution
NA	4	Responsive	REGORAFENIB	CID11167602	55606881	A	KIT mutation in exon 9,11,13,14 or 17	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	SO:1000002	55524085	Sensitive	substitution
NA	12	Resistant	mAb	CHEMBL2109423	25403870	A	KRAS oncogenic mutation	KRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	NA	SO:1000002	25357723	Resistant	substitution
NA	15	Responsive	TRETINOIN	CID444795	74340153	A	PML-RARA fusion	PML	NA	acute promyelocytic leukemia	leukemia	DOID:0060318	NA	SO:0001902	74287014	Sensitive	splice_region
C	6	Responsive	CRIZOTINIB	CID11626560	117710940	A	ROS1 fusion	ROS1	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0001902	117710940	Sensitive	splice_region
NA	NA	1	NA	NA	NA	A	NA	JAK1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	XPO1	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	IL7R	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	RAD21	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	WT1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ATM	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PTPN11	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PRPF8	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	TP53	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA	NA	NA	Unknown	Unknown
NA	17	1	NA	NA	74732960	A	SRSF2 codon(s) 95 missense	SRSF2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0001583	74732958	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	ZRSR2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	19	1	NA	NA	13055303	A	CALR exon(s) 9 frameshift	CALR	NA	essential thrombocythemia	bone marrow cancer	DOID:2224	NA	SO:0000865	13054527	Unknown	frameshift
G	7	1	NA	NA	55259515	A	EGFR L858R	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	T	SO:0001583	55259515	Unknown	missense_variant
NA	1	1	NA	NA	115252204	A	NRAS codon(s) 12, 13, 61, 146 any	NRAS	NA	melanoma	cell type cancer	DOID:1909	NA		115252202	Unknown	Unknown
NA	1	1	NA	NA	115252204	A	NRAS codon(s) 12, 13, 61, 146 any	NRAS	NA	follicular thyroid carcinoma	thyroid cancer	DOID:3962	NA		115252202	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	NRAS	NA	follicular thyroid carcinoma	thyroid cancer	DOID:3962	NA	NA	NA	Unknown	Unknown
T	4	1	NA	NA	55152093	A	PDGFRA D842V	PDGFRA	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	A	SO:0001583	55152093	Unknown	missense_variant
NA	1	1	NA	NA	120458436	A	NOTCH2 I2304fs	NOTCH2	NA	Marginal Zone B Cell Lymphoma	B-cell lymphoma morphology	SNOMEDCT:128803008	NA	SO:0000865	120458436	Unknown	frameshift
NA	NA	1	NA	NA	NA	A	NA	MDM2	NA	bladder urachal urothelial carcinoma	urinary bladder cancer	DOID:7244	NA	NA	NA	Unknown	Unknown
NA	7	1	NA	NA	140453140	A	BRAF T599_V600insV	BRAF	NA	papillary carcinoma	carcinoma	DOID:3113	NA	SO:0000667	140453140	Unknown	insertion
NA	NA	1	NA	NA	NA	A	NA	EGFR	NA	bladder urachal urothelial carcinoma	urinary bladder cancer	DOID:7244	NA	NA	NA	Unknown	Unknown
NA	4	1	NA	NA	55592216	A	KIT exon(s) 9 insertion	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	SO:0000667	55592023	Unknown	insertion
NA	9	1	NA	NA	139392010	A	NOTCH1 exon(s) 34 frameshift	NOTCH1	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA	SO:0000865	139388896	Unknown	frameshift
C	4	1	NA	NA	55593610	A	KIT V559A	KIT	NA	melanoma	cell type cancer	DOID:1909	T	SO:0001583	55593610	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	MAP2K1	NA	follicular lymphoma	lymphoma	DOID:0050873	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	BTK	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ABL1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PTCH1	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR3	NA	bladder urachal urothelial carcinoma	urinary bladder cancer	DOID:7244	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ERBB4	NA	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	NA	NA	Unknown	Unknown
NA	15	1	NA	NA	90631839	A	IDH2 codon(s) 172 missense	IDH2	NA	NA	NA	NA	NA	SO:0001583	90631837	Unknown	missense_variant
T	1	resistant	CETUXIMAB	CHEMBL1201577	115252204	A	NRAS A146T 	NRAS	[u'A146T']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	115252204	Resistant	Unknown
None	2	Positive	NA	NA	114036527	A	EXPRESSION	PAX8	EXPRESSION	female reproductive organ cancer	reproductive organ cancer	DOID:120	None		113973574	Sensitive	Unknown
None	19	Better Outcome	NA	NA	13054727	A	EXON 9 FRAMESHIFT	CALR	FRAMESHIFT	myelofibrosis	hematologic cancer	DOID:4971	None	SO:0001791	13054527	Sensitive	exon_variant
T	6	Increased Toxicity (Myelosupression)	Purine	CID1044	18134078	A	TPMT biallelic inactivation	TPMT	NA	cancer	cancer	DOID:162	C		18134078	Sensitive	Unknown
T	6	Increased Toxicity (Myelosupression)	Guanine	CID764	18134078	A	TPMT splice acceptor variant	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18134078	Sensitive	substitution
T	6	Increased Toxicity (Ototoxicity)	Cisplatin	CHEMBL2068237	18134078	A	TPMT splice acceptor variant	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18134078	Sensitive	substitution
NA	9	Responsive	EVEROLIMUS	CID6442177	135820020	A	TSC1 oncogenic mutation	TSC1	NA	kidney angiomyolipoma	urinary system benign neoplasm	DOID:8411	NA	SO:1000002	135766735	Sensitive	substitution
C	11	Positive	NA	NA	118349801	A	MLL-MLLT3	KMT2A	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	G	SO:0001886	118349801	Sensitive	transcript_fusion
G	X	Positive	NA	NA	48117216	A	SS18-SSX1	SSX1	NA	synovial sarcoma	connective tissue cancer	DOID:5485	A	SO:0001886	48117216	Sensitive	transcript_fusion
None	10	Sensitivity	TEMOZOLOMIDE	CID5394	131265656	A	PROMOTER METHYLATION	MGMT	METHYLATION	glioblastoma multiforme	malignant glioma	DOID:3068	None		131264495	Sensitive	Unknown
None	5	Positive	NA	NA	170837569	A	EXON 12 MUTATION	NPM1	MUTATION	acute myeloid leukemia	hematologic cancer	DOID:9119	None	SO:0001791	170837531	Sensitive	exon_variant
None	22	Sensitivity	Imatinib	CID5291	23632600	A	BCR-ABL	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	None	SO:0001886	23522397	Sensitive	transcript_fusion
C	4	Positive	NA	NA	55139713	A	PDGFRA FUSIONS	PDGFRA	FUSIONS	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1	hematologic cancer	DOID:0080164	T	SO:0001886	55139713	Sensitive	transcript_fusion
None	2	Poor Outcome	NA	NA	198299815	A	MUTATION	SF3B1	MUTATION	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	None	SO:0001818	198254508	Resistant	protein_altering_variant
None	9	Poor Outcome	NA	NA	139440314	A	MUTATION	NOTCH1	MUTATION	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	None	SO:0001818	139388896	Resistant	protein_altering_variant
TTATA	4	1	Imatinib	CID5291	55146070	A	FIP1L1-PDGFRA Fusion	PDGFRA	FIP1L1-PDGFRA Fusion	leukemia	immune system cancer	DOID:1240	T		55146069	Unknown	Unknown
G	7	1	TRAMETINIB	CID11707110	140534535	A	V600K	BRAF	V600K	melanoma	cell type cancer	DOID:1909	A	SO:0001583	140534535	Unknown	missense_variant
A	12	R1	CETUXIMAB	CHEMBL1201577	25368402	A	G10dup	KRAS	Oncogenic Mutations	colorectal cancer	intestinal cancer	DOID:9256	C		25368402	Unknown	Unknown
A	9	1	Imatinib	CID5291	133760359	A	BCR-ABL1 Fusion	ABL1	BCR-ABL1 Fusion	Acute Lymphoid Leukemia	NA	MEDDRA:10060555	G		133760359	Unknown	Unknown
A	9	1	Imatinib	CID5291	133760359	A	BCR-ABL1 Fusion	ABL1	BCR-ABL1 Fusion	chronic myeloid leukemia	hematologic cancer	DOID:8552	G		133760359	Unknown	Unknown
NA	4	1	REGORAFENIB	CID11167602	55606881	A	Exon 17 mutations	KIT	Exon 17 mutations	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA		55524085	Unknown	Unknown
A	7	1	GEFITINIB	CID123631	55241707	A	G719S	EGFR	G719S	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55241707	Unknown	missense_variant
G	7	1	GEFITINIB	CID123631	55270347	A	L747P	EGFR	L747P	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	55270347	Unknown	missense_variant
C	7	1	GEFITINIB	CID123631	55086994	A	Exon 19 insertion	EGFR	Exon 19 insertion	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001821	55086994	Unknown	inframe_insertion
-	7	MET c.2887+49_2945delTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411960	A	MET c.2887+49_2945delTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAG	MET	[u'c.2887+49_2945delTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAG']	lung adenocarcinoma	lung cancer	DOID:3910	TCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAG	SO:0000188	116411757	Sensitive	intron
TA	12	KRAS G13Y confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
T	7	BRAF V600E confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	140453136	A	BRAF V600E	BRAF	[u'V600E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	A	SO:0001583	140453136	Resistant	missense_variant
T	7	BRAF V600E confers sensitivity to Vemurafenib in patients with MM - Malignant melanoma of skin	VEMURAFENIB	CID42611257	140453136	A	BRAF V600E	BRAF	[u'V600E']	skin melanoma	integumentary system cancer	DOID:8923	A	SO:0001583	140453136	Sensitive	missense_variant
AT	12	KRAS G13I confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13I	KRAS	[u'G13I']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
TA	12	KRAS G12Y confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
T	6	CD74-ROS1 L2026M confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	117638365	A	CD74-ROS1 L2026M	ROS1	[u'L2026M']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117638365	Sensitive	fusion
G	7	MET c.3028+3A>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3028+3A>G	MET	[u'c.3028+3A>G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001627	116412046	Sensitive	intron_variant
TA	12	KRAS G12Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	MET c.2888-42_2888-2delATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411901	A	MET c.2888-42_2888-2delATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA	MET	[u'c.2888-42_2888-2delATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA']	lung adenocarcinoma	lung cancer	DOID:3910	ATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA	SO:0000188	116411861	Sensitive	intron
CAAC	7	EGFR E746_A750>QP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242478	A	EGFR E746_A750>QP	EGFR	[u'E746_A750delinsQP']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAG	SO:0000159	55242466	Sensitive	deletion
NA	7	PDCD1 and Wild-Type BRAF confers sensitivity to nivolumab in patients with MM - Malignant melanoma of skin	NIVOLUMAB	CHEMBL2108738	140624564	A	Wild-Type	BRAF	[]	skin melanoma	integumentary system cancer	DOID:8923	NA	NA	140419127	Sensitive	Unknown
	12	KRAS Q61 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380277	A	KRAS Q61	KRAS	[u'61Q']	lung adenocarcinoma	lung cancer	DOID:3910			25380275	Resistant	Unknown
C	7	EGFR G719A confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55241708	A	EGFR G719A	EGFR	[u'G719A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241708	Sensitive	missense_variant
GTGGCC	7	EGFR N771>SGH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR N771>SGH	EGFR	[u'N771delinsSGH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
A	7	MET c.3028+1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3028+1G>A	MET	[u'c.3028+1G>A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001627	116412044	Sensitive	intron_variant
TT	12	KRAS G12N confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12N	KRAS	[u'G12N']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
AT	12	KRAS G12I confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12I	KRAS	[u'G12I']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
AT	12	KRAS G13D confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13D	KRAS	[u'G13D']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GC		25398280	Resistant	Unknown
GCACCGTGG	7	EGFR D770_N771insAPW confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insAPW	EGFR	[u'D770_N771insAPW']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
AT	12	KRAS G13I confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13I	KRAS	[u'G13I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
G	2	ALK V1180L confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	29443679	A	ALK V1180L	ALK	[u'V1180L']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	29443679	Sensitive	missense_variant
G	12	KRAS Q61P confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
A	17	ERBB2 S310Y confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37868208	A	ERBB2 S310Y	ERBB2	[u'S310Y']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	37868208	Sensitive	missense_variant
CCACGTG	7	EGFR V774_C775insHV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249024	A	EGFR V774_C775insHV	EGFR	[u'V774_C775insHV', u'V774_C775insHV']	lung adenocarcinoma	lung cancer	DOID:3910	G		55249024	Resistant	Unknown
AA	12	KRAS G13F confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13F	KRAS	[u'G13F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS Q61L confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
AG	12	KRAS G12L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12L	KRAS	[u'G12L']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
NA	4		PRALIDOXIME MESYLATE	CID53405145	55606881	A	KIT	KIT	[]	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	NA	55524085	Unknown	Unknown
TGGCCAGCG	7	EGFR A767_V769dup confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55248999	A	EGFR A767_V769dup	EGFR	[u'A767_V769']	lung adenocarcinoma	lung cancer	DOID:3910	-		55248998	Resistant	Unknown
-	7	MET c.3022_3028+13delCCAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412056	A	MET c.3022_3028+13delCCAGAAGGTATATTTCAGTT	MET	[u'c.3022_3028+13delCCAGAAGGTATATTTCAGTT']	lung adenocarcinoma	lung cancer	DOID:3910	CCAGAAGGTATATTTCAGTT	SO:0000188	116412037	Sensitive	intron
-	7	MET c.2888-15_2900delTCTCTCTGTTTTAAGATCTGGGCAGTGA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411915	A	MET c.2888-15_2900delTCTCTCTGTTTTAAGATCTGGGCAGTGA	MET	[u'c.2888-15_2900delTCTCTCTGTTTTAAGATCTGGGCAGTGA']	lung adenocarcinoma	lung cancer	DOID:3910	TCTCTCTGTTTTAAGATCTGGGCAGTGA	SO:0000188	116411888	Sensitive	intron
-	12	KRAS G12fs*3 confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0000159	25398284	Resistant	deletion
NA	17	ERBB2 Amplification confers sensitivity to Docetaxel anhydrous, Trastuzumab and Pertuzumab in patients with Neoplasm of breast	PERTUZUMAB	CHEMBL2007641	37886679	A	ERBB2 Amplification	ERBB2	[]	breast cancer	thoracic cancer	DOID:1612	NA	SO:0001889	37844167	Sensitive	transcript_amplification
AA	12	KRAS G12F confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12F	KRAS	[u'G12F']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
A	12	KRAS G12V confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398284	A	KRAS G12V	KRAS	[u'G12V']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
T	12	KRAS G13S confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13S	KRAS	[u'G13S']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
G	12	KRAS G13A confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398281	A	KRAS G13A	KRAS	[u'G13A']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G13V confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398281	A	KRAS G13V	KRAS	[u'G13V']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398281	Resistant	missense_variant
C	12	KRAS G13G confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398280	A	KRAS G13G	KRAS	[u'G13G']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001815	25398280	Resistant	synonymous
G	12	KRAS Q61H confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001815	25380275	Resistant	synonymous
C	12	KRAS G13G confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398280	A	KRAS G13G	KRAS	[u'G13G']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001815	25398280	Resistant	synonymous
T	12	KRAS G12S confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12S	KRAS	[u'G12S']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398285	Resistant	synonymous
T	12	KRAS G12G confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398283	A	KRAS G12G	KRAS	[u'G12G']	breast cancer	thoracic cancer	DOID:1612	A	SO:0001815	25398283	Resistant	synonymous
T	12	KRAS G13S confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13S	KRAS	[u'G13S']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
A	12	KRAS G13C confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13C	KRAS	[u'G13C']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
T	12	KRAS G12S confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12S	KRAS	[u'G12S']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398285	Resistant	synonymous
AG	12	KRAS G12L confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12L	KRAS	[u'G12L']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS Q61H confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001815	25380275	Resistant	synonymous
GTAACCCTCATG	7	EGFR H773_V774insGNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249023	A	EGFR H773_V774insGNPH	EGFR	[u'H773_V774insGNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
-	7	EGFR L747_E749delLRE confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242477	A	EGFR L747_E749delLRE	EGFR	[u'L747_E749del', u'L747_E749del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAA	SO:0000159	55242469	Sensitive	deletion
-	7	MET c.2888-23_2891delTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411906	A	MET c.2888-23_2891delTCTTTCTTTCTCTCTGTTTTAAGATCT	MET	[u'c.2888-23_2891delTCTTTCTTTCTCTCTGTTTTAAGATCT']	lung adenocarcinoma	lung cancer	DOID:3910	TCTTTCTTTCTCTCTGTTTTAAGATCT	SO:0000188	116411880	Sensitive	intron
AA	12	KRAS G12F confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12F	KRAS	[u'G12F']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS G12A confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12A	KRAS	[u'G12A']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
-	7	MET c.2888-30_2888-5delAACAAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411898	A	MET c.2888-30_2888-5delAACAAGCTCTTTCTTTCTCTCTGTTT	MET	[u'c.2888-30_2888-5delAACAAGCTCTTTCTTTCTCTCTGTTT']	lung adenocarcinoma	lung cancer	DOID:3910	AACAAGCTCTTTCTTTCTCTCTGTTT	SO:0000188	116411873	Sensitive	intron
GT	12	KRAS G12T confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12T	KRAS	[u'G12T']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
T	17	ERBB2 V777L confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37881000	A	ERBB2 V777L	ERBB2	[u'V777L']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37881000	Sensitive	missense_variant
C	7	EGFR L747S confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242470	A	EGFR L747S	EGFR	[u'L747S']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55242470	Sensitive	missense_variant
G	12	KRAS G12A confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398284	A	KRAS G12A	KRAS	[u'G12A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
TT	12	KRAS G12N confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12N	KRAS	[u'G12N']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
	12	KRAS Q61 confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380277	A	KRAS Q61	KRAS	[u'61Q']	lung adenocarcinoma	lung cancer	DOID:3910			25380275	Resistant	Unknown
CA	7	MET c.2888-3_2888-2insAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-3_2888-2insAC	MET	[u'c.2888-3_2888-2insAC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411901	Sensitive	intron
AG	12	KRAS G12L confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12L	KRAS	[u'G12L']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
T	7	EGFR G339* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55224234	A	EGFR G339*	EGFR	[u'G339*']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001587	55224234	Sensitive	stop_gained
TT	7	BRAF V600K confers sensitivity to Trametinib in patients with Metastasis from malignant melanoma of skin	TRAMETINIB	CID11707110	140453137	A	BRAF V600K	BRAF	[u'V600K']	skin melanoma	integumentary system cancer	DOID:8923	AC	SO:0001583	140453136	Sensitive	missense_variant
GTAGACAAC	7	EGFR N771_P772insVDN confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249016	A	EGFR N771_P772insVDN	EGFR	[u'V769_N771dupVDN']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249015	Resistant	Unknown
GCACCGTGG	7	EGFR D770_N771insAPW confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insAPW	EGFR	[u'D770_N771insAPW']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
AG	12	KRAS G12L confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12L	KRAS	[u'G12L']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
A	12	KRAS G12V confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12V	KRAS	[u'G12V']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
-	7	MET c.3020_3028+2delTTCCAGAAGGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412045	A	MET c.3020_3028+2delTTCCAGAAGGT	MET	[u'c.3020_3028+2delTTCCAGAAGGT']	lung adenocarcinoma	lung cancer	DOID:3910	TTCCAGAAGGT	SO:0000188	116412035	Sensitive	intron
-	7	EGFR T751_E758del confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242503	A	EGFR T751_E758del	EGFR	[u'T751_E758delTSPKANKE']	lung adenocarcinoma	lung cancer	DOID:3910	AACATCTCCGAAAGCCAACAAGGA	SO:0000159	55242480	Sensitive	deletion
CCACGTG	7	EGFR V774_C775insHV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249024	A	EGFR V774_C775insHV	EGFR	[u'V774_C775insHV', u'V774_C775insHV']	lung adenocarcinoma	lung cancer	DOID:3910	G		55249024	Resistant	Unknown
A	12	KRAS Q61L confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
T	7	EGFR Q276* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55221782	A	EGFR Q276*	EGFR	[u'Q276*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55221782	Sensitive	stop_gained
CAC	7	EGFR E746_A750delinsAP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242478	A	EGFR E746_A750delinsAP	EGFR	[u'E746_A750delinsAP']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAG	SO:0000159	55242467	Sensitive	deletion
TAA	7	MET D1010* confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116414936	A	MET D1010*	MET	[u'D1010*']	lung adenocarcinoma	lung cancer	DOID:3910	GAT	SO:0001587	116412043	Sensitive	stop_gained
CCA	12	KRAS G12W confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12W	KRAS	[u'G12W']	lung adenocarcinoma	lung cancer	DOID:3910	ACC	SO:0001583	25398283	Resistant	missense_variant
CT	12	KRAS G12E confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12E	KRAS	[u'G12E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	AC	SO:0001583	25398283	Resistant	missense_variant
-	7	MET c.2888-5_2907delTTAAGATCTGGGCAGTGAATTAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411922	A	MET c.2888-5_2907delTTAAGATCTGGGCAGTGAATTAGTT	MET	[u'c.2888-5_2907delTTAAGATCTGGGCAGTGAATTAGTT']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGATCTGGGCAGTGAATTAGTT	SO:0000188	116411898	Sensitive	intron
C	17	ERBB2 G309A confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37868205	A	ERBB2 G309A	ERBB2	[u'G309A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37868205	Sensitive	missense_variant
-	7	EGFR L747_E749delLRE confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55242477	A	EGFR L747_E749delLRE	EGFR	[u'L747_E749del', u'L747_E749del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAA	SO:0000159	55242469	Sensitive	deletion
C	7	EGFR L747S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55242470	A	EGFR L747S	EGFR	[u'L747S']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55242470	Sensitive	missense_variant
A	12	KRAS Q61L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
TT	12	KRAS G13E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G13E	KRAS	[u'G13E']	lung adenocarcinoma	lung cancer	DOID:3910	GC	SO:0001583	25398280	Resistant	missense_variant
AACCAC	7	EGFR H773_V774insNH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249022	A	EGFR H773_V774insNH	EGFR	[u'H773_V774insNH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
G	3	TFG-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	100432637	A	TFG-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	100432637	Sensitive	fusion
A	7	EGFR C311* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55223566	A	EGFR C311*	EGFR	[u'C311*']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001587	55223566	Sensitive	stop_gained
-	7	MET c.3025_3028+11delGAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412054	A	MET c.3025_3028+11delGAAGGTATATTTCAG	MET	[u'c.3025_3028+11delGAAGGTATATTTCAG']	lung adenocarcinoma	lung cancer	DOID:3910	GAAGGTATATTTCAG	SO:0000188	116412040	Sensitive	intron
TTC	7	EGFR E746_T751delinsVP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242481	A	EGFR E746_T751delinsVP	EGFR	[u'E746_T751delinsVP']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAA	SO:0000159	55242467	Sensitive	deletion
A	12	KRAS G13V confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G13V	KRAS	[u'G13V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
AACCCTCAT	7	EGFR H773_V774insNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249022	A	EGFR H773_V774insNPH	EGFR	[u'N771_H773dupNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
	12	KRAS Q61 confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380277	A	KRAS Q61	KRAS	[u'61Q']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984			25380275	Resistant	Unknown
NA	2	PDCD1 confers sensitivity to Pembrolizumab in patients with MM - Malignant melanoma of skin	PEMBROLIZUMAB	CHEMBL3137343	242801060	A	PDCD1	PDCD1	[]	skin melanoma	integumentary system cancer	DOID:8923	NA	NA	242792033	Sensitive	Unknown
GCGTAGACA	7	EGFR D770_N771insSVD confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR D770_N771insSVD	EGFR	[u'S768_D770dupSVD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
TGCGTG	7	EGFR V769_D770insCV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249010	A	EGFR V769_D770insCV	EGFR	[u'V769_D770insCV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249009	Resistant	Unknown
GGGGAC	7	EGFR D770_N771insGD confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insGD	EGFR	[u'D770_N771insGD', u'D770_N771insGD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
NA	4	KIT confers sensitivity to Sunitinib malate in patients with Gastrointestinal stromal tumor	NAFOMINE MALATE	CID31748	55606881	A	KIT	KIT	[]	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	NA	55524085	Sensitive	Unknown
GG	12	KRAS G13P confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13P	KRAS	[u'G13P']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
TCCGTGATGGCT	17	ERBB2 A745_G746insSVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880997	A	ERBB2 A745_G746insSVMA	ERBB2	[u'A745_G746insSVMA']	lung adenocarcinoma	lung cancer	DOID:3910	-		37880996	Sensitive	Unknown
	12	KRAS G12 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12	KRAS	[u'12G']	lung adenocarcinoma	lung cancer	DOID:3910			25398283	Resistant	Unknown
-	7	EGFR L747_T751del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55242484	A	EGFR L747_T751del	EGFR	[u'L747_T751del', u'L747_T751del']	lung adenocarcinoma	lung cancer	DOID:3910	TAAGAGAAGCAACAT	SO:0000159	55242470	Sensitive	deletion
TGCACC	12	KRAS G12_G13insAG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398281	Resistant	Unknown
GACACACCC	7	EGFR P772_H773insTHP confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249018	A	EGFR P772_H773insTHP	EGFR	[u'P772_H773insTHP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249017	Resistant	Unknown
AACCCCCCG	7	EGFR P772_H773insPNP confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249012	A	EGFR P772_H773insPNP	EGFR	[u'P772_H773insPNP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
AG	12	KRAS G12L confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12L	KRAS	[u'G12L']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
T	2	EML4-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	42396763	A	EML4-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000806	42396763	Sensitive	fusion
CAT	12	KRAS G13M confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13M	KRAS	[u'G13M']	lung adenocarcinoma	lung cancer	DOID:3910	GCC	SO:0001583	25398280	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
-	7	MET c.2888-23_2889delTCTTTCTTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411904	A	MET c.2888-23_2889delTCTTTCTTTCTCTCTGTTTTAAGAT	MET	[u'c.2888-23_2889delTCTTTCTTTCTCTCTGTTTTAAGAT']	lung adenocarcinoma	lung cancer	DOID:3910	TCTTTCTTTCTCTCTGTTTTAAGAT	SO:0000188	116411880	Sensitive	intron
GGT	7	EGFR D770_N771insG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insG	EGFR	[u'D770_N771insG', u'D770_N771insG']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
TGCGTG	7	EGFR V769_D770insCV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249010	A	EGFR V769_D770insCV	EGFR	[u'V769_D770insCV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249009	Resistant	Unknown
T	2	ALK I1171N confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	29445213	A	ALK I1171N	ALK	[u'I1171N']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	29445213	Sensitive	missense_variant
T	2	EML4-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	42396763	A	EML4-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000806	42396763	Sensitive	fusion
-	7	MET c.3027_3028+3delAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3027_3028+3delAGGTA	MET	[u'c.3027_3028+3delAGGTA']	lung adenocarcinoma	lung cancer	DOID:3910	AGGTA	SO:0000188	116412042	Sensitive	intron
CCACGTG	7	EGFR V774_C775insHV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249024	A	EGFR V774_C775insHV	EGFR	[u'V774_C775insHV', u'V774_C775insHV']	lung adenocarcinoma	lung cancer	DOID:3910	G		55249024	Resistant	Unknown
TT	12	KRAS G13N confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13N	KRAS	[u'G13N']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
TGT	12	KRAS G13_V14>DI confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	lung adenocarcinoma	lung cancer	DOID:3910	ACA		25398279	Resistant	Unknown
G	2	ALK G1128A confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	29445450	A	ALK G1128A	ALK	[u'G1128A']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	29445450	Sensitive	missense_variant
G	12	KRAS G12R confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12R	KRAS	[u'G12R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398285	Resistant	missense_variant
GAGGGGTGA	7	EGFR V769_D770insERG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249012	A	EGFR V769_D770insERG	EGFR	[u'V769_D770insERG']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249011	Resistant	Unknown
A	7	EGFR G719D confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55241708	A	EGFR G719D	EGFR	[u'G719D']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241708	Sensitive	missense_variant
CAG	7	EGFR H773_V774insQ confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249022	A	EGFR H773_V774insQ	EGFR	[u'H773_V774insQ']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
A	12	KRAS G12C confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12C	KRAS	[u'G12C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
AT	12	KRAS G13I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13I	KRAS	[u'G13I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
GCCATA	7	EGFR A767_S768insIA confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249001	A	EGFR A767_S768insIA	EGFR	[u'A767_S768insIA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249000	Resistant	Unknown
-	7	MET c.3026_3028+11delAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412054	A	MET c.3026_3028+11delAAGGTATATTTCAG	MET	[u'c.3026_3028+11delAAGGTATATTTCAG']	lung adenocarcinoma	lung cancer	DOID:3910	AAGGTATATTTCAG	SO:0000188	116412041	Sensitive	intron
-	7	MET c.2888-24_2888-1delCTCTTTCTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-24_2888-1delCTCTTTCTTTCTCTCTGTTTTAAG	MET	[u'c.2888-24_2888-1delCTCTTTCTTTCTCTCTGTTTTAAG']	lung adenocarcinoma	lung cancer	DOID:3910	CTCTTTCTTTCTCTCTGTTTTAAG	SO:0000188	116411879	Sensitive	intron
AACAAC	7	EGFR N771_P772insN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249015	A	EGFR N771_P772insN	EGFR	[u'N771dupN']	lung adenocarcinoma	lung cancer	DOID:3910	AAC		55249013	Resistant	Unknown
T	12	KRAS G13S confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13S	KRAS	[u'G13S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
CCACGT	7	EGFR V774_C775insPR confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249025	A	EGFR V774_C775insPR	EGFR	[u'V774_C775insPR']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249024	Resistant	Unknown
CAT	7	EGFR H773_V774insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249022	A	EGFR H773_V774insH	EGFR	[u'H773dupH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
C	17	ERBB2 D769H confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880261	A	ERBB2 D769H	ERBB2	[u'D769H']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37880261	Sensitive	missense_variant
-	7	MET c.2900_2887+35delCCTTAAGAACACAGTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411915	A	MET c.2900_2887+35delCCTTAAGAACACAGTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGA	MET	[u'c.2900_2887+35delCCTTAAGAACACAGTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGA']	lung adenocarcinoma	lung cancer	DOID:3910	CCTTAAGAACACAGTCATTACAGTTTAAGATTGTCGTCGATTCTTGTGTGCTGTCTTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGA	SO:0000188	116411743	Sensitive	intron
T	12	KRAS G12S confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12S	KRAS	[u'G12S']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398285	Resistant	synonymous
G	12	KRAS Q61H confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	25380275	Resistant	synonymous
T	12	KRAS G13S confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13S	KRAS	[u'G13S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
G	7	EGFR L861R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55259524	A	EGFR L861R	EGFR	[u'L861R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
-	7	MET c.2888-30_2898delAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411913	A	MET c.2888-30_2898delAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT	MET	[u'c.2888-30_2898delAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT']	lung adenocarcinoma	lung cancer	DOID:3910	AACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT	SO:0000188	116411873	Sensitive	intron
GGTATATTTT	7	MET c.3021_3028+9delTCCAGAAGGTATATTTCinsGGTATATTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412052	A	MET c.3021_3028+9delTCCAGAAGGTATATTTCinsGGTATATTTT	MET	[u'c.3021_3028+9delTCCAGAAGGTATATTTCinsGGTATATTTT']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116412036	Sensitive	intron
CAAGCGTAG	7	EGFR V769_D770insASV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249011	A	EGFR V769_D770insASV	EGFR	[u'A767_V769dupASV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
GGT	7	EGFR D770_N771insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insG	EGFR	[u'D770_N771insG', u'D770_N771insG']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	MET c.2888-22_2911delCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411926	A	MET c.2888-22_2911delCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT	MET	[u'c.2888-22_2911delCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT']	lung adenocarcinoma	lung cancer	DOID:3910	CTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT	SO:0000188	116411881	Sensitive	intron
T	7	EGFR S768I confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249005	A	EGFR S768I	EGFR	[u'S768I']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55249005	Sensitive	missense_variant
GGGGAC	7	EGFR D770_N771insGD confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insGD	EGFR	[u'D770_N771insGD', u'D770_N771insGD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
C	12	KRAS G13G confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398280	A	KRAS G13G	KRAS	[u'G13G']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	25398280	Resistant	synonymous
GTT	7	EGFR D770>GY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249011	A	EGFR D770>GY	EGFR	[u'D770delinsGY']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
AT	12	KRAS G13D confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13D	KRAS	[u'G13D']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GC		25398280	Resistant	Unknown
-	7	MET c.2888-69_3028+530delCTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412573	A	MET c.2888-69_3028+530delCTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAG	MET	[u'c.2888-69_3028+530delCTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAG']	lung adenocarcinoma	lung cancer	DOID:3910	CTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAG		116411834	Sensitive	Unknown
G	12	KRAS G13A confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G13A	KRAS	[u'G13A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
T	17	ERBB2 R896C confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37881616	A	ERBB2 R896C	ERBB2	[u'R896C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	37881616	Sensitive	missense_variant
GCGTAGAGA	7	EGFR D770_N771insSVE confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR D770_N771insSVE	EGFR	[u'D770_N771insSVE']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
A	12	KRAS G13C confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13C	KRAS	[u'G13C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
-	7	MET c.3004_3028+3delGACTACCGAGCTACTTTTCCAGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3004_3028+3delGACTACCGAGCTACTTTTCCAGAAGGTA	MET	[u'c.3004_3028+3delGACTACCGAGCTACTTTTCCAGAAGGTA']	lung adenocarcinoma	lung cancer	DOID:3910	GACTACCGAGCTACTTTTCCAGAAGGTA	SO:0000188	116412019	Sensitive	intron
T	12	KRAS G12G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398283	A	KRAS G12G	KRAS	[u'G12G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001815	25398283	Resistant	synonymous
CCA	12	KRAS G12W confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12W	KRAS	[u'G12W']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	ACC	SO:0001583	25398283	Resistant	missense_variant
TAC	7	EGFR D770_N771insY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insY	EGFR	[u'D770_N771insY', u'D770_N771insY']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
C	12	KRAS Q61E confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
A	12	KRAS G13 confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25368462	A	KRAS G13	KRAS	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		25368462	Resistant	Unknown
	12	KRAS G12 confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12	KRAS	[u'12G']	lung adenocarcinoma	lung cancer	DOID:3910			25398283	Resistant	Unknown
C	12	KRAS Q61E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
T	7	EGFR T790M confers sensitivity to Afatinib and Cetuximab in patients with Neoplasm of lung	CETUXIMAB	CHEMBL1201577	55249071	A	EGFR T790M	EGFR	[u'T790M']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	55249071	Sensitive	missense_variant
A	6	GOPC-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	117642448	A	GOPC-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117642448	Sensitive	fusion
G	7	EGFR L858R confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55259515	A	EGFR L858R	EGFR	[u'L858R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	55259515	Sensitive	synonymous
NA	NA	1	NA	NA	NA	A	NA	NRAS	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	RIT1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CBLB	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	GATA2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	5	1	NA	NA	170837548	A	NPM1 codon(s) 288 frameshift	NPM1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0000865	170837546	Unknown	frameshift
NA	NA	1	NA	NA	NA	A	NA	SMC3	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ETV6	NA	acute T cell leukemia	leukemia	DOID:5603	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CTCF	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	RUNX1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CRLF2	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	BCOR	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	SMC1A	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	STAG2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	BCORL1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PHF6	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	1	1	NA	NA	1747229	A	GNB1 codon(s) 57 missense	GNB1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0001583	1747227	Unknown	missense_variant
A	7	1	NA	NA	140453136	A	BRAF V600E	BRAF	NA	melanoma	cell type cancer	DOID:1909	T	SO:0001583	140453136	Unknown	missense_variant
NA	7	1	NA	NA	55259525	A	EGFR codon(s) 861 any	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA		55259523	Unknown	Unknown
A	7	1	NA	NA	55241677	A	EGFR E709K	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	G	SO:0001583	55241677	Unknown	missense_variant
NA	12	1	NA	NA	25378562	A	KRAS codon(s) 12, 13, 61, 117, 146 any	KRAS	NA	adenocarcinoma	carcinoma	DOID:299	NA		25378560	Unknown	Unknown
NA	1	1	NA	NA	115252204	A	NRAS codon(s) 12, 13, 61, 146 any	NRAS	NA	adenocarcinoma	carcinoma	DOID:299	NA		115252202	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FLCN	NA	renal cell carcinoma	kidney cancer	DOID:4450	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	AR	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
G	23	1	NA	NA	66943552	A	AR T878A	AR	NA	adenocarcinoma	carcinoma	DOID:299	A	SO:0001583	66943552	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	BRAF	NA	follicular thyroid carcinoma	thyroid cancer	DOID:3962	NA	NA	NA	Unknown	Unknown
NA	7	1	NA	NA	55241681	A	EGFR E709_T710delinsD	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	SO:0000159	55241679	Unknown	deletion
CC	7	1	NA	NA	55242470	A	EGFR L747P	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	TT	SO:0001583	55242469	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	PIK3CA	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	MAP2K2	NA	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	MAP2K1	NA	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	KRAS	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	GNAQ	NA	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR2	NA	glioblastoma classical subtype	astrocytoma	DOID:0050803	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR2	NA	bladder urachal urothelial carcinoma	urinary bladder cancer	DOID:7244	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR1	NA	squamous cell carcinoma	carcinoma	DOID:1749	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	BRCA2	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDK4	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	MET	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
T	7	1	NA	NA	55249005	A	EGFR S768I	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	G	SO:0001583	55249005	Unknown	missense_variant
C	4	1	NA	NA	55594258	A	KIT V654A	KIT	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:0001583	55594258	Unknown	missense_variant
G	7	1	NA	NA	55259524	A	EGFR L861R	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	T	SO:0001583	55259524	Unknown	missense_variant
G	2	not applicable	NA	NA	198257186	A	SF3B1  mutant	SF3B1	[u'']	myelodysplastic syndrome	hematologic cancer	DOID:0050908	C	SO:1000002	198257186	Unknown	substitution
G	1	resistant	PANITUMUMAB	CHEMBL1201827	115251171	A	NRAS G13X 	NRAS	[u'G13X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
G	1	resistant	PANITUMUMAB	CHEMBL1201827	115251171	A	NRAS G12X 	NRAS	[u'G12X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
T	7	predicted – resistant	CETUXIMAB	CHEMBL1201577	140453136	A	BRAF V600E 	BRAF	[u'V600E']	colorectal cancer	intestinal cancer	DOID:9256	A	NA	140453136	Resistant	Unknown
T	7	sensitive	DABRAFENIB	CID44462760	140453136	A	BRAF V600E 	BRAF	[u'V600E']	melanoma	cell type cancer	DOID:1909	A	NA	140453136	Sensitive	Unknown
T	7	sensitive	DABRAFENIB	CID44462760	140453136	A	BRAF V600E 	BRAF	[u'V600E']	melanoma	cell type cancer	DOID:1909	A	NA	140453136	Sensitive	Unknown
C	13	sensitive	OLAPARIB	CID23725625	32893443	A	BRCA2  mutant	BRCA2	[u'']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:1000002	32893443	Sensitive	substitution
G	6	sensitive	Imatinib	CID5291	49425518	A	KIT  act mut	KIT	[u'']	melanoma	cell type cancer	DOID:1909	A	SO:0002053	49425518	Sensitive	gain_of_function_variant
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25368402	A	KRAS G13X 	KRAS	[u'G13X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
G	17	sensitive	NERATINIB	CID9915743	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
G	2	sensitive	AP26113	CID57390074	29484957	A	ALK  positive	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0000475	29484957	Sensitive	positively_autoregulated
NA	7	sensitive	AFATINIB	CID10184653	55324313	A	EGFR E746_A750del 	EGFR	[u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	NA	55086714	Sensitive	Unknown
NA	7	sensitive	Erlotinib	CID176870	55324313	A	EGFR E746_A750del 	EGFR	[u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	NA	55086714	Sensitive	Unknown
G	7	sensitive	Erlotinib	CID176870	55259515	A	EGFR L858R 	EGFR	[u'L858R']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	NA	55259515	Sensitive	Unknown
C	12	resistant	CETUXIMAB	CHEMBL1201577	25380282	A	KRAS A59G 	KRAS	[u'A59G']	colorectal cancer	intestinal cancer	DOID:9256	G	NA	25380282	Resistant	Unknown
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25378562	A	KRAS A146T 	KRAS	[u'A146T']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25378562	Resistant	Unknown
A	12	resistant	CETUXIMAB	CHEMBL1201577	25368402	A	KRAS Q61X 	KRAS	[u'Q61X']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:0001587	25368402	Resistant	stop_gained
G	7	sensitive	DABRAFENIB	CID44462760	140534535	A	BRAF V600X 	BRAF	[u'V600X']	melanoma	cell type cancer	DOID:1909	A	SO:0001587	140534535	Sensitive	stop_gained
G	7	sensitive	VEMURAFENIB	CID42611257	140534535	A	BRAF V600X 	BRAF	[u'V600X']	melanoma	cell type cancer	DOID:1909	A	SO:0001587	140534535	Sensitive	stop_gained
G	7	sensitive	DABRAFENIB	CID44462760	140534535	A	BRAF V600X 	BRAF	[u'V600X']	melanoma	cell type cancer	DOID:1909	A	SO:0001587	140534535	Sensitive	stop_gained
None	1	Resistance or Non-Response	CETUXIMAB	CHEMBL1201577	115259515	A	MUTATION	NRAS	MUTATION	colorectal cancer	intestinal cancer	DOID:9256	None	SO:0002053	115247090	Resistant	gain_of_function_variant
C	4	Negative	NA	NA	55139713	A	PDGFRA FUSIONS	PDGFRA	FUSIONS	chronic myelomonocytic leukemia	hematologic cancer	DOID:0080188	T	SO:0001886	55139713	Unknown	transcript_fusion
A	9	Resistant	NILOTINIB	CID644241	133738363	A	ABL1:E255K	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	G	SO:1000002	133738363	Resistant	substitution
A	9	Resistant	Imatinib	CID5291	133729545	A	ABL1:I242T	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133729545	Resistant	substitution
NA	9	Responsive	BOSUTINIB MONOHYDRATE	CID5328940	133763062	A	ABL1-BCR fusion	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	SO:0001902	133589333	Sensitive	splice_region
NA	9	Responsive	Imatinib	CID5291	133763062	A	ABL1-BCR fusion	ABL1	NA	Chronic myeloid leukemia;Acute lymphoblastic leukemia	hematologic cancer	DOID:8552	NA	SO:0001902	133589333	Sensitive	splice_region
NA	9	Responsive	NILOTINIB	CID644241	133763062	A	ABL1-BCR fusion	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	SO:0001902	133589333	Sensitive	splice_region
T	2	Responsive	CERITINIB	CID57379345	29443631	A	ALK:L1196M	ALK	NA	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:1000002	29443631	Sensitive	substitution
A	X	Responsive	CERITINIB	CID57379345	64924202	A	ALK fusion	ALK	NA	Non-small cell lung;Lung adenocarcinoma	lung cancer	DOID:3908	G	SO:0001902	64924202	Sensitive	splice_region
A	X	Responsive	ALECTINIB	CID49806720	64924202	A	ALK fusion	ALK	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001902	64924202	Sensitive	splice_region
T	7	Responsive	DABRAFENIB	CID44462760	140453136	A	BRAF:V600E	BRAF	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:1000002	140453136	Sensitive	substitution
T	7	Responsive	VEMURAFENIB	CID42611257	140453136	A	BRAF:V600E	BRAF	NA	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	lung cancer	DOID:3908	A	SO:1000002	140453136	Sensitive	substitution
T	7	Responsive	TRAMETINIB	CID11707110	140453136	A	BRAF:V600E	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	A	SO:1000002	140453136	Sensitive	substitution
NA	13	Responsive	OLAPARIB	CID23725625	32973805	A	BRCA2 oncogenic mutation	BRCA2	NA	ovarian cancer	reproductive organ cancer	DOID:2394	NA	SO:1000002	32889611	Sensitive	substitution
C	1	Increased Toxicity	TEGAFUR	CID5386	97981303	A	DPYD splice donor variant	DPYD	NA	cancer	cancer	DOID:162	G	SO:1000002	97981303	Sensitive	substitution
C	1	Increased Toxicity	CAPECITABINE	CID60953	97981343	A	DPYD:I560S	DPYD	NA	cancer	cancer	DOID:162	A	SO:1000002	97981343	Sensitive	substitution
NA	7	Responsive	Erlotinib	CID176870	55324313	A	EGFR exon 19 deletions	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	SO:1000002	55086714	Sensitive	substitution
G	7	Responsive	GEFITINIB	CID123631	55259515	A	EGFR:L858R	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:1000002	55259515	Sensitive	substitution
NA	17	Responsive	mAb	CHEMBL2109423	37886679	A	ERBB2 amplification	ERBB2	NA	Stomach;Gastroesophageal junction adenocarcinoma	gastrointestinal system cancer	DOID:10534	NA	SO:0001880	37844167	Sensitive	feature_amplification
G	17	Responsive	Lapatinib	CID208908	37883691	A	ERBB2 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
T	6	Increased Toxicity (Ototoxicity)	Cisplatin	CHEMBL2068237	18134078	A	TPMT biallelic inactivation	TPMT	NA	cancer	cancer	DOID:162	C		18134078	Sensitive	Unknown
T	6	Increased Toxicity (Myelosupression)	Purine	CID1044	18134078	A	TPMT splice acceptor variant	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18134078	Sensitive	substitution
G	6	Increased Toxicity (Myelosupression)	Guanine	CID764	18143955	A	TPMT:A80P	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18143955	Sensitive	substitution
NA	9	Responsive	EVEROLIMUS	CID6442177	135820020	A	TSC1 oncogenic mutation	TSC1	NA	Giant cell astrocytoma	NA	MEDDRA:10073233	NA	SO:1000002	135766735	Sensitive	substitution
NA	4	Responsive	Imatinib	CID5291	55606881	A	KIT mutation in exon 9,11,13,14 or 17	KIT	NA	skin melanoma	integumentary system cancer	DOID:8923	NA	SO:1000002	55524085	Sensitive	substitution
NA	12	Resistant	mAb	CHEMBL2109423	25403870	A	KRAS oncogenic mutation	KRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	NA	SO:1000002	25357723	Resistant	substitution
NA	22	Responsive	Imatinib	CID5291	39640756	A	PDGFB-COL1A1 fusion	PDGFB	NA	Dermatofibrosarcoma	NA	MEDDRA:10057043	NA	SO:0001902	39619364	Sensitive	splice_region
C	4	Responsive	Imatinib	CID5291	55133777	A	PDGFRA (552-596,631-668,814-854)	PDGFRA	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:1000002	55133777	Sensitive	substitution
NA	4	Responsive	Imatinib	CID5291	55164414	A	PDGFRA inframe deletion (I843)	PDGFRA	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	SO:1000002	55095264	Sensitive	substitution
NA	15	Responsive	Arsenic	CID23969	74340153	A	PML-RARA fusion	PML	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0001902	74287014	Sensitive	splice_region
None	22	Sensitivity	Imatinib	CID5291	23632600	A	BCR-ABL	ABL1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	None	SO:0001886	23522397	Sensitive	transcript_fusion
None	22	Positive	NA	NA	23632600	A	BCR-ABL	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	None	SO:0001886	23522397	Sensitive	transcript_fusion
None	13	Sensitivity	OLAPARIB	CID23725625	32973347	A	MUTATION	BRCA2	MUTATION	cancer	cancer	DOID:162	None	SO:0001564	32889611	Sensitive	gene_variant
C	9	Positive	NA	NA	5089742	A	PCM1-JAK2	JAK2	NA	hematologic cancer	immune system cancer	DOID:2531	T	SO:0001886	5089742	Sensitive	transcript_fusion
C	12	Positive	NA	NA	57911196	A	FUS-DDIT3	DDIT3	NA	myxoid liposarcoma	connective tissue cancer	DOID:5363	A	SO:0001565	57911196	Sensitive	gene_fusion
T	1	Adverse Response	CAPECITABINE	CID60953	97915614	A	DPYD*2A HOMOZYGOSITY	DPYD	HOMOZYGOSITY	cancer	cancer	DOID:162	C	SO:0001575	97915614	Resistant	splice_donor_variant
A	1	Adverse Response	CAPECITABINE	CID60953	97547947	A	RS67376798 HOMOZYGOSITY	DPYD	HOMOZYGOSITY	cancer	cancer	DOID:162	T	SO:0001025	97547947	Resistant	polymorphic_sequence_variant
None	8	Positive	NA	NA	38325363	A	FGFR1 FUSIONS	FGFR1	FUSIONS	hematologic cancer	immune system cancer	DOID:2531	None	SO:0001886	38268656	Sensitive	transcript_fusion
T	5	Positive	NA	NA	149499573	A	PDGFRB FUSIONS	PDGFRB	FUSIONS	hematologic cancer	immune system cancer	DOID:2531	A	SO:0001886	149499573	Sensitive	transcript_fusion
G	2	1	CERITINIB	CID57379345	29484957	A	Fusions	ALK	Fusions	non-small cell lung carcinoma	lung cancer	DOID:3908	C		29484957	Unknown	Unknown
C	4	1	Imatinib	CID5291	55139713	A	Fusions	PDGFRA	Fusions	myeloproliferative neoplasm	hematologic cancer	DOID:2226	T		55139713	Unknown	Unknown
C	7	1	GEFITINIB	CID123631	55086994	A	E709_T710delinsD	EGFR	E709_T710delinsD	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001822	55086994	Unknown	inframe_deletion
C	7	1	GEFITINIB	CID123631	55242478	A	A750P	EGFR	A750P	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55242478	Unknown	missense_variant
T	7	1	OSIMERTINIB	CID71496458	55249071	A	T790M	EGFR	T790M	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	55249071	Unknown	missense_variant
A	7	1	GEFITINIB	CID123631	55259524	A	L861Q	EGFR	L861Q	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:0001583	55259524	Unknown	missense_variant
NA	NA	1	NIVOLUMAB	CHEMBL2108738	NA	A	Microsatellite Instability-High	NA	Microsatellite Instability-High	colorectal cancer	intestinal cancer	DOID:9256	NA		NA	Unknown	Unknown
G	7	1	TRAMETINIB	CID11707110	140534535	A	V600R	BRAF	V600R	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	140534535	Unknown	missense_variant
C	7	1	TRAMETINIB	CID11707110	140453136	A	V600G	BRAF	V600G	melanoma	cell type cancer	DOID:1909	A	SO:0001583	140453136	Unknown	missense_variant
GGGGAC	7	EGFR D770_N771insGD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insGD	EGFR	[u'D770_N771insGD', u'D770_N771insGD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
AA	12	KRAS G13F confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13F	KRAS	[u'G13F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
TT	12	KRAS G13E confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13E	KRAS	[u'G13E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GC	SO:0001583	25398280	Resistant	missense_variant
TAC	7	EGFR D770_N771insY confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insY	EGFR	[u'D770_N771insY', u'D770_N771insY']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
AT	12	KRAS G12I confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12I	KRAS	[u'G12I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS Q61P confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
A	7	MET c.2888-1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-1G>A	MET	[u'c.2888-1G>A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001627	116411902	Sensitive	intron_variant
	12	KRAS Q61 confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380277	A	KRAS Q61	KRAS	[u'61Q']	lung adenocarcinoma	lung cancer	DOID:3910			25380275	Resistant	Unknown
-	7	MET c.2888-22_2888-3delCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-22_2888-3delCTTTCTTTCTCTCTGTTTTA	MET	[u'c.2888-22_2888-3delCTTTCTTTCTCTCTGTTTTA']	lung adenocarcinoma	lung cancer	DOID:3910	CTTTCTTTCTCTCTGTTTTA	SO:0000188	116411881	Sensitive	intron
A	12	KRAS G13C confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13C	KRAS	[u'G13C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
GT	12	KRAS G12T confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12T	KRAS	[u'G12T']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
G	3	TFG-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	100432637	A	TFG-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	100432637	Sensitive	fusion
GCAGCGTGG	7	EGFR V769_D770insGSV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249011	A	EGFR V769_D770insGSV	EGFR	[u'V769_D770insGSV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
T	7	BRAF V600E confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	140453136	A	BRAF V600E	BRAF	[u'V600E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	A	SO:0001583	140453136	Resistant	missense_variant
TGCACC	12	KRAS G12_G13insAG confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398281	Resistant	Unknown
CT	12	KRAS G12E confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398284	A	KRAS G12E	KRAS	[u'G12E']	lung adenocarcinoma	lung cancer	DOID:3910	AC	SO:0001583	25398283	Resistant	missense_variant
T	2	ALK L1196M confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29443631	A	ALK L1196M	ALK	[u'L1196M']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	29443631	Sensitive	missense_variant
TTT	17	ERBB2 G746delinsVC confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880998	A	ERBB2 G746delinsVC	ERBB2	[u'G746_746delinsVC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000667	37880997	Sensitive	insertion
NA	7	MET Amplification confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	116438440	A	MET Amplification	MET	[]	lung adenocarcinoma	lung cancer	DOID:3910	NA	SO:0001889	116312444	Resistant	transcript_amplification
-	7	MET c.2888-9_2908delTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411923	A	MET c.2888-9_2908delTGTTTTAAGATCTGGGCAGTGAATTAGTTC	MET	[u'c.2888-9_2908delTGTTTTAAGATCTGGGCAGTGAATTAGTTC']	lung adenocarcinoma	lung cancer	DOID:3910	TGTTTTAAGATCTGGGCAGTGAATTAGTTC	SO:0000188	116411894	Sensitive	intron
T	12	KRAS Q61K confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	G	SO:0001583	25380277	Resistant	missense_variant
A	7	EGFR H773>PNPY confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55259501	A	EGFR H773>PNPY	EGFR	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		55259501	Resistant	Unknown
-	7	EGFR L747_S752del confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55242486	A	EGFR L747_S752del	EGFR	[u'L747_S752del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAAGCAACATCT	SO:0000159	55242469	Sensitive	deletion
AACCCCT	7	EGFR P772_H773insTP confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249018	A	EGFR P772_H773insTP	EGFR	[u'P772_H773insTP']	lung adenocarcinoma	lung cancer	DOID:3910	C		55249018	Resistant	Unknown
A	12	KRAS G12V confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398284	A	KRAS G12V	KRAS	[u'G12V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
NA	2	CTLA4 confers sensitivity to Ipilimumab in patients with MM - Malignant melanoma of skin	IPILIMUMAB	CHEMBL1789844	204738683	A	CTLA4	CTLA4	[]	skin melanoma	integumentary system cancer	DOID:8923	NA	NA	204732509	Sensitive	Unknown
-	7	MET c.3022_3028+14delCCAGAAGGTATATTTCAGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412057	A	MET c.3022_3028+14delCCAGAAGGTATATTTCAGTTT	MET	[u'c.3022_3028+14delCCAGAAGGTATATTTCAGTTT']	lung adenocarcinoma	lung cancer	DOID:3910	CCAGAAGGTATATTTCAGTTT	SO:0000188	116412037	Sensitive	intron
C	7	MET c.3028+2T>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412045	A	MET c.3028+2T>C	MET	[u'c.3028+2T>C']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001627	116412045	Sensitive	intron_variant
GGCACA	7	EGFR D770_N771insGT confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insGT	EGFR	[u'D770_N771insGT']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	EGFR E746_A750del confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242480	A	EGFR E746_A750del	EGFR	[u'E746_A750del', u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCA	SO:0000159	55242466	Sensitive	deletion
AG	12	KRAS G12L confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12L	KRAS	[u'G12L']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
AGGTAGCGT	7	EGFR A767_S768insSVG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249009	A	EGFR A767_S768insSVG	EGFR	[u'V769_D770insGSV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249008	Resistant	Unknown
GT	12	KRAS G12T confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12T	KRAS	[u'G12T']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
AA	12	KRAS G12F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12F	KRAS	[u'G12F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	EGFR E746delE confers sensitivity to Gefitinib in patients with Non-small cell lung cancer	GEFITINIB	CID123631	55242466	A	EGFR E746delE	EGFR	[u'E746del']	non-small cell lung carcinoma	lung cancer	DOID:3908	AGG	SO:0000159	55242464	Sensitive	deletion
TT	12	KRAS G12N confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12N	KRAS	[u'G12N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
TT	12	KRAS G13E confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G13E	KRAS	[u'G13E']	lung adenocarcinoma	lung cancer	DOID:3910	GC	SO:0001583	25398280	Resistant	missense_variant
C	12	KRAS Q61R confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
T	12	KRAS G12S confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12S	KRAS	[u'G12S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
ACC	12	KRAS G13_V14insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398279	Resistant	Unknown
C	7	EGFR L861P confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55259524	A	EGFR L861P	EGFR	[u'L861P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
CC	7	MET c.2888-52_2927delGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411942	A	MET c.2888-52_2927delGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACAinsCC	MET	[u'c.2888-52_2927delGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACAinsCC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411851	Sensitive	intron
T	2	ALK G1123S confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29445466	A	ALK G1123S	ALK	[u'G1123S']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	29445466	Sensitive	missense_variant
A	2	ALK L1198F confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	29443625	A	ALK L1198F	ALK	[u'L1198F']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	29443625	Sensitive	missense_variant
T	14	AKT1 E17K confers sensitivity to Everolimus in patients with Neoplasm of breast	EVEROLIMUS	CID6442177	105246551	A	AKT1 E17K	AKT1	[u'E17K']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	105246551	Sensitive	missense_variant
NA	NA	ERBB2 Loss and ER/PR positive confers sensitivity to Fulvestrant and Pd-0332991	FULVESTRANT	CID104741	NA	A	ER/PR positive	ERBB2	[]	breast cancer	thoracic cancer	DOID:1612	NA	SO:0001019	NA	Sensitive	copy_number_variation
G	12	KRAS G13R confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13R	KRAS	[u'G13R']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
TT	12	KRAS G13E confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398281	A	KRAS G13E	KRAS	[u'G13E']	breast cancer	thoracic cancer	DOID:1612	GC	SO:0001583	25398280	Resistant	missense_variant
TA	12	KRAS G13Y confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G13V confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398281	A	KRAS G13V	KRAS	[u'G13V']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398281	Resistant	missense_variant
C	12	KRAS Q61R confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
AG	12	KRAS G12L confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12L	KRAS	[u'G12L']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS G13R confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13R	KRAS	[u'G13R']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398282	Resistant	missense_variant
AT	12	KRAS G13D confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398281	A	KRAS G13D	KRAS	[u'G13D']	breast cancer	thoracic cancer	DOID:1612	GC		25398280	Resistant	Unknown
C	12	KRAS G13G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398280	A	KRAS G13G	KRAS	[u'G13G']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	25398280	Resistant	synonymous
C	2	ALK I1171S confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	29445213	A	ALK I1171S	ALK	[u'I1171S']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	29445213	Sensitive	missense_variant
G	12	LRIG3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	59280599	A	LRIG3-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	59280599	Sensitive	fusion
NNN	7	EGFR P772_H773insX confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249016	A	EGFR P772_H773insX	EGFR	[u'P772_H773insX']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249015	Resistant	Unknown
GGGTTA	7	EGFR D770_N771insGL confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insGL	EGFR	[u'D770_N771insGL']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
T	7	BRAF V600E confers sensitivity to Trametinib in patients with Metastasis from malignant melanoma of skin	TRAMETINIB	CID11707110	140453136	A	BRAF V600E	BRAF	[u'V600E']	skin melanoma	integumentary system cancer	DOID:8923	A	SO:0001583	140453136	Sensitive	missense_variant
T	12	KRAS G13S confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13S	KRAS	[u'G13S']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
G	7	EGFR L858R confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	55259515	A	EGFR L858R	EGFR	[u'L858R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001815	55259515	Sensitive	synonymous
A	12	KRAS G13V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G13V	KRAS	[u'G13V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
AT	12	KRAS G13I confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13I	KRAS	[u'G13I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
GGCACA	7	EGFR D770_N771insGT confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insGT	EGFR	[u'D770_N771insGT']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
TA	12	KRAS G12Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	MET c.2888-20_2899delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411914	A	MET c.2888-20_2899delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG	MET	[u'c.2888-20_2899delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG	SO:0000188	116411883	Sensitive	intron
	12	KRAS G12 confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12	KRAS	[u'12G']	lung adenocarcinoma	lung cancer	DOID:3910			25398283	Resistant	Unknown
T	12	KRAS G12D confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12D	KRAS	[u'G12D']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
CAT	12	KRAS G13M confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13M	KRAS	[u'G13M']	lung adenocarcinoma	lung cancer	DOID:3910	GCC	SO:0001583	25398280	Resistant	missense_variant
NA	4	EGF confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	110933422	A	EGF	EGF	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	110834040	Sensitive	Unknown
A	17	ERBB2 V842I confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37881332	A	ERBB2 V842I	ERBB2	[u'V842I']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37881332	Sensitive	missense_variant
-	7	EGFR L747_T751del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55242484	A	EGFR L747_T751del	EGFR	[u'L747_T751del', u'L747_T751del']	lung adenocarcinoma	lung cancer	DOID:3910	TAAGAGAAGCAACAT	SO:0000159	55242470	Sensitive	deletion
T	6	EZR-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	159191857	A	EZR-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000806	159191857	Sensitive	fusion
-	7	EGFR T751_E758del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55242503	A	EGFR T751_E758del	EGFR	[u'T751_E758delTSPKANKE']	lung adenocarcinoma	lung cancer	DOID:3910	AACATCTCCGAAAGCCAACAAGGA	SO:0000159	55242480	Sensitive	deletion
T	7	EGFR R255* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55221719	A	EGFR R255*	EGFR	[u'R255*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55221719	Sensitive	stop_gained
T	12	KRAS G12G confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398283	A	KRAS G12G	KRAS	[u'G12G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001815	25398283	Resistant	synonymous
G	12	KRAS G12R confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12R	KRAS	[u'G12R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398285	Resistant	missense_variant
CCCACG	7	EGFR H773_V774insAH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249023	A	EGFR H773_V774insAH	EGFR	[u'H773_V774insAH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
T	12	KRAS G12G confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398283	A	KRAS G12G	KRAS	[u'G12G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001815	25398283	Resistant	synonymous
TA	12	KRAS G13Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
CCACCA	12	KRAS G12_G13insG confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	CCA		25398280	Resistant	Unknown
G	12	KRAS G12R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12R	KRAS	[u'G12R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398285	Resistant	missense_variant
TA	2	UGT1A1*37 and UGT1A1 UGT1A1*28 confers an unfavorable response to Irinotecan hydrochloride in patients with Neoplasm of colorectum	Irinotecan	CID60838	234668882	A	UGT1A1 UGT1A1*28	UGT1A1	[u'', u'UGT1A1*28']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-	SO:0000289	234668881	Unknown	microsatellite
G	12	KRAS G13R confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13R	KRAS	[u'G13R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
CCA	12	KRAS G12W confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12W	KRAS	[u'G12W']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	ACC	SO:0001583	25398283	Resistant	missense_variant
T	12	KRAS G13S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13S	KRAS	[u'G13S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
T	12	KRAS G12S confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12S	KRAS	[u'G12S']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398285	Resistant	synonymous
-	12	KRAS G12fs*3 confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000159	25398284	Resistant	deletion
NA	12	KRAS confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25403870	A	KRAS	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	25357723	Resistant	Unknown
ACC	12	KRAS G13_V14insG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398279	Resistant	Unknown
G	12	KRAS G12R confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12R	KRAS	[u'G12R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398285	Resistant	missense_variant
A	12	KRAS G13C confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13C	KRAS	[u'G13C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
GGGTTT	7	EGFR D770_N771insGF confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insGF	EGFR	[u'D770_N771insGF']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
C	12	KRAS Q61E confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
ATCTCG	7	EGFR E746_P753>IS confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242489	A	EGFR E746_P753>IS	EGFR	[u'E746_P753delinsIS']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCAACATCTCCG	SO:0000159	55242466	Sensitive	deletion
G	12	KRAS G13R confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13R	KRAS	[u'G13R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
CAG	7	EGFR H773_V774insQ confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249022	A	EGFR H773_V774insQ	EGFR	[u'H773_V774insQ']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
G	3	TFG-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	100432637	A	TFG-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	100432637	Sensitive	fusion
NA	12	KRAS confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25403870	A	KRAS	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	25357723	Resistant	Unknown
AT	12	KRAS G13D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G13D	KRAS	[u'G13D']	lung adenocarcinoma	lung cancer	DOID:3910	GC		25398280	Resistant	Unknown
TGCACC	12	KRAS G12_G13insAG confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398281	Resistant	Unknown
NA	1	Wild-Type NRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	115259515	A	Wild-Type	NRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	115247090	Sensitive	Unknown
TCCCT	7	EGFR E746_A750>VP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242480	A	EGFR E746_A750>VP	EGFR	[u'E746_A750delinsVP']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCA	SO:0000159	55242467	Sensitive	deletion
A	7	EGFR W200* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55219026	A	EGFR W200*	EGFR	[u'W200*']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001587	55219026	Sensitive	stop_gained
CAT	7	EGFR H773_V774insH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249022	A	EGFR H773_V774insH	EGFR	[u'H773dupH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
CCACCA	12	KRAS G12_G13insG confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	CCA		25398280	Resistant	Unknown
TT	12	KRAS G13N confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13N	KRAS	[u'G13N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G13 confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25368462	A	KRAS G13	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C		25368462	Resistant	Unknown
TT	12	KRAS G13N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13N	KRAS	[u'G13N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
GCATACGTGATG	17	ERBB2 E770_A771insGIRD confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880983	A	ERBB2 E770_A771insGIRD	ERBB2	[u'E770_A771insGIRD']	lung adenocarcinoma	lung cancer	DOID:3910	-		37880982	Sensitive	Unknown
G	7	EGFR L858R confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55259515	A	EGFR L858R	EGFR	[u'L858R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	55259515	Sensitive	synonymous
CCCCCACGT	7	EGFR V774_C775insPHV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249014	A	EGFR V774_C775insPHV	EGFR	[u'P772_V774dupPHV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249014	Resistant	Unknown
TA	12	KRAS G12Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
TTGT	17	ERBB2 G776>LC confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880997	A	ERBB2 G776>LC	ERBB2	[u'G776delinsLC', u'G776delinsLC', u'G776delinsLC']	lung adenocarcinoma	lung cancer	DOID:3910	G		37880997	Sensitive	Unknown
NA	7	EGFR confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	55324313	A	EGFR	EGFR	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	55086714	Sensitive	Unknown
G	2	ALK G1269A confers sensitivity to Ceritinib in patients with Non-small cell lung cancer	CERITINIB	CID57379345	29432682	A	ALK G1269A	ALK	[u'G1269A']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	29432682	Sensitive	missense_variant
C	10	RET M918T confers sensitivity to Vandetanib in patients with Medullary thyroid carcinoma	VANDETANIB	CID3081361	43617416	A	RET M918T	RET	[u'M918T']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	T	SO:0001583	43617416	Sensitive	missense_variant
G	2	ALK I1171T confers sensitivity to Ceritinib in patients with Non-small cell lung cancer	CERITINIB	CID57379345	29445213	A	ALK I1171T	ALK	[u'I1171T']	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	29445213	Sensitive	missense_variant
-	7	MET c.3028_3028+5delGGTATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412048	A	MET c.3028_3028+5delGGTATA	MET	[u'c.3028_3028+5delGGTATA']	lung adenocarcinoma	lung cancer	DOID:3910	GGTATA	SO:0000188	116412043	Sensitive	intron
C	2	ALK L1152R confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29445270	A	ALK L1152R	ALK	[u'L1152R']	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	29445270	Sensitive	missense_variant
-	12	KRAS G12fs*3 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000159	25398284	Resistant	deletion
G	12	KRAS G12A confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398284	A	KRAS G12A	KRAS	[u'G12A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	MET c.3024_3028+13delAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412056	A	MET c.3024_3028+13delAGAAGGTATATTTCAGTT	MET	[u'c.3024_3028+13delAGAAGGTATATTTCAGTT']	lung adenocarcinoma	lung cancer	DOID:3910	AGAAGGTATATTTCAGTT	SO:0000188	116412039	Sensitive	intron
GG	12	KRAS G13P confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13P	KRAS	[u'G13P']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS G13A confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13A	KRAS	[u'G13A']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398281	Resistant	missense_variant
-	7	EGFR L747_E749delLRE confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55242477	A	EGFR L747_E749delLRE	EGFR	[u'L747_E749del', u'L747_E749del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAA	SO:0000159	55242469	Sensitive	deletion
C	7	EGFR L861P confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55259524	A	EGFR L861P	EGFR	[u'L861P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
CAAGCGTAG	7	EGFR V769_D770insASV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249011	A	EGFR V769_D770insASV	EGFR	[u'A767_V769dupASV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
CGC	12	KRAS G12_G13insA confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398282	Resistant	Unknown
T	6	EZR-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	159191857	A	EZR-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000806	159191857	Sensitive	fusion
TGTGGG	17	ERBB2 V777_G778insCG confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37881003	A	ERBB2 V777_G778insCG	ERBB2	[u'V777_G778insCG']	lung adenocarcinoma	lung cancer	DOID:3910	-		37881002	Sensitive	Unknown
-	7	EGFR E746delE confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242466	A	EGFR E746delE	EGFR	[u'E746del']	non-small cell lung carcinoma	lung cancer	DOID:3908	AGG	SO:0000159	55242464	Sensitive	deletion
GTAACCCTCATG	7	EGFR H773_V774insGNPH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249023	A	EGFR H773_V774insGNPH	EGFR	[u'H773_V774insGNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
-	7	MET c.3028+1_3028+2delGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412045	A	MET c.3028+1_3028+2delGT	MET	[u'c.3028+1_3028+2delGT']	lung adenocarcinoma	lung cancer	DOID:3910	GT	SO:0000188	116412044	Sensitive	intron
G	10	KIF5B-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	32310205	A	KIF5B-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	32310205	Sensitive	fusion
-	7	EGFR E746_S752delinsA confers sensitivity to Erlotinib hydrochloride in patients with Non-small cell lung cancer	Erlotinib	CID176870	55242484	A	EGFR E746_S752delinsA	EGFR	[u'E746_S752delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACAT	SO:0000159	55242467	Sensitive	deletion
GGGTTT	7	EGFR D770_N771insGF confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insGF	EGFR	[u'D770_N771insGF']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
T	2	ALK C1156Y confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	29445258	A	ALK C1156Y	ALK	[u'C1156Y']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	29445258	Sensitive	missense_variant
TGT	12	KRAS G13_V14>DI confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	ACA		25398279	Resistant	Unknown
TATGTAATGGCA	17	ERBB2 A775_G776insYVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880997	A	ERBB2 A775_G776insYVMA	ERBB2	[u'Y772_A775dupYVMA']	lung adenocarcinoma	lung cancer	DOID:3910	-		37880996	Sensitive	Unknown
G	2	ALK G1269A confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	29432682	A	ALK G1269A	ALK	[u'G1269A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	29432682	Sensitive	missense_variant
T	7	EGFR G719C confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55241707	A	EGFR G719C	EGFR	[u'G719C']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241707	Sensitive	missense_variant
CT	12	KRAS G12E confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12E	KRAS	[u'G12E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	AC	SO:0001583	25398283	Resistant	missense_variant
GTCATG	7	EGFR H773_V774insGH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249023	A	EGFR H773_V774insGH	EGFR	[u'H773_V774insGH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
A	12	KRAS G13V confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G13V	KRAS	[u'G13V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G13C confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13C	KRAS	[u'G13C']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
-	7	MET c.2888-14_2905delCTCTCTGTTTTAAGATCTGGGCAGTGAATTAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411920	A	MET c.2888-14_2905delCTCTCTGTTTTAAGATCTGGGCAGTGAATTAG	MET	[u'c.2888-14_2905delCTCTCTGTTTTAAGATCTGGGCAGTGAATTAG']	lung adenocarcinoma	lung cancer	DOID:3910	CTCTCTGTTTTAAGATCTGGGCAGTGAATTAG	SO:0000188	116411889	Sensitive	intron
CCTCAT	7	EGFR H773_V774insPH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249022	A	EGFR H773_V774insPH	EGFR	[u'P772_H773dupPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
C	14	KLC1-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	104153420	A	KLC1-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	104153420	Sensitive	fusion
T	10	CCDC6-RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	CABOZANTINIB	CID25102847	61666033	A	CCDC6-RET	RET	[]	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	61666033	Sensitive	fusion
TTAAAACTG	7	MET c.2888-33_2888-7delTTTAACAAGCTCTTTCTTTCTCTCTGTinsTTAAAACTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411896	A	MET c.2888-33_2888-7delTTTAACAAGCTCTTTCTTTCTCTCTGTinsTTAAAACTG	MET	[u'c.2888-33_2888-7delTTTAACAAGCTCTTTCTTTCTCTCTGTinsTTAAAACTG']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411870	Sensitive	intron
CGC	12	KRAS G12_G13insA confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398282	Resistant	Unknown
TA	12	KRAS G12Y confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
AATTAAGA	7	EGFR E746fs*15 confers sensitivity to Erlotinib hydrochloride in patients with Non-small cell lung cancer	Erlotinib	CID176870	55242482	A	EGFR E746fs*15	EGFR	[u'E746Nfs*15']	non-small cell lung carcinoma	lung cancer	DOID:3908	TATCAAGGAATTAAGAGAAGCAAC		55242459	Sensitive	Unknown
-	7	MET c.2888-14_2888-3delCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-14_2888-3delCTCTCTGTTTTA	MET	[u'c.2888-14_2888-3delCTCTCTGTTTTA']	lung adenocarcinoma	lung cancer	DOID:3910	CTCTCTGTTTTA	SO:0000188	116411889	Sensitive	intron
NA	NA	sensitive	DABRAFENIB	CID44462760	NA	A	BRAF V600E/K 	BRAF	[u'V600E/K']	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Sensitive	Unknown
NA	NA	sensitive	DABRAFENIB	CID44462760	NA	A	BRAF V600E/K 	BRAF	[u'V600E/K']	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Sensitive	Unknown
G	2	sensitive	CRIZOTINIB	CID11626560	29484957	A	ALK  rearrange	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0000138	29484957	Sensitive	gene_rearranged_at_DNA_level
G	7	sensitive	AFATINIB	CID10184653	55259515	A	EGFR L858R 	EGFR	[u'L858R']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	NA	55259515	Sensitive	Unknown
G	7	sensitive	GEFITINIB	CID123631	55259515	A	EGFR L858R 	EGFR	[u'L858R']	non-small cell lung carcinoma	lung cancer	DOID:3908	T	NA	55259515	Sensitive	Unknown
G	17	sensitive	TRASTUZUMAB	CHEMBL1201585	37883691	A	ERBB2  amp	ERBB2	[u'']	gastric adenocarcinoma	stomach cancer	DOID:3717	C	SO:0001880	37883691	Sensitive	feature_amplification
G	17	sensitive	TRASTUZUMAB	CHEMBL1201585	37883691	A	ERBB2  amp	ERBB2	[u'']	gastroesophageal junction adenocarcinoma	gastrointestinal system cancer	DOID:4944	C	SO:0001880	37883691	Sensitive	feature_amplification
G	17	sensitive	LETROZOLE	CID3902	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12D 	KRAS	[u'G12D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398284	Resistant	Unknown
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25378561	A	KRAS A146V 	KRAS	[u'A146V']	colorectal cancer	intestinal cancer	DOID:9256	G	NA	25378561	Resistant	Unknown
G	12	resistant	PANITUMUMAB	CHEMBL1201827	25378647	A	KRAS K117N 	KRAS	[u'K117N']	colorectal cancer	intestinal cancer	DOID:9256	T	NA	25378647	Resistant	Unknown
C	12	resistant	PANITUMUMAB	CHEMBL1201827	25380282	A	KRAS A59G 	KRAS	[u'A59G']	colorectal cancer	intestinal cancer	DOID:9256	G	NA	25380282	Resistant	Unknown
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25368402	A	KRAS  mutant	KRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:1000002	25368402	Resistant	substitution
A	17	sensitive	OLAPARIB	CID23725625	41245877	A	BRCA1  mutant	BRCA1	[u'']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:1000002	41245877	Sensitive	substitution
T	7	sensitive	VEMURAFENIB	CID42611257	140453136	A	BRAF V600E 	BRAF	[u'V600E']	melanoma	cell type cancer	DOID:1909	A	NA	140453136	Sensitive	Unknown
A	12	Resistant	mAb	CHEMBL2109423	25368402	A	KRAS (12,13)	KRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	C	SO:1000002	25368402	Resistant	substitution
A	12	Resistant	mAb	CHEMBL2109423	25368402	A	KRAS (12,13,59,61,117,146)	KRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	C	SO:1000002	25368402	Resistant	substitution
C	11	Responsive	Daunorubicin	CID30323	118356490	A	MLL fusion	NA	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	T	SO:0001902	118356490	Sensitive	splice_region
C	3	Responsive	IBRUTINIB	CID24821094	38182641	A	MYD88:L265P	MYD88	NA	Waldenström macroglobulinemia	NA	ORDO:Orphanet_33226	T	SO:1000002	38182641	Sensitive	substitution
TTATA	4	Responsive	Imatinib	CID5291	55146070	A	PDGFRA fusion	PDGFRA	NA	Myelodisplasic syndrome;Myelodisplasic proliferative syndrome	Nephrotic syndrome	SNOMEDCT:197589005	T	SO:0001902	55146069	Sensitive	splice_region
NA	9	Responsive	VISMODEGIB	CID24776445	98279339	A	PTCH1 oncogenic mutation	PTCH1	NA	Basal cell carcinoma;Medulloblastoma	skin cancer	DOID:2513	NA	SO:1000002	98205262	Sensitive	substitution
C	10	Responsive	VANDETANIB	CID3081361	43615639	A	RET (618,620,634,768,791,891,918,C634W,M918T)	RET	NA	thyroid carcinoma	endocrine gland cancer	DOID:3963	G	SO:1000002	43615639	Sensitive	substitution
G	9	Responsive	DASATINIB	CID3062316	133748414	A	ABL1:F359V	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	T	SO:1000002	133748414	Sensitive	substitution
A	9	Responsive	NILOTINIB	CID644241	133748257	A	ABL1:T315A	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748257	Sensitive	substitution
T	9	Responsive	PONATINIB	CID24826799	133748283	A	ABL1:T315I	ABL1	NA	Chronic myeloid leukemia;Acute lymphoblastic leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748283	Sensitive	substitution
NA	9	Responsive	DASATINIB	CID3062316	133763062	A	ABL1-BCR fusion	ABL1	NA	Chronic myeloid leukemia;Acute lymphoblastic leukemia	hematologic cancer	DOID:8552	NA	SO:0001902	133589333	Sensitive	splice_region
T	7	Responsive	VEMURAFENIB	CID42611257	140453136	A	BRAF:V600E	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	A	SO:1000002	140453136	Sensitive	substitution
NA	2	Responsive	Daunorubicin	CID30323	25565459	A	DNMT3A oncogenic mutation	DNMT3A	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:1000002	25455845	Sensitive	substitution
C	1	Increased Toxicity	TEGAFUR	CID5386	97981303	A	DPYD biallelic inactivation	DPYD	NA	cancer	cancer	DOID:162	G		97981303	Sensitive	Unknown
C	1	Increased Toxicity	2-fluoropyrimidine	CID141643	97981343	A	DPYD:I560S	DPYD	NA	cancer	cancer	DOID:162	A	SO:1000002	97981343	Sensitive	substitution
C	1	Increased Toxicity	TEGAFUR	CID5386	97981343	A	DPYD:I560S	DPYD	NA	cancer	cancer	DOID:162	A	SO:1000002	97981343	Sensitive	substitution
NA	7	Responsive	AFATINIB	CID10184653	55324313	A	EGFR exon 19 deletions	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	SO:1000002	55086714	Sensitive	substitution
T	7	Responsive	Erlotinib	CID176870	55229310	A	EGFR (L858R,L861,G719,S768I)	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:1000002	55229310	Sensitive	substitution
A	7	Responsive	AFATINIB	CID10184653	55259524	A	EGFR:L861Q	EGFR	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	T	SO:1000002	55259524	Sensitive	substitution
NA	17	Responsive	mAb	CHEMBL2109423	37886679	A	ERBB2 amplification	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	NA	SO:0001880	37844167	Sensitive	feature_amplification
NA	17	Responsive	Lapatinib	CID208908	37886679	A	ERBB2 amplification	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	NA	SO:0001880	37844167	Sensitive	feature_amplification
G	17	Responsive	EVEROLIMUS	CID6442177	37883691	A	ERBB2 expression + ESR1 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
G	17	Responsive	FULVESTRANT	CID104741	37883691	A	ERBB2 expression + ESR1 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
G	17	Responsive	mAb	CHEMBL2109423	37883691	A	ERBB2 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
A	23	Increased Toxicity (Haemolytic Anemia)	DABRAFENIB	CID44462760	153762634	A	G6PD:S218F	G6PD	NA	cancer	cancer	DOID:162	G	SO:1000002	153762634	Sensitive	substitution
None	12	N/A	NA	NA	25403737	A	MUTATION	KRAS	MUTATION	non-small cell lung carcinoma	lung cancer	DOID:3908	None	SO:0001818	25362365	Unknown	protein_altering_variant
None	12	Resistance or Non-Response	CETUXIMAB	CHEMBL1201577	25398329	A	EXON 2 MUTATION	KRAS	MUTATION	colorectal cancer	intestinal cancer	DOID:9256	None	SO:0001583	25398208	Resistant	missense_variant
None	8	Negative	NA	NA	38325363	A	FGFR1 FUSIONS	FGFR1	FUSIONS	chronic myelomonocytic leukemia	hematologic cancer	DOID:0080188	None	SO:0001886	38268656	Unknown	transcript_fusion
None	2	Poor Outcome	NA	NA	16087129	A	AMPLIFICATION	MYCN	AMPLIFICATION	neuroblastoma	peripheral nervous system neoplasm	DOID:769	None	SO:0001889	16080686	Resistant	transcript_amplification
T	5	Sensitivity	Imatinib	CID5291	149499573	A	PDGFRB FUSIONS	PDGFRB	FUSIONS	myeloproliferative neoplasm	hematologic cancer	DOID:2226	A	SO:0001886	149499573	Sensitive	transcript_fusion
None	17	Poor Outcome	NA	NA	7590856	A	MUTATION	TP53	MUTATION	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	None	SO:0001818	7571720	Resistant	protein_altering_variant
G	6	Increased Toxicity (Myelosupression)	Purine	CID1044	18143955	A	TPMT:A80P	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18143955	Sensitive	substitution
G	6	Increased Toxicity (Ototoxicity)	Cisplatin	CHEMBL2068237	18143955	A	TPMT:A80P	TPMT	NA	cancer	cancer	DOID:162	C	SO:1000002	18143955	Sensitive	substitution
T	2	Increased Toxicity (Hyperbilirubinemia)	PAZOPANIB	CID10113978	234669686	A	UGT1A1 biallelic inactivation	UGT1A1	NA	cancer	cancer	DOID:162	A		234669686	Sensitive	Unknown
NA	NA	1	NA	NA	NA	A	NA	DNMT3A	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CXCR4	NA	lymphoplasmacytic lymphoma	lymphoma	DOID:0050747	NA	NA	NA	Unknown	Unknown
NA	2	1	NA	NA	209113113	A	IDH1 codon(s) 132 any	IDH1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA		209113111	Unknown	Unknown
NA	3	1	NA	NA	178952086	A	PIK3CA codon(s) 542, 545, 1047 any	PIK3CA	NA	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	NA		178952084	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	IKZF1	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	EZH2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	PAX5	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	NT5C2	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	15	1	NA	NA	90631839	A	IDH2 codon(s) 140, 172 any	IDH2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA		90631837	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CREBBP	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	STAT3	NA	NK Cell Lymphoproliferative Disorder	NA	EVS:Thesaurus.owl#C39591	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	JAK3	NA	NK Cell Lymphoproliferative Disorder	NA	EVS:Thesaurus.owl#C39591	NA	NA	NA	Unknown	Unknown
NA	21	1	NA	NA	44524457	A	U2AF1 codon(s) 34 missense	U2AF1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:0001583	44524455	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	MAP2K1	NA	hairy cell leukemia	leukemia	DOID:285	NA	NA	NA	Unknown	Unknown
A	7	1	NA	NA	140453136	A	BRAF V600E	BRAF	NA	papillary carcinoma	carcinoma	DOID:3113	T	SO:0001583	140453136	Unknown	missense_variant
NA	7	1	NA	NA	55242480	A	EGFR E746_A750delinsI	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	SO:1000032	55242468	Unknown	indel
NA	7	1	NA	NA	55249171	A	EGFR exon(s) 20 insertion	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	SO:0000667	55248986	Unknown	insertion
NA	15	1	NA	NA	90631839	A	IDH2 codon(s) 140, 172 any	IDH2	NA	Astrocytoma, Anaplastic	malignant glioma	DOID:3069	NA		90631837	Unknown	Unknown
NA	12	1	NA	NA	25378562	A	KRAS codon(s) 12, 13, 61, 117, 146 any	KRAS	NA	adenocarcinoma	carcinoma	DOID:299	NA		25378560	Unknown	Unknown
NA	3	1	NA	NA	178952086	A	PIK3CA codon(s) 542, 545, 1047 any	PIK3CA	NA	adenocarcinoma	carcinoma	DOID:299	NA		178952084	Unknown	Unknown
T	7	1	NA	NA	55249005	A	EGFR S768I	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	G	SO:0001583	55249005	Unknown	missense_variant
NA	7	1	NA	NA	55242462	A	EGFR K745_E746insIPVAIK	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	SO:0000667	55242461	Unknown	insertion
G	7	1	NA	NA	140453146	A	BRAF L597V	BRAF	NA	melanoma	cell type cancer	DOID:1909	C	SO:0001583	140453146	Unknown	missense_variant
G	7	1	NA	NA	140453193	A	BRAF N581S	BRAF	NA	melanoma	cell type cancer	DOID:1909	A	SO:0001583	140453193	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	GNA11	NA	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Unknown	Unknown
T	7	1	NA	NA	128850341	A	SMO W535L	SMO	NA	medulloblastoma	central nervous system cancer	DOID:0050902	G	SO:0001583	128850341	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	MDM2	NA	liposarcoma	connective tissue cancer	DOID:3382	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDC73	NA	carcinoma	cell type cancer	DOID:305	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	AKT1	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
C	9	1	NA	NA	98229426	A	PTCH1 W844C	PTCH1	NA	basal cell carcinoma	skin cancer	DOID:2513	G	SO:0001583	98229426	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	MET	NA	papillary renal cell carcinoma	kidney cancer	DOID:4465	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR2	NA	squamous cell carcinoma	carcinoma	DOID:1749	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR1	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR1	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	EML4	NA	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	NA	NA	Unknown	Unknown
NA	7	1	NA	NA	140453155	A	BRAF codon(s) 594 any	BRAF	NA	melanoma	cell type cancer	DOID:1909	NA		140453153	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ERBB2	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	KRAS	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
G	1	resistant	CETUXIMAB	CHEMBL1201577	115251171	A	NRAS Q61X 	NRAS	[u'Q61X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
NA	NA	1	PEMBROLIZUMAB	CHEMBL3137343	NA	A	Microsatellite Instability-High	NA	Microsatellite Instability-High	cancer	cancer	DOID:162	NA		NA	Unknown	Unknown
A	1	R1	CETUXIMAB	CHEMBL1201577	115258744	A	G13V	NRAS	Oncogenic Mutations	colorectal cancer	intestinal cancer	DOID:9256	C		115258744	Unknown	Unknown
T	7	1	TRAMETINIB	CID11707110	140453137	A	V600M	BRAF	V600M	melanoma	cell type cancer	DOID:1909	C	SO:0001583	140453137	Unknown	missense_variant
C	6	1	CRIZOTINIB	CID11626560	117710940	A	Fusions	ROS1	Fusions	non-small cell lung carcinoma	lung cancer	DOID:3908	T		117710940	Unknown	Unknown
T	5	1	Imatinib	CID5291	149499573	A	Fusions	PDGFRB	Fusions	myelodysplastic syndrome	hematologic cancer	DOID:0050908	A		149499573	Unknown	Unknown
T	4	R1	Imatinib	CID5291	55152093	A	D842V	PDGFRA	D842V	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	A	SO:0001583	55152093	Unknown	missense_variant
NA	7	1	GEFITINIB	CID123631	55324313	A	Exon 19 deletion	EGFR	Exon 19 deletion	non-small cell lung carcinoma	lung cancer	DOID:3908	NA	SO:0001822	55086714	Unknown	inframe_deletion
C	7	1	GEFITINIB	CID123631	55241708	A	G719A	EGFR	G719A	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55241708	Unknown	missense_variant
TATATATATATATA	2	Adverse Response	BELINOSTAT	CID6918638	234668882	A	UGT1A1*28	UGT1A1	UGT1A1*28	cancer	cancer	DOID:162	None	SO:0000289	234668881	Resistant	microsatellite
A	15	1	Enasidenib	CID89683805	90631838	A	R172M	IDH2	R172M	acute myeloid leukemia	hematologic cancer	DOID:9119	C	SO:0001583	90631838	Unknown	missense_variant
T	15	1	Enasidenib	CID89683805	90631838	A	R172K	IDH2	R172K	acute myeloid leukemia	hematologic cancer	DOID:9119	C	SO:0001583	90631838	Unknown	missense_variant
T	4	1	SUNITINIB	CID5329102	55595519	A	T670I	KIT	T670I	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	C	SO:0001583	55595519	Unknown	missense_variant
T	20	SDC4-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	43956042	A	SDC4-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	43956042	Sensitive	fusion
	12	KRAS Q61 confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380277	A	KRAS Q61	KRAS	[u'61Q']	lung adenocarcinoma	lung cancer	DOID:3910			25380275	Resistant	Unknown
C	1	TPM3-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	154143173	A	TPM3-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	154143173	Sensitive	fusion
A	12	KRAS Q61L confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
A	7	MET c.3028+2T>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412045	A	MET c.3028+2T>A	MET	[u'c.3028+2T>A']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001627	116412045	Sensitive	intron_variant
T	7	MET c.2888-15_2915delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGAinsT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411930	A	MET c.2888-15_2915delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGAinsT	MET	[u'c.2888-15_2915delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGAinsT']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411888	Sensitive	intron
T	17	ERBB2 S310F confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37868208	A	ERBB2 S310F	ERBB2	[u'S310F']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	37868208	Sensitive	missense_variant
GG	12	KRAS G13P confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13P	KRAS	[u'G13P']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
GGGTTA	7	EGFR D770_N771insGL confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249013	A	EGFR D770_N771insGL	EGFR	[u'D770_N771insGL']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	EGFR T751_E758del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55242503	A	EGFR T751_E758del	EGFR	[u'T751_E758delTSPKANKE']	lung adenocarcinoma	lung cancer	DOID:3910	AACATCTCCGAAAGCCAACAAGGA	SO:0000159	55242480	Sensitive	deletion
AA	12	KRAS G13F confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13F	KRAS	[u'G13F']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
TA	12	KRAS G13Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
A	7	EGFR G719S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55241707	A	EGFR G719S	EGFR	[u'G719S']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	55241707	Sensitive	synonymous
AT	12	KRAS G13D confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G13D	KRAS	[u'G13D']	lung adenocarcinoma	lung cancer	DOID:3910	GC		25398280	Resistant	Unknown
G	1	TRIM33-RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	CABOZANTINIB	CID25102847	115053290	A	TRIM33-RET	RET	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	115053290	Sensitive	fusion
T	7	BRAF V600E confers sensitivity to Vemurafenib resistance and nivolumab in patients with MM - Malignant melanoma of skin	NIVOLUMAB	CHEMBL2108738	140453136	A	BRAF V600E	BRAF	[u'V600E']	skin melanoma	integumentary system cancer	DOID:8923	A	SO:0001583	140453136	Sensitive	missense_variant
-	7	EGFR E746_A750del confers sensitivity to Afatinib in patients with Non-small cell lung cancer	AFATINIB	CID10184653	55242480	A	EGFR E746_A750del	EGFR	[u'E746_A750del', u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCA	SO:0000159	55242466	Sensitive	deletion
A	17	BRCA1 Loss and germline BRCA1 confers sensitivity to Olaparib in patients with Carcinoma of ovary	OLAPARIB	CID23725625	41245877	A	germline BRCA1	BRCA1	[u'BRCA1']	ovarian cancer	reproductive organ cancer	DOID:2394	T	SO:0001587	41245877	Sensitive	stop_gained
C	7	EGFR G719A confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55241708	A	EGFR G719A	EGFR	[u'G719A']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241708	Sensitive	missense_variant
TA	12	KRAS G12Y confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	MET c.2888-27_2890delAAGCTCTTTCTTTCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411905	A	MET c.2888-27_2890delAAGCTCTTTCTTTCTCTCTGTTTTAAGATC	MET	[u'c.2888-27_2890delAAGCTCTTTCTTTCTCTCTGTTTTAAGATC']	lung adenocarcinoma	lung cancer	DOID:3910	AAGCTCTTTCTTTCTCTCTGTTTTAAGATC	SO:0000188	116411876	Sensitive	intron
CT	12	KRAS G12E confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398284	A	KRAS G12E	KRAS	[u'G12E']	lung adenocarcinoma	lung cancer	DOID:3910	AC	SO:0001583	25398283	Resistant	missense_variant
-	7	MET c.3012_3028+7delAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412050	A	MET c.3012_3028+7delAGCTACTTTTCCAGAAGGTATATT	MET	[u'c.3012_3028+7delAGCTACTTTTCCAGAAGGTATATT']	lung adenocarcinoma	lung cancer	DOID:3910	AGCTACTTTTCCAGAAGGTATATT	SO:0000188	116412027	Sensitive	intron
AGGTAGCGT	7	EGFR A767_S768insSVG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249009	A	EGFR A767_S768insSVG	EGFR	[u'V769_D770insGSV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249008	Resistant	Unknown
T	12	KRAS Q61K confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	G	SO:0001583	25380277	Resistant	missense_variant
T	12	KRAS G12S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12S	KRAS	[u'G12S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
GG	12	KRAS G13P confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13P	KRAS	[u'G13P']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
GCAGCGTGG	7	EGFR V769_D770insGSV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249011	A	EGFR V769_D770insGSV	EGFR	[u'V769_D770insGSV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
T	12	KRAS G12D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398284	A	KRAS G12D	KRAS	[u'G12D']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	EGFR T751_E758del confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55242503	A	EGFR T751_E758del	EGFR	[u'T751_E758delTSPKANKE']	lung adenocarcinoma	lung cancer	DOID:3910	AACATCTCCGAAAGCCAACAAGGA	SO:0000159	55242480	Sensitive	deletion
T	7	MET c.2888-1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-1G>T	MET	[u'c.2888-1G>T']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001627	116411902	Sensitive	intron_variant
AA	12	KRAS G12F confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12F	KRAS	[u'G12F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
A	7	EGFR G719D confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55241708	A	EGFR G719D	EGFR	[u'G719D']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55241708	Sensitive	missense_variant
T	12	KRAS Q61K confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
NA	7	EGFR Amplification confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	55324313	A	EGFR Amplification	EGFR	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	SO:0001889	55086714	Sensitive	transcript_amplification
NA	9	CD274 Amplification confers sensitivity to nivolumab in patients with Neoplasm of lung	NIVOLUMAB	CHEMBL2108738	5470566	A	CD274 Amplification	CD274	[]	lung adenocarcinoma	lung cancer	DOID:3910	NA	NA	5450503	Sensitive	Unknown
CT	12	KRAS G12E confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398284	A	KRAS G12E	KRAS	[u'G12E']	lung adenocarcinoma	lung cancer	DOID:3910	AC	SO:0001583	25398283	Resistant	missense_variant
-	7	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAG	MET	[u'c.2888-17_2888-1delTTTCTCTCTGTTTTAAG']	lung adenocarcinoma	lung cancer	DOID:3910	TTTCTCTCTGTTTTAAG	SO:0000188	116411886	Sensitive	intron
CT	12	KRAS G12E confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398284	A	KRAS G12E	KRAS	[u'G12E']	lung adenocarcinoma	lung cancer	DOID:3910	AC	SO:0001583	25398283	Resistant	missense_variant
NA	NA	ER/PR positive confers sensitivity to Fulvestrant in patients with Neoplasm of breast	FULVESTRANT	CID104741	NA	A	ER/PR positive	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA		NA	Sensitive	Unknown
NA	6	ESR1 and ESR1 Amplification confers sensitivity to Anastrozole in patients with Neoplasm of breast	ANASTROZOLE	CID2187	152450754	A	ESR1 Amplification	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA	NA	151977826	Sensitive	Unknown
NA	NA	ERBB2 Loss and ER/PR positive confers sensitivity to Exemestane and Everolimus in patients with Neoplasm of breast	EVEROLIMUS	CID6442177	NA	A	ER/PR positive	ERBB2	[]	breast cancer	thoracic cancer	DOID:1612	NA	SO:0001019	NA	Sensitive	copy_number_variation
-	12	KRAS G12fs*3 confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	breast cancer	thoracic cancer	DOID:1612	C	SO:0000159	25398284	Resistant	deletion
CT	12	KRAS G12E confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398284	A	KRAS G12E	KRAS	[u'G12E']	breast cancer	thoracic cancer	DOID:1612	AC	SO:0001583	25398283	Resistant	missense_variant
T	12	KRAS G12G confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398283	A	KRAS G12G	KRAS	[u'G12G']	breast cancer	thoracic cancer	DOID:1612	A	SO:0001815	25398283	Resistant	synonymous
AT	12	KRAS G13D confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398281	A	KRAS G13D	KRAS	[u'G13D']	breast cancer	thoracic cancer	DOID:1612	GC		25398280	Resistant	Unknown
TT	12	KRAS G13E confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398281	A	KRAS G13E	KRAS	[u'G13E']	breast cancer	thoracic cancer	DOID:1612	GC	SO:0001583	25398280	Resistant	missense_variant
A	12	KRAS Q61L confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
C	12	KRAS Q61E confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001583	25380277	Resistant	missense_variant
NA	15	CYP19A1 Amplification confers resistance to Anastrozole in patients with Neoplasm of breast	ANASTROZOLE	CID2187	51630807	A	CYP19A1 Amplification	CYP19A1	[]	breast cancer	thoracic cancer	DOID:1612	NA	NA	51500254	Resistant	Unknown
G	12	KRAS G12R confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12R	KRAS	[u'G12R']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398285	Resistant	missense_variant
TA	12	KRAS G12Y confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
C	12	KRAS Q61R confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
AA	12	KRAS G12F confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12F	KRAS	[u'G12F']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
T	12	KRAS G12D confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398284	A	KRAS G12D	KRAS	[u'G12D']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
CT	12	KRAS G12E confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398284	A	KRAS G12E	KRAS	[u'G12E']	breast cancer	thoracic cancer	DOID:1612	AC	SO:0001583	25398283	Resistant	missense_variant
A	12	KRAS Q61L confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	breast cancer	thoracic cancer	DOID:1612	T	SO:0001583	25380276	Resistant	missense_variant
TT	12	KRAS G13N confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13N	KRAS	[u'G13N']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
TA	12	KRAS G13Y confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS G12R confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12R	KRAS	[u'G12R']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001583	25398285	Resistant	missense_variant
A	12	KRAS G12C confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12C	KRAS	[u'G12C']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398285	Resistant	synonymous
TA	12	KRAS G12Y confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
AT	12	KRAS G12I confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12I	KRAS	[u'G12I']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
C	7	MET D1010H confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412043	A	MET D1010H	MET	[u'D1010H']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	116412043	Sensitive	missense_variant
C	12	KRAS Q61R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
C	7	MET c.3028+3A>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3028+3A>C	MET	[u'c.3028+3A>C']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001627	116412046	Sensitive	intron_variant
T	7	BRAF V600E confers sensitivity to Dabrafenib resistance, Vemurafenib resistance and Trametinib + Dabrafenib in patients with MM - Malignant melanoma of skin	DABRAFENIB	CID44462760	140453136	A	BRAF V600E	BRAF	[u'V600E']	skin melanoma	integumentary system cancer	DOID:8923	A	SO:0001583	140453136	Sensitive	missense_variant
-	7	MET c.2888-11_2904delTCTGTTTTAAGATCTGGGCAGTGAATTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411919	A	MET c.2888-11_2904delTCTGTTTTAAGATCTGGGCAGTGAATTA	MET	[u'c.2888-11_2904delTCTGTTTTAAGATCTGGGCAGTGAATTA']	lung adenocarcinoma	lung cancer	DOID:3910	TCTGTTTTAAGATCTGGGCAGTGAATTA	SO:0000188	116411892	Sensitive	intron
C	12	KRAS Q61E confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	G	SO:0001583	25380277	Resistant	missense_variant
AACCCCT	7	EGFR P772_H773insTP confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249018	A	EGFR P772_H773insTP	EGFR	[u'P772_H773insTP']	lung adenocarcinoma	lung cancer	DOID:3910	C		55249018	Resistant	Unknown
G	12	KRAS G13R confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13R	KRAS	[u'G13R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
-	7	MET c.2888-35_3011delTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412026	A	MET c.2888-35_3011delTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG	MET	[u'c.2888-35_3011delTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG']	lung adenocarcinoma	lung cancer	DOID:3910	TCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG	SO:0000188	116411868	Sensitive	intron
TCATAACCC	7	EGFR N771_P772insPHN confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249018	A	EGFR N771_P772insPHN	EGFR	[u'N771_H773dupNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249017	Resistant	Unknown
A	6	GOPC-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	117642448	A	GOPC-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117642448	Sensitive	fusion
GACAACCCT	7	EGFR P772_H773insDNP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249019	A	EGFR P772_H773insDNP	EGFR	[u'D770_P772dupDNP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
CAT	12	KRAS G13M confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13M	KRAS	[u'G13M']	lung adenocarcinoma	lung cancer	DOID:3910	GCC	SO:0001583	25398280	Resistant	missense_variant
A	17	ERBB2 G309E confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37868205	A	ERBB2 G309E	ERBB2	[u'G309E']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	37868205	Sensitive	missense_variant
T	7	EGFR T790M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249071	A	EGFR T790M	EGFR	[u'T790M']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	55249071	Resistant	missense_variant
GTC	7	EGFR N771>SH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR N771>SH	EGFR	[u'N771delinsSH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
A	12	KRAS G12C confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12C	KRAS	[u'G12C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
T	4	SLC34A2-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	25664146	A	SLC34A2-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	25664146	Sensitive	fusion
G	12	KRAS G12R confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398285	A	KRAS G12R	KRAS	[u'G12R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398285	Resistant	missense_variant
G	12	LRIG3-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	59280599	A	LRIG3-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	59280599	Sensitive	fusion
G	12	KRAS Q61H confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	25380275	Resistant	synonymous
TT	12	KRAS G13N confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13N	KRAS	[u'G13N']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS G13R confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398282	A	KRAS G13R	KRAS	[u'G13R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
TT	12	KRAS G12N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12N	KRAS	[u'G12N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
T	7	EGFR G573* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55231511	A	EGFR G573*	EGFR	[u'G573*']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001587	55231511	Sensitive	stop_gained
TCT	7	EGFR E746_P753delinsVS confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242487	A	EGFR E746_P753delinsVS	EGFR	[u'E746_P753delinsVS']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACATCTC	SO:0000159	55242467	Sensitive	deletion
GGGTCGTGG	7	EGFR V769_D770insGVV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249011	A	EGFR V769_D770insGVV	EGFR	[u'V769_D770insGVV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
T	12	KRAS G12G confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398283	A	KRAS G12G	KRAS	[u'G12G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001815	25398283	Resistant	synonymous
-	7	MET c.2887+91_3028+266delTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412309	A	MET c.2887+91_3028+266delTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTA	MET	[u'c.2887+91_3028+266delTATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTA']	lung adenocarcinoma	lung cancer	DOID:3910	TATATGTAGTCCATAAAACCCATGAGTTCTGGGCACTGGGTCAAAGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTA		116411799	Sensitive	Unknown
A	7	MET D1010N confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412043	A	MET D1010N	MET	[u'D1010N']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	116412043	Sensitive	missense_variant
TA	12	KRAS G13Y confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13Y	KRAS	[u'G13Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
-	7	MET c.2888-17_2953delTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411968	A	MET c.2888-17_2953delTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA	MET	[u'c.2888-17_2953delTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA']	lung adenocarcinoma	lung cancer	DOID:3910	TTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA	SO:0000188	116411886	Sensitive	intron
CCCACG	7	EGFR H773_V774insAH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249023	A	EGFR H773_V774insAH	EGFR	[u'H773_V774insAH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249022	Resistant	Unknown
T	7	EGFR Q486* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55227989	A	EGFR Q486*	EGFR	[u'Q486*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55227989	Sensitive	stop_gained
-	7	EGFR E746_T751delinsA confers sensitivity to Gefitinib in patients with Non-small cell lung cancer	GEFITINIB	CID123631	55242481	A	EGFR E746_T751delinsA	EGFR	[u'E746_T751delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAA	SO:0000159	55242467	Sensitive	deletion
-	7	MET c.2888-20_2898delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411913	A	MET c.2888-20_2898delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT	MET	[u'c.2888-20_2898delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTTTCTCTCTGTTTTAAGATCTGGGCAGT	SO:0000188	116411883	Sensitive	intron
TT	12	KRAS G12N confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12N	KRAS	[u'G12N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
CCACCA	12	KRAS G12_G13insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CCA		25398280	Resistant	Unknown
CCA	12	KRAS G12W confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12W	KRAS	[u'G12W']	lung adenocarcinoma	lung cancer	DOID:3910	ACC	SO:0001583	25398283	Resistant	missense_variant
T	7	EGFR T790M confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55249071	A	EGFR T790M	EGFR	[u'T790M']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	55249071	Sensitive	missense_variant
-	7	EGFR E746_S752delinsA confers sensitivity to Gefitinib in patients with Non-small cell lung cancer	GEFITINIB	CID123631	55242484	A	EGFR E746_S752delinsA	EGFR	[u'E746_S752delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACAT	SO:0000159	55242467	Sensitive	deletion
-	7	MET c.2888-28_3028+692delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAGGGGTCAATATCATCAGCTTTGTAAAACACTATGCCTAGTAATGTTCAGGTTAATCAGAGTTTTCATGTTGTTTTATTTAAATCTCCTGGTAAAAGCAAAAGGTCTGTATTGTATCAGCTCCATTATCTTTAGAAGTTACAGGATGTGAGTCAAGTACAAGCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412735	A	MET c.2888-28_3028+692delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAGGGGTCAATATCATCAGCTTTGTAAAACACTATGCCTAGTAATGTTCAGGTTAATCAGAGTTTTCATGTTGTTTTATTTAAATCTCCTGGTAAAAGCAAAAGGTCTGTATTGTATCAGCTCCATTATCTTTAGAAGTTACAGGATGTGAGTCAAGTACAAGCA	MET	[u'c.2888-28_3028+692delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAGGGGTCAATATCATCAGCTTTGTAAAACACTATGCCTAGTAATGTTCAGGTTAATCAGAGTTTTCATGTTGTTTTATTTAAATCTCCTGGTAAAAGCAAAAGGTCTGTATTGTATCAGCTCCATTATCTTTAGAAGTTACAGGATGTGAGTCAAGTACAAGCA']	lung adenocarcinoma	lung cancer	DOID:3910	CAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATTTCACAAAAAGGTTAATTTGAGCAAAAGTAATTTGTTTATCATCTAAGTGCAATAGTAAGAAATTGCGAAGCTCTCTTTTACAATCCAGGAAGAGTTAAGTTACAAAATATACTTATTTAAATGTAAGTTGGAACTGCTACATTTTTTACCTGTTGAAGCCCAAACATTGAAATTATACTGTTAGTAATTCTTCGAAGTGTTTTCAATGAACTGTTAGTACACAGCCTTTTTCCCACCATATTCTAGGACTTGAATGTATTTTGAGACTTAGCCAAGGAAAACCTTCAATTATGCCATGAAAAAAAGGAGGGGTCAATATCATCAGCTTTGTAAAACACTATGCCTAGTAATGTTCAGGTTAATCAGAGTTTTCATGTTGTTTTATTTAAATCTCCTGGTAAAAGCAAAAGGTCTGTATTGTATCAGCTCCATTATCTTTAGAAGTTACAGGATGTGAGTCAAGTACAAGCA		116411875	Sensitive	Unknown
T	6	CD74-ROS1 L2026M confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	117638365	A	CD74-ROS1 L2026M	ROS1	[u'L2026M']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117638365	Sensitive	fusion
-	7	MET exon 14 deletion confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116414936	A	MET exon 14 deletion	MET	[u'exon']	lung adenocarcinoma	lung cancer	DOID:3910			116411708	Sensitive	Unknown
ACC	7	EGFR N771_P772insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249017	A	EGFR N771_P772insH	EGFR	[u'N771_P772insH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249016	Resistant	Unknown
CGCTGGCCA	7	EGFR A767_S768insTLA confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249005	A	EGFR A767_S768insTLA	EGFR	[u'A767_S768insTLA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249004	Resistant	Unknown
GT	12	KRAS G12T confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12T	KRAS	[u'G12T']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
-	12	KRAS G12fs*3 confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000159	25398284	Resistant	deletion
-	7	MET c.2888-13_2888-2delTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411901	A	MET c.2888-13_2888-2delTCTCTGTTTTAA	MET	[u'c.2888-13_2888-2delTCTCTGTTTTAA']	lung adenocarcinoma	lung cancer	DOID:3910	TCTCTGTTTTAA	SO:0000188	116411890	Sensitive	intron
-	7	EGFR L747_T751del confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242484	A	EGFR L747_T751del	EGFR	[u'L747_T751del', u'L747_T751del']	lung adenocarcinoma	lung cancer	DOID:3910	TAAGAGAAGCAACAT	SO:0000159	55242470	Sensitive	deletion
AT	12	KRAS G13D confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G13D	KRAS	[u'G13D']	lung adenocarcinoma	lung cancer	DOID:3910	GC		25398280	Resistant	Unknown
-	7	MET c.2888-14_2890delCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411905	A	MET c.2888-14_2890delCTCTCTGTTTTAAGATC	MET	[u'c.2888-14_2890delCTCTCTGTTTTAAGATC']	lung adenocarcinoma	lung cancer	DOID:3910	CTCTCTGTTTTAAGATC	SO:0000188	116411889	Sensitive	intron
AA	7	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAGinsAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411902	A	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAGinsAA	MET	[u'c.2888-17_2888-1delTTTCTCTCTGTTTTAAGinsAA']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411886	Sensitive	intron
G	7	EGFR L858R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55259515	A	EGFR L858R	EGFR	[u'L858R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	55259515	Sensitive	synonymous
A	12	KRAS G13V confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G13V	KRAS	[u'G13V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
-	7	MET c.3024_3028+20delAGAAGGTATATTTCAGTTTATTGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412063	A	MET c.3024_3028+20delAGAAGGTATATTTCAGTTTATTGTT	MET	[u'c.3024_3028+20delAGAAGGTATATTTCAGTTTATTGTT']	lung adenocarcinoma	lung cancer	DOID:3910	AGAAGGTATATTTCAGTTTATTGTT	SO:0000188	116412039	Sensitive	intron
CAG	7	EGFR H773_V774insQ confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249022	A	EGFR H773_V774insQ	EGFR	[u'H773_V774insQ']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
AACAAC	7	EGFR N771_P772insN confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249015	A	EGFR N771_P772insN	EGFR	[u'N771dupN']	lung adenocarcinoma	lung cancer	DOID:3910	AAC		55249013	Resistant	Unknown
T	7	MET D1010Y confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412043	A	MET D1010Y	MET	[u'D1010Y']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	116412043	Sensitive	missense_variant
T	12	KRAS G12G confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398283	A	KRAS G12G	KRAS	[u'G12G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001815	25398283	Resistant	synonymous
C	12	ERBB3 G284R confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	56481922	A	ERBB3 G284R	ERBB3	[u'G284R']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	56481922	Sensitive	missense_variant
T	12	KRAS Q61K confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
NA	2	CTLA4 and PDCD1 confers sensitivity to Nivolumab + Ipilimumab in patients with MM - Malignant melanoma of skin	IPILIMUMAB	CHEMBL1789844	242801060	A	PDCD1	PDCD1	[]	skin melanoma	integumentary system cancer	DOID:8923	NA	NA	242792033	Sensitive	Unknown
-	7	MET c.3009_3028+7delCCGAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412050	A	MET c.3009_3028+7delCCGAGCTACTTTTCCAGAAGGTATATT	MET	[u'c.3009_3028+7delCCGAGCTACTTTTCCAGAAGGTATATT']	lung adenocarcinoma	lung cancer	DOID:3910	CCGAGCTACTTTTCCAGAAGGTATATT	SO:0000188	116412024	Sensitive	intron
ACC	12	KRAS G13_V14insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398280	A	KRAS G13_V14insG	KRAS	[u'G13dupG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398279	Resistant	Unknown
GGGTTT	7	EGFR D770_N771insGF confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insGF	EGFR	[u'D770_N771insGF']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
T	12	KRAS Q61K confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
CCACCA	12	KRAS G12_G13insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	CCA		25398280	Resistant	Unknown
C	2	ALK F1174V confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29443697	A	ALK F1174V	ALK	[u'F1174V']	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	29443697	Sensitive	missense_variant
-	7	EGFR S752_I759del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55242507	A	EGFR S752_I759del	EGFR	[u'S752_I759del', u'S752_I759del']	lung adenocarcinoma	lung cancer	DOID:3910	TCTCCGAAAGCCAACAAGGAAATC	SO:0000159	55242484	Sensitive	deletion
CCACCA	12	KRAS G12_G13insG confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	CCA		25398280	Resistant	Unknown
-	7	EGFR E746delE confers sensitivity to Erlotinib hydrochloride in patients with Non-small cell lung cancer	Erlotinib	CID176870	55242466	A	EGFR E746delE	EGFR	[u'E746del']	non-small cell lung carcinoma	lung cancer	DOID:3908	AGG	SO:0000159	55242464	Sensitive	deletion
CGCTGGCCA	7	EGFR A767_S768insTLA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249005	A	EGFR A767_S768insTLA	EGFR	[u'A767_S768insTLA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249004	Resistant	Unknown
-	7	MET c.2888-16_2889delTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411904	A	MET c.2888-16_2889delTTCTCTCTGTTTTAAGAT	MET	[u'c.2888-16_2889delTTCTCTCTGTTTTAAGAT']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTCTCTGTTTTAAGAT	SO:0000188	116411887	Sensitive	intron
G	10	KIF5B-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	32310205	A	KIF5B-ALK	ALK	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	32310205	Sensitive	fusion
-	7	MET c.2888-28_2896delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411911	A	MET c.2888-28_2896delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA	MET	[u'c.2888-28_2896delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA']	lung adenocarcinoma	lung cancer	DOID:3910	CAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA	SO:0000188	116411875	Sensitive	intron
A	7	EGFR Y270* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55221766	A	EGFR Y270*	EGFR	[u'Y270*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55221766	Sensitive	stop_gained
CT	17	ERBB2 G776L confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880998	A	ERBB2 G776L	ERBB2	[u'G776L']	lung adenocarcinoma	lung cancer	DOID:3910	GG	SO:0001583	37880997	Sensitive	missense_variant
ACC	7	EGFR N771_P772insH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249017	A	EGFR N771_P772insH	EGFR	[u'N771_P772insH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249016	Resistant	Unknown
C	2	ALK F1174C confers sensitivity to Alectinib in patients with Non-small cell lung cancer	ALECTINIB	CID49806720	29443696	A	ALK F1174C	ALK	[u'F1174C']	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	29443696	Sensitive	missense_variant
G	12	KRAS G13A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G13A	KRAS	[u'G13A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
T	7	BRAF V600E confers sensitivity to Dabrafenib resistance, Vemurafenib resistance and Vemurafenib + Cobimetinib in patients with MM - Malignant melanoma of skin	COBIMETINIB	CID16222096	140453136	A	BRAF V600E	BRAF	[u'V600E']	skin melanoma	integumentary system cancer	DOID:8923	A	SO:0001583	140453136	Sensitive	missense_variant
AA	12	KRAS G13F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13F	KRAS	[u'G13F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
AA	12	KRAS G13F confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13F	KRAS	[u'G13F']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
A	7	EGFR H773>PNPY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55259501	A	EGFR H773>PNPY	EGFR	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		55259501	Resistant	Unknown
T	7	EGFR Q701* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55241653	A	EGFR Q701*	EGFR	[u'Q701*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55241653	Sensitive	stop_gained
A	12	KRAS G12C confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12C	KRAS	[u'G12C']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398285	Resistant	synonymous
TGT	12	KRAS G13_V14>DI confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	lung adenocarcinoma	lung cancer	DOID:3910	ACA		25398279	Resistant	Unknown
C	10	RET C630R confers sensitivity to Cabozantinib in patients with Medullary thyroid carcinoma	CABOZANTINIB	CID25102847	43609936	A	RET C630R	RET	[u'C630R']	thyroid medullary carcinoma	thyroid cancer	DOID:3973	T	SO:0001583	43609936	Sensitive	missense_variant
T	20	SDC4-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	43956042	A	SDC4-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	43956042	Sensitive	fusion
AACCCTCAT	7	EGFR H773_V774insNPH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249022	A	EGFR H773_V774insNPH	EGFR	[u'N771_H773dupNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
-	7	EGFR E746_A750del confers sensitivity to Gefitinib in patients with Non-small cell lung cancer	GEFITINIB	CID123631	55242480	A	EGFR E746_A750del	EGFR	[u'E746_A750del', u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCA	SO:0000159	55242466	Sensitive	deletion
-	7	EGFR E746_A750del confers sensitivity to Erlotinib hydrochloride in patients with Non-small cell lung cancer	Erlotinib	CID176870	55242480	A	EGFR E746_A750del	EGFR	[u'E746_A750del', u'E746_A750del']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCA	SO:0000159	55242466	Sensitive	deletion
CAGCGTGGA	7	EGFR S768_D770dup confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249003	A	EGFR S768_D770dup	EGFR	[u'S768_D770']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249002	Resistant	Unknown
TT	12	KRAS G13E confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398281	A	KRAS G13E	KRAS	[u'G13E']	lung adenocarcinoma	lung cancer	DOID:3910	GC	SO:0001583	25398280	Resistant	missense_variant
C	7	EGFR E746_E749delinsA confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242476	A	EGFR E746_E749delinsA	EGFR	[u'E746_E749delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGA	SO:0000159	55242467	Sensitive	deletion
A	12	KRAS G13V confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398281	A	KRAS G13V	KRAS	[u'G13V']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G12V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398284	A	KRAS G12V	KRAS	[u'G12V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
GCGTAGACA	7	EGFR D770_N771insSVD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR D770_N771insSVD	EGFR	[u'S768_D770dupSVD']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
C	7	MET M995Ifs*19 confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116340340	A	MET M995Ifs*19	MET	[]	lung adenocarcinoma	lung cancer	DOID:3910	T		116340340	Sensitive	Unknown
TCC	7	EGFR E746_A750>DP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242479	A	EGFR E746_A750>DP	EGFR	[u'E746_A750delinsDP']	non-small cell lung carcinoma	lung cancer	DOID:3908	ATTAAGAGAAGC	SO:0000159	55242468	Sensitive	deletion
GCCATA	7	EGFR A767_S768insIA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249001	A	EGFR A767_S768insIA	EGFR	[u'A767_S768insIA']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249000	Resistant	Unknown
CCAGCGTGG	7	EGFR D770_N771insQRG confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249012	A	EGFR D770_N771insQRG	EGFR	[u'D770_N771insQRG']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249011	Resistant	Unknown
GTT	7	EGFR P772_H773insV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249019	A	EGFR P772_H773insV	EGFR	[u'P772_H773insV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
-	7	EGFR L747_E749delLRE confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55242477	A	EGFR L747_E749delLRE	EGFR	[u'L747_E749del', u'L747_E749del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAA	SO:0000159	55242469	Sensitive	deletion
G	2	sensitive	ALECTINIB	CID49806720	29484957	A	ALK  rearrange	ALK	[u'']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0000138	29484957	Sensitive	gene_rearranged_at_DNA_level
G	13	sensitive	MIDOSTAURIN	CID9829523	28644736	A	FLT3  mutant	FLT3	[u'']	acute myeloid leukemia	hematologic cancer	DOID:9119	T	SO:1000002	28644736	Sensitive	substitution
T	15	sensitive	Enasidenib	CID89683805	90627534	A	IDH2  mutant	IDH2	[u'']	acute myeloid leukemia	hematologic cancer	DOID:9119	G	SO:1000002	90627534	Sensitive	substitution
A	4	sensitive	Imatinib	CID5291	55594184	A	KIT  positive	KIT	[u'']	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	C	SO:0000475	55594184	Sensitive	positively_autoregulated
T	4	resistant	Imatinib	CID5291	55599321	A	KIT D816V 	KIT	[u'D816V']	Indication other than cancer	NA	RID:#RID49442	A	NA	55599321	Resistant	Unknown
A	12	resistant	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12C 	KRAS	[u'G12C']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398285	Resistant	Unknown
T	12	resistant	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12D 	KRAS	[u'G12D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398284	Resistant	Unknown
T	12	resistant	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12D 	KRAS	[u'G12D']	colorectal cancer	intestinal cancer	DOID:9256	C	NA	25398284	Resistant	Unknown
G	7	sensitive	COBIMETINIB	CID16222096	140534535	A	BRAF V600X 	BRAF	[u'V600X']	melanoma	cell type cancer	DOID:1909	A	SO:0001587	140534535	Sensitive	stop_gained
NA	NA	sensitive	TRAMETINIB	CID11707110	NA	A	BRAF V600E/K 	BRAF	[u'V600E/K']	melanoma	cell type cancer	DOID:1909	NA	NA	NA	Sensitive	Unknown
T	7	sensitive	OSIMERTINIB	CID71496458	55249071	A	EGFR T790M 	EGFR	[u'T790M']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	NA	55249071	Sensitive	Unknown
G	17	sensitive	Cyclophosphamide	CID2907	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
G	17	predicted – sensitive	TRASTUZUMAB	CHEMBL1201585	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
G	17	predicted – sensitive	TRASTUZUMAB	CHEMBL1201585	37883691	A	ERBB2  positive	ERBB2	[u'']	Her2-receptor positive breast cancer	thoracic cancer	DOID:0060079	C	SO:0000475	37883691	Sensitive	positively_autoregulated
G	1	resistant	PANITUMUMAB	CHEMBL1201827	115251171	A	NRAS Q61X 	NRAS	[u'Q61X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
G	1	resistant	PANITUMUMAB	CHEMBL1201827	115251171	A	NRAS  mutant	NRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:1000002	115251171	Resistant	substitution
G	1	resistant	CETUXIMAB	CHEMBL1201577	115251171	A	NRAS G12X 	NRAS	[u'G12X']	colorectal cancer	intestinal cancer	DOID:9256	T	SO:0001587	115251171	Resistant	stop_gained
None	17	Sensitivity	TRASTUZUMAB	CHEMBL1201585	37884915	A	AMPLIFICATION	ERBB2	AMPLIFICATION	breast cancer	thoracic cancer	DOID:1612	None	SO:0001889	37856333	Sensitive	transcript_amplification
None	17	Sensitivity	TRASTUZUMAB	CHEMBL1201585	37884915	A	AMPLIFICATION	ERBB2	AMPLIFICATION	gastric adenocarcinoma	stomach cancer	DOID:3717	None	SO:0001889	37856333	Sensitive	transcript_amplification
None	13	Poor Outcome	NA	NA	28608351	A	ITD	FLT3	ITD	acute myeloid leukemia	hematologic cancer	DOID:9119	None	SO:0001821	28608219	Resistant	inframe_insertion
	13	Sensitivity	MIDOSTAURIN	CID9829523	28674729	A	MUTATION	FLT3	MUTATION	acute myeloid leukemia	hematologic cancer	DOID:9119	None	SO:0001576	28577411	Sensitive	transcript_variant
None	12	Resistance or Non-Response	SELUMETINIB	CID10127622	25403737	A	MUTATION	KRAS	MUTATION	non-small cell lung carcinoma	lung cancer	DOID:3908	None	SO:0001818	25362365	Resistant	protein_altering_variant
None	12	Resistance or Non-Response	PANITUMUMAB	CHEMBL1201827	25403737	A	MUTATION	KRAS	MUTATION	colorectal cancer	intestinal cancer	DOID:9256	None	SO:0001818	25362365	Resistant	protein_altering_variant
A	12	resistant	PANITUMUMAB	CHEMBL1201827	25368402	A	KRAS  mutant	KRAS	[u'']	colorectal cancer	intestinal cancer	DOID:9256	C	SO:1000002	25368402	Resistant	substitution
T	7	sensitive	VEMURAFENIB	CID42611257	140453136	A	BRAF V600E 	BRAF	[u'V600E']	melanoma	cell type cancer	DOID:1909	A	NA	140453136	Sensitive	Unknown
T	7	sensitive	COBIMETINIB	CID16222096	140453136	A	BRAF V600E 	BRAF	[u'V600E']	melanoma	cell type cancer	DOID:1909	A	NA	140453136	Sensitive	Unknown
T	7	sensitive	DABRAFENIB	CID44462760	140453136	A	BRAF V600E 	BRAF	[u'V600E']	non-small cell lung carcinoma	lung cancer	DOID:3908	A	NA	140453136	Sensitive	Unknown
T	7	not applicable	NA	NA	140453136	A	BRAF V600E 	BRAF	[u'V600E']	hairy cell leukemia	leukemia	DOID:285	A	NA	140453136	Unknown	Unknown
T	5	Negative	NA	NA	149499573	A	PDGFRB FUSIONS	PDGFRB	FUSIONS	chronic myelomonocytic leukemia	hematologic cancer	DOID:0080188	A	SO:0001886	149499573	Unknown	transcript_fusion
None	15	Positive	NA	NA	74325755	A	PML-RARA	PML	NA	acute promyelocytic leukemia	leukemia	DOID:0060318	None	SO:0001886	74287058	Sensitive	transcript_fusion
None	15	Sensitivity	Arsenic	CID23969	74325755	A	PML-RARA	PML	NA	acute promyelocytic leukemia	leukemia	DOID:0060318	None	SO:0001886	74287058	Sensitive	transcript_fusion
None	11	Poor Outcome	NA	NA	108239826	A	MUTATION	ATM	MUTATION	chronic lymphocytic leukemia	hematologic cancer	DOID:1040	None	SO:0001549	108093559	Resistant	transcription_variant
NA	12	Resistant	EGFR	SID160769799	25403870	A	KRAS oncogenic mutation	KRAS	NA	lung cancer	respiratory system cancer	DOID:1324	NA	SO:1000002	25357723	Resistant	substitution
NA	5	Responsive	Daunorubicin	CID30323	170838141	A	NPM1 oncogenic mutation	NPM1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	SO:1000002	170814120	Sensitive	substitution
G	1	Resistant	mAb	CHEMBL2109423	115251171	A	NRAS (12,13,59,61,117,146)	NRAS	NA	colorectal adenocarcinoma	intestinal cancer	DOID:0050861	T	SO:1000002	115251171	Resistant	substitution
C	4	Responsive	SUNITINIB	CID5329102	55133777	A	PDGFRA (552-596,631-668,814-854)	PDGFRA	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:1000002	55133777	Sensitive	substitution
NA	4	Responsive	Imatinib	CID5291	55164414	A	PDGFRA-FIP1L1 fusion	PDGFRA	NA	Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia	NA	MEDDRA:10065872	NA	SO:0001902	55095264	Sensitive	splice_region
C	3	1	NA	NA	38182641	A	MYD88 L265P	MYD88	NA	lymphoplasmacytic lymphoma	lymphoma	DOID:0050747	T	SO:0001583	38182641	Unknown	missense_variant
NA	3	1	NA	NA	41266138	A	CTNNB1 codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any	CTNNB1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA		41266136	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	SETD2	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
T	4	1	NA	NA	55152093	A	PDGFRA D842V	PDGFRA	NA	myeloproliferative neoplasm	hematologic cancer	DOID:2226	A	SO:0001583	55152093	Unknown	missense_variant
NA	9	1	NA	NA	5070052	A	JAK2 exon(s) 12 insertion	JAK2	NA	essential thrombocythemia	bone marrow cancer	DOID:2224	NA	SO:0000667	5069925	Unknown	insertion
NA	9	1	NA	NA	139399556	A	NOTCH1 exon(s) 26 missense	NOTCH1	NA	acute T cell leukemia	leukemia	DOID:5603	NA	SO:0001583	139399125	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	SF1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	EED	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	12	1	NA	NA	25378562	A	KRAS codon(s) 12, 13, 61, 117, 146 any	KRAS	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA		25378560	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	SH2B3	NA	B-cell adult acute lymphocytic leukemia	leukemia	DOID:0060592	NA	NA	NA	Unknown	Unknown
C	13	1	NA	NA	28592641	A	FLT3 D835A	FLT3	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	A	SO:0001583	28592641	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	ASXL1	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	20	1	NA	NA	57484422	A	GNAS codon(s) 201, 844 any	GNAS	NA	myelodysplastic syndrome	hematologic cancer	DOID:0050908	NA		57484420	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	RPL10	NA	acute T cell leukemia	leukemia	DOID:5603	NA	NA	NA	Unknown	Unknown
NA	7	1	NA	NA	55249072	A	EGFR codon(s) 790 any	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA		55249070	Unknown	Unknown
NA	7	1	NA	NA	55242513	A	EGFR codon(s) 761 any	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA		55242511	Unknown	Unknown
G	4	1	NA	NA	55599340	A	KIT N822K	KIT	NA	melanoma	cell type cancer	DOID:1909	T	SO:0001583	55599340	Unknown	missense_variant
NA	1	1	NA	NA	115252204	A	NRAS codon(s) 12, 13, 61, 146 any	NRAS	NA	NA	NA	NA	NA		115252202	Unknown	Unknown
A	7	1	NA	NA	140453136	A	BRAF V600E	BRAF	NA	Langerhans Cell Histiocytosis	NA	MEDDRA:10069698	T	SO:0001583	140453136	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	DNAJB1	NA	hepatocellular carcinoma	liver cancer	DOID:684	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	CDKN2B	NA	glioblastoma classical subtype	astrocytoma	DOID:0050803	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR1	NA	invasive ductal carcinoma	breast cancer	DOID:3008	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	TP53	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	FGFR1	NA	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	KIT	NA	Astrocytoma, Anaplastic	malignant glioma	DOID:3069	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	EGFR	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
A	2	1	NA	NA	25457243	A	DNMT3A codon(s) 882 missense	DNMT3A	NA	acute myeloid leukemia	hematologic cancer	DOID:9119	G	SO:0001583	25457241	Unknown	missense_variant
NA	NA	1	NA	NA	NA	A	NA	CDC73	NA	NA	NA	NA	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	AKT3	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ERBB2	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
NA	NA	1	NA	NA	NA	A	NA	ERBB2	NA	adenocarcinoma	carcinoma	DOID:299	NA	NA	NA	Unknown	Unknown
A	9	Responsive	BOSUTINIB MONOHYDRATE	CID5328940	133748257	A	ABL1:T315A	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748257	Sensitive	substitution
T	9	Resistant	BOSUTINIB MONOHYDRATE	CID5328940	133748283	A	ABL1:T315I	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748283	Resistant	substitution
T	9	Responsive	PONATINIB	CID24826799	133748283	A	ABL1:T315I	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	C	SO:1000002	133748283	Sensitive	substitution
G	2	Responsive	CERITINIB	CID57379345	29484957	A	ALK inframe insertion (1151T)	ALK	NA	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:1000002	29484957	Sensitive	substitution
T	7	Responsive	DABRAFENIB	CID44462760	140453136	A	BRAF:V600E	BRAF	NA	skin melanoma	integumentary system cancer	DOID:8923	A	SO:1000002	140453136	Sensitive	substitution
NA	13	Responsive	RUCAPARIB	CID9931954	32973805	A	BRCA2 oncogenic mutation	BRCA2	NA	ovarian cancer	reproductive organ cancer	DOID:2394	NA	SO:1000002	32889611	Sensitive	substitution
C	1	Increased Toxicity	CAPECITABINE	CID60953	97981303	A	DPYD biallelic inactivation	DPYD	NA	cancer	cancer	DOID:162	G		97981303	Sensitive	Unknown
C	1	Increased Toxicity	CAPECITABINE	CID60953	97981303	A	DPYD splice donor variant	DPYD	NA	cancer	cancer	DOID:162	G	SO:1000002	97981303	Sensitive	substitution
G	17	Responsive	PALBOCICLIB	CID5330286	37883691	A	ERBB2 expression + ESR1 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
G	17	Responsive	mAb	CHEMBL2109423	37883691	A	ERBB2 overexpression	ERBB2	NA	breast adenocarcinoma	breast cancer	DOID:3458	C	SO:0001025	37883691	Sensitive	polymorphic_sequence_variant
T	6	Increased Toxicity (Myelosupression)	Guanine	CID764	18134078	A	TPMT biallelic inactivation	TPMT	NA	cancer	cancer	DOID:162	C		18134078	Sensitive	Unknown
T	2	Increased Toxicity	Irinotecan	CID60838	234669686	A	UGT1A1 biallelic inactivation	UGT1A1	NA	cancer	cancer	DOID:162	A		234669686	Sensitive	Unknown
T	2	Increased Toxicity (Hyperbilirubinemia)	NILOTINIB	CID644241	234669686	A	UGT1A1 biallelic inactivation	UGT1A1	NA	cancer	cancer	DOID:162	A		234669686	Sensitive	Unknown
A	2	Increased Toxicity	Irinotecan	CID60838	234669144	A	UGT1A1:G71R	UGT1A1	NA	cancer	cancer	DOID:162	G	SO:1000002	234669144	Sensitive	substitution
None	22	Sensitivity	Imatinib	CID5291	23632600	A	BCR-ABL	ABL1	NA	chronic myeloid leukemia	hematologic cancer	DOID:8552	None	SO:0001886	23522397	Sensitive	transcript_fusion
None	17	Sensitivity	OLAPARIB	CID23725625	41277387	A	MUTATION	BRCA1	MUTATION	cancer	cancer	DOID:162	None	SO:0001564	41196312	Sensitive	gene_variant
None	9	Better Outcome	NA	NA	21974865	A	p16 EXPRESSION	CDKN2A	EXPRESSION	oropharynx cancer	gastrointestinal system cancer	DOID:8557	None		21968055	Sensitive	Unknown
None	2	Poor Outcome	NA	NA	25457243	A	R882	DNMT3A	R882	acute myeloid leukemia	hematologic cancer	DOID:9119	None	SO:0001583	25457241	Resistant	missense_variant
A	4	1	SUNITINIB	CID5329102	55594184	A	V560E	KIT	Oncogenic Mutations	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	C		55594184	Unknown	Unknown
C	4	1	SUNITINIB	CID5329102	55594258	A	V654A	KIT	V654A	gastrointestinal stromal tumor	gastrointestinal system cancer	DOID:9253	T	SO:0001583	55594258	Unknown	missense_variant
C	7	1	TRAMETINIB	CID11707110	140426304	A	V600D	BRAF	V600D	melanoma	cell type cancer	DOID:1909	G	SO:0001583	140426304	Unknown	missense_variant
G	7	1	TRAMETINIB	CID11707110	140534535	A	V600R	BRAF	V600R	melanoma	cell type cancer	DOID:1909	A	SO:0001583	140534535	Unknown	missense_variant
C	7	1	TRAMETINIB	CID11707110	140453136	A	V600G	BRAF	V600G	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	140453136	Unknown	missense_variant
T	7	1	TRAMETINIB	CID11707110	140453136	A	V600E	BRAF	V600E	non-small cell lung carcinoma	lung cancer	DOID:3908	A	SO:0001583	140453136	Unknown	missense_variant
A	17	1	NIRAPARIB	CID24958200	41245877	A	Q1811R	BRCA1	Oncogenic Mutations	ovarian cancer	reproductive organ cancer	DOID:2394	T		41245877	Unknown	Unknown
T	7	R1	GEFITINIB	CID123631	55249071	A	T790M	EGFR	T790M	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	55249071	Unknown	missense_variant
T	7	1	GEFITINIB	CID123631	55249005	A	S768I	EGFR	S768I	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55249005	Unknown	missense_variant
A	7	1	GEFITINIB	CID123631	55241677	A	E709K	EGFR	E709K	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	55241677	Unknown	missense_variant
C	7	1	GEFITINIB	CID123631	55086994	A	EGFR-KDD	EGFR	EGFR-KDD	non-small cell lung carcinoma	lung cancer	DOID:3908	G		55086994	Unknown	Unknown
C	7	R1	GEFITINIB	CID123631	55086994	A	Exon 20 insertion	EGFR	Exon 20 insertion	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001821	55086994	Unknown	inframe_insertion
NA	17	1	TRASTUZUMAB	CHEMBL1201585	37886679	A	Amplification	ERBB2	Amplification	Esophagogastric Cancer	Overlapping sites	SNOMEDCT:264111006	NA		37844167	Unknown	Unknown
NA	17	1	TRASTUZUMAB	CHEMBL1201585	37886679	A	Amplification	ERBB2	Amplification	breast cancer	thoracic cancer	DOID:1612	NA		37844167	Unknown	Unknown
C	13	1	NIRAPARIB	CID24958200	32893443	A	R2336P	BRCA2	Oncogenic Mutations	ovarian cancer	reproductive organ cancer	DOID:2394	T		32893443	Unknown	Unknown
A	12	1	CETUXIMAB	CHEMBL1201577	25368402	A	Wildtype	KRAS	Wildtype	colorectal cancer	intestinal cancer	DOID:9256	C		25368402	Unknown	Unknown
T	5	1	Imatinib	CID5291	149499573	A	Fusions	PDGFRB	Fusions	dermatofibrosarcoma protuberans	connective tissue cancer	DOID:3507	A		149499573	Unknown	Unknown
T	7	EGFR R531* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55229284	A	EGFR R531*	EGFR	[u'R531*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55229284	Sensitive	stop_gained
T	7	EGFR T790M confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249071	A	EGFR T790M	EGFR	[u'T790M']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	55249071	Sensitive	missense_variant
GT	12	KRAS G12T confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12T	KRAS	[u'G12T']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS G12A confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12A	KRAS	[u'G12A']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
CGC	12	KRAS G12_G13insA confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398282	Resistant	Unknown
CAC	7	EGFR N771>TH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR N771>TH	EGFR	[u'N771delinsTH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
G	12	KRAS G13R confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13R	KRAS	[u'G13R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
-	7	MET c.2888-13_2908delTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411923	A	MET c.2888-13_2908delTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC	MET	[u'c.2888-13_2908delTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC']	lung adenocarcinoma	lung cancer	DOID:3910	TCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC	SO:0000188	116411890	Sensitive	intron
CGC	12	KRAS G12_G13insA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398282	Resistant	Unknown
G	12	KRAS G12A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398284	A	KRAS G12A	KRAS	[u'G12A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	MET c.3009_3028+10delCCGAGCTACTTTTCCAGAAGGTATATTTCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412053	A	MET c.3009_3028+10delCCGAGCTACTTTTCCAGAAGGTATATTTCA	MET	[u'c.3009_3028+10delCCGAGCTACTTTTCCAGAAGGTATATTTCA']	lung adenocarcinoma	lung cancer	DOID:3910	CCGAGCTACTTTTCCAGAAGGTATATTTCA	SO:0000188	116412024	Sensitive	intron
TT	12	KRAS G12N confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12N	KRAS	[u'G12N']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
G	7	MET c.3022_3028+5delCCAGAAGGTATAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412048	A	MET c.3022_3028+5delCCAGAAGGTATAinsG	MET	[u'c.3022_3028+5delCCAGAAGGTATAinsG']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116412037	Sensitive	intron
-	7	MET c.2995_3028+221delGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412264	A	MET c.2995_3028+221delGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATT	MET	[u'c.2995_3028+221delGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATT']	lung adenocarcinoma	lung cancer	DOID:3910	GAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGTATATTTCAGTTTATTGTTCTGAGAAATACCTATACATATACCTCAGTGGGTTGTGACATTGTTGTTTATTTTTGGTTTTGCATTTATATTTTTATAAAAACCTAAAGGAAGTATTTACCTCTGCCAAGTAAGTATTTGACACAAAATTACATGGCTCTTAATTTTAAAAGAACCCATGTATATATTACATTATGATTTTAGAGTCCATAAGCTCTCATT	SO:0000188	116412010	Sensitive	intron
T	10	KIF5B-RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	CABOZANTINIB	CID25102847	32326287	A	KIF5B-RET	RET	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	32326287	Sensitive	fusion
-	7	MET c.3022_3028+1delCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3022_3028+1delCCAGAAGG	MET	[u'c.3022_3028+1delCCAGAAGG']	lung adenocarcinoma	lung cancer	DOID:3910	CCAGAAGG	SO:0000188	116412037	Sensitive	intron
-	7	MET c.2888-29_2891delACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411906	A	MET c.2888-29_2891delACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT	MET	[u'c.2888-29_2891delACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT']	lung adenocarcinoma	lung cancer	DOID:3910	ACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT	SO:0000188	116411874	Sensitive	intron
GGGTCGTGG	7	EGFR V769_D770insGVV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249011	A	EGFR V769_D770insGVV	EGFR	[u'V769_D770insGVV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
AGAC	7	EGFR E746_A750>RP confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242478	A	EGFR E746_A750>RP	EGFR	[u'E746_A750delinsRP']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAG	SO:0000159	55242466	Sensitive	deletion
A	12	KRAS G13V confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13V	KRAS	[u'G13V']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398281	Resistant	missense_variant
AT	12	KRAS G13D confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G13D	KRAS	[u'G13D']	lung adenocarcinoma	lung cancer	DOID:3910	GC		25398280	Resistant	Unknown
C	12	KRAS G13G confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398280	A	KRAS G13G	KRAS	[u'G13G']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001815	25398280	Resistant	synonymous
T	12	KRAS G12S confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12S	KRAS	[u'G12S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
-	7	EGFR E746_S752delinsA confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242484	A	EGFR E746_S752delinsA	EGFR	[u'E746_S752delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACAT	SO:0000159	55242467	Sensitive	deletion
TAC	7	EGFR D770_N771insY confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249013	A	EGFR D770_N771insY	EGFR	[u'D770_N771insY', u'D770_N771insY']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
-	7	EGFR L747_S752del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	55242486	A	EGFR L747_S752del	EGFR	[u'L747_S752del']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGAGAAGCAACATCT	SO:0000159	55242469	Sensitive	deletion
GTT	7	EGFR D770>GY confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249011	A	EGFR D770>GY	EGFR	[u'D770delinsGY']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
T	12	KRAS G12D confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398284	A	KRAS G12D	KRAS	[u'G12D']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
-	7	EGFR E746_S752delinsA confers sensitivity to Afatinib in patients with Non-small cell lung cancer	AFATINIB	CID10184653	55242484	A	EGFR E746_S752delinsA	EGFR	[u'E746_S752delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAACAT	SO:0000159	55242467	Sensitive	deletion
T	12	KRAS G12D confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398284	A	KRAS G12D	KRAS	[u'G12D']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
TT	7	BRAF V600K confers sensitivity to Trametinib + Dabrafenib in patients with MM - Malignant melanoma of skin	DABRAFENIB	CID44462760	140453137	A	BRAF V600K	BRAF	[u'V600K']	skin melanoma	integumentary system cancer	DOID:8923	AC	SO:0001583	140453136	Sensitive	missense_variant
A	12	KRAS G12V confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398284	A	KRAS G12V	KRAS	[u'G12V']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001815	25398284	Resistant	synonymous
T	12	KRAS G12D confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398284	A	KRAS G12D	KRAS	[u'G12D']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
G	12	KRAS Q61H confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001815	25380275	Resistant	synonymous
T	7	EGFR Q71* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55210101	A	EGFR Q71*	EGFR	[u'Q71*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55210101	Sensitive	stop_gained
GACAACCCT	7	EGFR P772_H773insDNP confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249019	A	EGFR P772_H773insDNP	EGFR	[u'D770_P772dupDNP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
A	12	KRAS G13C confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13C	KRAS	[u'G13C']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
A	2	ALK C1156F confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	29445258	A	ALK C1156F	ALK	[u'C1156F']	non-small cell lung carcinoma	lung cancer	DOID:3908	C	SO:0001583	29445258	Sensitive	missense_variant
T	7	MET c.3028+1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3028+1G>T	MET	[u'c.3028+1G>T']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001627	116412044	Sensitive	intron_variant
NA	NA	ER/PR positive confers sensitivity to Letrozole in patients with Neoplasm of breast	LETROZOLE	CID3902	NA	A	ER/PR positive	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA		NA	Sensitive	Unknown
NA	6	ESR1 Amplification confers sensitivity to Letrozole in patients with Neoplasm of breast	LETROZOLE	CID3902	152450754	A	ESR1 Amplification	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA	NA	151977826	Sensitive	Unknown
NA	NA	ER/PR positive confers sensitivity to Anastrozole in patients with Neoplasm of breast	ANASTROZOLE	CID2187	NA	A	ER/PR positive	ESR1	[]	breast cancer	thoracic cancer	DOID:1612	NA		NA	Sensitive	Unknown
AT	12	KRAS G13I confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13I	KRAS	[u'G13I']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
AA	12	KRAS G13F confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398282	A	KRAS G13F	KRAS	[u'G13F']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398281	Resistant	missense_variant
T	12	KRAS Q61K confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	breast cancer	thoracic cancer	DOID:1612	G	SO:0001583	25380277	Resistant	missense_variant
TT	12	KRAS G12N confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12N	KRAS	[u'G12N']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
AT	12	KRAS G12I confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398285	A	KRAS G12I	KRAS	[u'G12I']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
G	12	KRAS G12A confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398284	A	KRAS G12A	KRAS	[u'G12A']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
A	12	KRAS G12V confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398284	A	KRAS G12V	KRAS	[u'G12V']	breast cancer	thoracic cancer	DOID:1612	C	SO:0001815	25398284	Resistant	synonymous
-	12	KRAS G12fs*3 confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	breast cancer	thoracic cancer	DOID:1612	C	SO:0000159	25398284	Resistant	deletion
CGC	12	KRAS G12_G13insA confers resistance to Afatinib in patients with Neoplasm of breast	AFATINIB	CID10184653	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	breast cancer	thoracic cancer	DOID:1612	-		25398282	Resistant	Unknown
TT	12	KRAS G12N confers resistance to Lapatinib in patients with Neoplasm of breast	Lapatinib	CID208908	25398285	A	KRAS G12N	KRAS	[u'G12N']	breast cancer	thoracic cancer	DOID:1612	CC	SO:0001583	25398284	Resistant	missense_variant
AACCCTCAT	7	EGFR H773_V774insNPH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249022	A	EGFR H773_V774insNPH	EGFR	[u'N771_H773dupNPH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
AT	12	KRAS G13I confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13I	KRAS	[u'G13I']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
G	12	KRAS G12R confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12R	KRAS	[u'G12R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398285	Resistant	missense_variant
A	7	EGFR L861Q confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55259524	A	EGFR L861Q	EGFR	[u'L861Q']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
C	12	KRAS Q61R confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
-	7	MET c.2888-15_2911delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411926	A	MET c.2888-15_2911delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT	MET	[u'c.2888-15_2911delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT']	lung adenocarcinoma	lung cancer	DOID:3910	TCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT	SO:0000188	116411888	Sensitive	intron
T	12	KRAS G13S confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398282	A	KRAS G13S	KRAS	[u'G13S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
TGCACC	12	KRAS G12_G13insAG confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398281	Resistant	Unknown
CCA	7	EGFR H773dup confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249018	A	EGFR H773dup	EGFR	[u'H773dup']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249017	Resistant	Unknown
T	7	EGFR S768I confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249005	A	EGFR S768I	EGFR	[u'S768I']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	55249005	Sensitive	missense_variant
-	7	EGFR E746delE confers sensitivity to Afatinib in patients with Non-small cell lung cancer	AFATINIB	CID10184653	55242466	A	EGFR E746delE	EGFR	[u'E746del']	non-small cell lung carcinoma	lung cancer	DOID:3908	AGG	SO:0000159	55242464	Sensitive	deletion
AT	12	KRAS G12I confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12I	KRAS	[u'G12I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
GG	12	KRAS G13P confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13P	KRAS	[u'G13P']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398281	Resistant	missense_variant
GG	12	KRAS G13P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13P	KRAS	[u'G13P']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
CAAGCGTAG	7	EGFR V769_D770insASV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249011	A	EGFR V769_D770insASV	EGFR	[u'A767_V769dupASV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
G	12	KRAS G12A confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398284	A	KRAS G12A	KRAS	[u'G12A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
GT	12	KRAS G12T confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12T	KRAS	[u'G12T']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
-	7	EGFR E746_T751delinsA confers sensitivity to Erlotinib hydrochloride in patients with Non-small cell lung cancer	Erlotinib	CID176870	55242481	A	EGFR E746_T751delinsA	EGFR	[u'E746_T751delinsA']	non-small cell lung carcinoma	lung cancer	DOID:3908	AATTAAGAGAAGCAA	SO:0000159	55242467	Sensitive	deletion
NA	9	CD274 Amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of lung	PEMBROLIZUMAB	CHEMBL3137343	5470566	A	CD274 Amplification	CD274	[]	lung adenocarcinoma	lung cancer	DOID:3910	NA	NA	5450503	Sensitive	Unknown
CAAACGTAG	7	EGFR V769_D770insANV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249011	A	EGFR V769_D770insANV	EGFR	[u'V769_D770insANV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
GCGTAGAGA	7	EGFR D770_N771insSVE confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249014	A	EGFR D770_N771insSVE	EGFR	[u'D770_N771insSVE']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
T	12	KRAS G12S confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12S	KRAS	[u'G12S']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
A	7	EGFR L861Q confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55259524	A	EGFR L861Q	EGFR	[u'L861Q']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	55259524	Sensitive	missense_variant
-	7	MET c.2888-44_2891delTGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411906	A	MET c.2888-44_2891delTGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT	MET	[u'c.2888-44_2891delTGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT']	lung adenocarcinoma	lung cancer	DOID:3910	TGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT	SO:0000188	116411859	Sensitive	intron
T	6	CD74-ROS1 L2026M confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	117638365	A	CD74-ROS1 L2026M	ROS1	[u'L2026M']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0000806	117638365	Sensitive	fusion
G	12	KRAS Q61H confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380275	A	KRAS Q61H	KRAS	[u'Q61H']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001815	25380275	Resistant	synonymous
-	7	MET c.3025_3028+3delGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3025_3028+3delGAAGGTA	MET	[u'c.3025_3028+3delGAAGGTA']	lung adenocarcinoma	lung cancer	DOID:3910	GAAGGTA	SO:0000188	116412040	Sensitive	intron
G	7	MET c.2888-6_2888-2delTTTAAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411901	A	MET c.2888-6_2888-2delTTTAAinsG	MET	[u'c.2888-6_2888-2delTTTAAinsG']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411897	Sensitive	intron
AT	12	KRAS G13I confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G13I	KRAS	[u'G13I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398281	Resistant	missense_variant
A	12	KRAS G12V confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398284	A	KRAS G12V	KRAS	[u'G12V']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
-	7	EGFR L747_T751del confers sensitivity to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55242484	A	EGFR L747_T751del	EGFR	[u'L747_T751del', u'L747_T751del']	lung adenocarcinoma	lung cancer	DOID:3910	TAAGAGAAGCAACAT	SO:0000159	55242470	Sensitive	deletion
NA	12	Wild-Type KRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25403870	A	Wild-Type	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	25357723	Sensitive	Unknown
C	12	KRAS G13G confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398280	A	KRAS G13G	KRAS	[u'G13G']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	G	SO:0001815	25398280	Resistant	synonymous
G	17	ERBB2 E321G confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37868241	A	ERBB2 E321G	ERBB2	[u'E321G']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	37868241	Sensitive	missense_variant
TGT	12	KRAS G13_V14>DI confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	lung adenocarcinoma	lung cancer	DOID:3910	ACA		25398279	Resistant	Unknown
CAT	7	EGFR H773_V774insH confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249022	A	EGFR H773_V774insH	EGFR	[u'H773dupH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249021	Resistant	Unknown
-	7	MET c.2888-59_3028+1delGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.2888-59_3028+1delGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGG	MET	[u'c.2888-59_3028+1delGTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGG']	lung adenocarcinoma	lung cancer	DOID:3910	GTCTCCTGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGG		116411844	Sensitive	Unknown
-	12	KRAS G12fs*3 confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398284	A	KRAS G12fs*3	KRAS	[u'G12Vfs*3']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0000159	25398284	Resistant	deletion
NA	7	MET Amplification confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116438440	A	MET Amplification	MET	[]	lung adenocarcinoma	lung cancer	DOID:3910	NA	SO:0001889	116312444	Sensitive	transcript_amplification
C	12	KRAS Q61E confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380277	A	KRAS Q61E	KRAS	[u'Q61E']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
CCACCA	12	KRAS G12_G13insG confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	lung adenocarcinoma	lung cancer	DOID:3910	CCA		25398280	Resistant	Unknown
TCT	17	ERBB2 G776>VC confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37880998	A	ERBB2 G776>VC	ERBB2	[u'G776delinsVC', u'G776delinsVC', u'G776delinsVC']	lung adenocarcinoma	lung cancer	DOID:3910	-		37880997	Sensitive	Unknown
-	7	MET c.2888-5_2944delTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411959	A	MET c.2888-5_2944delTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA	MET	[u'c.2888-5_2944delTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA']	lung adenocarcinoma	lung cancer	DOID:3910	TTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA	SO:0000188	116411898	Sensitive	intron
AAAC	7	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTAinsAAAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTAinsAAAC	MET	[u'c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTAinsAAAC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116411875	Sensitive	intron
TT	12	KRAS G13E confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G13E	KRAS	[u'G13E']	lung adenocarcinoma	lung cancer	DOID:3910	GC	SO:0001583	25398280	Resistant	missense_variant
G	12	KRAS G13A confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398281	A	KRAS G13A	KRAS	[u'G13A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
GACACACCC	7	EGFR P772_H773insTHP confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249018	A	EGFR P772_H773insTHP	EGFR	[u'P772_H773insTHP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249017	Resistant	Unknown
G	12	KRAS Q61P confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380276	A	KRAS Q61P	KRAS	[u'Q61P']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
G	12	KRAS G13R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398282	A	KRAS G13R	KRAS	[u'G13R']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398282	Resistant	missense_variant
G	12	KRAS G13A confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G13A	KRAS	[u'G13A']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398281	Resistant	missense_variant
T	12	KRAS Q61K confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25380277	A	KRAS Q61K	KRAS	[u'Q61K']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001583	25380277	Resistant	missense_variant
T	12	KRAS G13S confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398282	A	KRAS G13S	KRAS	[u'G13S']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C	SO:0001583	25398282	Resistant	missense_variant
AT	7	EGFR E746_S752>I confers sensitivity to Azd-9291 in patients with Non-small cell lung cancer	Azd	CID16736978	55242485	A	EGFR E746_S752>I	EGFR	[u'E746_S752delinsI', u'E746_S752delinsI', u'E746_S752delinsI']	non-small cell lung carcinoma	lung cancer	DOID:3908	GAATTAAGAGAAGCAACATC	SO:0000159	55242466	Sensitive	deletion
A	12	KRAS G12C confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12C	KRAS	[u'G12C']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398285	Resistant	synonymous
T	12	KRAS G12D confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398284	A	KRAS G12D	KRAS	[u'G12D']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001815	25398284	Resistant	synonymous
C	1	TPM3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	154143173	A	TPM3-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0000806	154143173	Sensitive	fusion
T	4	SLC34A2-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	ALECTINIB	CID49806720	25664146	A	SLC34A2-ROS1	ROS1	[]	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0000806	25664146	Sensitive	fusion
CC	7	MET c.3028_3028+3delGGTAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412046	A	MET c.3028_3028+3delGGTAinsCC	MET	[u'c.3028_3028+3delGGTAinsCC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116412043	Sensitive	intron
GTC	7	EGFR N771>SH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR N771>SH	EGFR	[u'N771delinsSH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
AT	12	KRAS G12I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12I	KRAS	[u'G12I']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
CGC	12	KRAS G12_G13insA confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398283	A	KRAS G12_G13insA	KRAS	[u'G12_G13insA']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	-		25398282	Resistant	Unknown
CAT	12	KRAS G13M confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398282	A	KRAS G13M	KRAS	[u'G13M']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	GCC	SO:0001583	25398280	Resistant	missense_variant
AATTAAGA	7	EGFR E746fs*15 confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55242482	A	EGFR E746fs*15	EGFR	[u'E746Nfs*15']	lung adenocarcinoma	lung cancer	DOID:3910	TATCAAGGAATTAAGAGAAGCAAC		55242459	Sensitive	Unknown
CCA	12	KRAS G12W confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398285	A	KRAS G12W	KRAS	[u'G12W']	lung adenocarcinoma	lung cancer	DOID:3910	ACC	SO:0001583	25398283	Resistant	missense_variant
ACC	7	MET c.3028+2_3028+4delTATinsACC confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412047	A	MET c.3028+2_3028+4delTATinsACC	MET	[u'c.3028+2_3028+4delTATinsACC']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000188	116412045	Sensitive	intron
GGCTCCCCA	17	ERBB2 G778_S779insLPS confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	37881004	A	ERBB2 G778_S779insLPS	ERBB2	[u'G778_S779insLPS']	lung adenocarcinoma	lung cancer	DOID:3910	-	SO:0000706	37881003	Sensitive	trans_splice_acceptor_site
TGCACC	12	KRAS G12_G13insAG confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398282	A	KRAS G12_G13insAG	KRAS	[u'G12_G13insAG']	lung adenocarcinoma	lung cancer	DOID:3910	-		25398281	Resistant	Unknown
TA	12	KRAS G12Y confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25398285	A	KRAS G12Y	KRAS	[u'G12Y']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
TGCGTG	7	EGFR V769_D770insCV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249010	A	EGFR V769_D770insCV	EGFR	[u'V769_D770insCV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249009	Resistant	Unknown
GACACACCC	7	EGFR P772_H773insTHP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249018	A	EGFR P772_H773insTHP	EGFR	[u'P772_H773insTHP']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249017	Resistant	Unknown
AA	12	KRAS G12F confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398285	A	KRAS G12F	KRAS	[u'G12F']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
C	7	MET c.3028+1G>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116412044	A	MET c.3028+1G>C	MET	[u'c.3028+1G>C']	lung adenocarcinoma	lung cancer	DOID:3910	G	SO:0001627	116412044	Sensitive	intron_variant
CAAACGTAG	7	EGFR V769_D770insANV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249011	A	EGFR V769_D770insANV	EGFR	[u'V769_D770insANV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249010	Resistant	Unknown
CCA	12	KRAS G12W confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25398285	A	KRAS G12W	KRAS	[u'G12W']	lung adenocarcinoma	lung cancer	DOID:3910	ACC	SO:0001583	25398283	Resistant	missense_variant
GTT	7	EGFR P772_H773insV confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	55249019	A	EGFR P772_H773insV	EGFR	[u'P772_H773insV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
CCACCA	12	KRAS G12_G13insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25398281	A	KRAS G12_G13insG	KRAS	[u'G13dupG']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CCA		25398280	Resistant	Unknown
C	12	KRAS Q61R confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
T	2	ALK L1196M confers sensitivity to Ceritinib in patients with Non-small cell lung cancer	CERITINIB	CID57379345	29443631	A	ALK L1196M	ALK	[u'L1196M']	non-small cell lung carcinoma	lung cancer	DOID:3908	G	SO:0001583	29443631	Sensitive	missense_variant
ACCGGC	7	EGFR N771_P772insRH confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249014	A	EGFR N771_P772insRH	EGFR	[u'N771_P772insRH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
C	12	KRAS Q61R confers resistance to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25380276	A	KRAS Q61R	KRAS	[u'Q61R']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	T	SO:0001583	25380276	Resistant	missense_variant
A	12	KRAS Q61L confers resistance to Gefitinib in patients with Neoplasm of lung	GEFITINIB	CID123631	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
GTAGACAAC	7	EGFR N771_P772insVDN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249016	A	EGFR N771_P772insVDN	EGFR	[u'V769_N771dupVDN']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249015	Resistant	Unknown
G	12	KRAS G13A confers resistance to Icotinib in patients with Neoplasm of lung	Icotinib	CID22024915	25398281	A	KRAS G13A	KRAS	[u'G13A']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001583	25398281	Resistant	missense_variant
ACCGGC	7	EGFR N771_P772insRH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	55249014	A	EGFR N771_P772insRH	EGFR	[u'N771_P772insRH']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249013	Resistant	Unknown
A	12	KRAS G13 confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25368462	A	KRAS G13	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	C		25368462	Resistant	Unknown
A	12	KRAS Q61L confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	25380276	A	KRAS Q61L	KRAS	[u'Q61L']	lung adenocarcinoma	lung cancer	DOID:3910	T	SO:0001583	25380276	Resistant	missense_variant
AG	12	KRAS G12L confers resistance to Cetuximab in patients with Neoplasm of colorectum	CETUXIMAB	CHEMBL1201577	25398285	A	KRAS G12L	KRAS	[u'G12L']	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	CC	SO:0001583	25398284	Resistant	missense_variant
TGT	12	KRAS G13_V14>DI confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25398281	A	KRAS G13_V14>DI	KRAS	[u'G13_V14delinsDI']	lung adenocarcinoma	lung cancer	DOID:3910	ACA		25398279	Resistant	Unknown
T	2	ALK L1196Q confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	29443630	A	ALK L1196Q	ALK	[u'L1196Q']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	29443630	Sensitive	missense_variant
T	7	EGFR R669* confers sensitivity to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55240761	A	EGFR R669*	EGFR	[u'R669*']	lung adenocarcinoma	lung cancer	DOID:3910	C	SO:0001587	55240761	Sensitive	stop_gained
GGCACA	7	EGFR D770_N771insGT confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249013	A	EGFR D770_N771insGT	EGFR	[u'D770_N771insGT']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249012	Resistant	Unknown
A	12	KRAS G13 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	Erlotinib	CID176870	25368462	A	KRAS G13	KRAS	[]	lung adenocarcinoma	lung cancer	DOID:3910	C		25368462	Resistant	Unknown
GTT	7	EGFR P772_H773insV confers resistance to Afatinib in patients with Neoplasm of lung	AFATINIB	CID10184653	55249019	A	EGFR P772_H773insV	EGFR	[u'P772_H773insV']	lung adenocarcinoma	lung cancer	DOID:3910	-		55249018	Resistant	Unknown
C	2	ALK F1245C confers resistance to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	29436859	A	ALK F1245C	ALK	[u'F1245C']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	29436859	Resistant	missense_variant
C	2	ALK F1245C confers sensitivity to Ceritinib in patients with Neoplasm of lung	CERITINIB	CID57379345	29436859	A	ALK F1245C	ALK	[u'F1245C']	lung adenocarcinoma	lung cancer	DOID:3910	A	SO:0001583	29436859	Sensitive	missense_variant
NA	12	Wild-Type KRAS confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	PANITUMUMAB	CHEMBL1201827	25403870	A	Wild-Type	KRAS	[]	rectal neoplasm	gastrointestinal system benign neoplasm	DOID:1984	NA	NA	25357723	Sensitive	Unknown
-	7	MET c.2888-16_2888-3delTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	CRIZOTINIB	CID11626560	116411900	A	MET c.2888-16_2888-3delTTCTCTCTGTTTTA	MET	[u'c.2888-16_2888-3delTTCTCTCTGTTTTA']	lung adenocarcinoma	lung cancer	DOID:3910	TTCTCTCTGTTTTA	SO:0000188	116411887	Sensitive	intron
AG	12	KRAS G12L confers resistance to Azd-9291 in patients with Neoplasm of lung	Azd	CID16736978	25398285	A	KRAS G12L	KRAS	[u'G12L']	lung adenocarcinoma	lung cancer	DOID:3910	CC	SO:0001583	25398284	Resistant	missense_variant
